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The UK National General Practice Study of Epilepsy (NGPSE) is a 
prospective,  population  based  study  of newly  diagnosed  epilepsy 
including  acute  symptomatic  seizures  and  single  seizures.  Patients
tK  «u
were followed for 11,400 person years (median follow-up [25  , 75 
centiles] is 11.8 years [10.6-12.7]). Out of 564 patients with definite 
and  228  with  probable  epilepsy,  149  and  50  deaths  respectively 
were  analysed.  Long-term  mortality was twice  that  of the  general 
population  (standardized  mortality  ratio  [SMR]  2.1  [95%
Confidence interval (CI)=1.8,2.4]). Multivariate Cox regression and 
time dependent co-variate analyses were utilised for the first time in 
a  study  of  mortality  in  epilepsy.  Patients  with  generalised  tonic 
clonic  seizures  had  an  increased  risk  of mortality  (hazard  ratio  or 
HR  6.2  [95%CI=1.4,27.7;  p=0.049]).  Time  dependent  co-variate 
analysis  examined  the  influence  of ongoing  factors  on  mortality. 
Seizure  recurrence  (HR  1.30  [95%CI=0.84,2.01])  and  AED 
treatment (HR 0.97 [95%CI=0.67,1.38]) did not influence mortality.
Treatment  patterns  in  564  patients  with  definite  epilepsy  were 
followed  prospectively  for  11-14  years.  Treatment  was  started  in 
433  (77%)  patients.  Only  15%  of single  seizure  (index  seizure  = 
first seizure) cases had any medication prescribed initially.  Due to 
subsequent  seizure  recurrence,  more  than  70%  of these  patients 
ultimately  received  antiepileptic  medication.  209/564  patients 
(37%)  were  on  treatment  for  epilepsy  at  last  follow-up.  98/209 
(47%)  of those  on  treatment  were  in  5-year  terminal  remission.
2Figures  from  this  study  suggest  that  of  30,000  patients  newly 
diagnosed  with  epilepsy  every  year  in  the  United  Kingdom, 
approximately  6000  have  inadequate  seizure  control  in  the  long 
term. A third of the patients in this group have one or more seizures 
monthly.  Only 2/3rds of these patients with  frequent  seizures  had 
switched  medication  in  order  to  try  and  achieve  better  seizure 
control. There is probably still considerable room for improvement 
in prescribing practice in the UK.
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12INTRODUCTION
Epidemiology is the study of the natural history of disease, which includes 
its frequency,  severity and course as well as the identification of the risk 
factors  that  influence  these  aspects.  Thus,  neuroepidemiology  is  the 
branch of epidemiology that deals with the disease processes or conditions 
that afflict the nervous system.  The natural history of any disease is best 
studied in population based cohorts where the disease spectrum is seen in 
its entirety rather than in hospital based groups where there is an inherent 
bias towards patients who have more severe disease and are likely to seek 
specialist  medical  help.  This  is particularly true of the  epilepsies where 
age,  demographics,  disease aetiology,  remission,  recurrence and  severity 
vary widely.
Apart  from  the  population-based  reports  from  the  Mayo  Clinic  in 
Rochester,  there were no  large-scale epidemiological  studies of epilepsy 
until the National General Practice Study of Epilepsy, which is unique in 
its  representation  of the  epilepsies  in  a  modern,  industrialised  nation 
context.  It is particularly attractive as a resource in the study of epilepsy 
because of its design as a prospective study that, through comprehensive 
and regular data collection, provides accurate information on its long-term 
prognosis  including  seizure  remission,  recurrence  and  mortality.  This 
study has already reported on the short and intermediate term mortality of 
epilepsy,  analysed  prospectively.  We  undertook  to  further  explore  the 
long-term aspects of mortality in epilepsy in this same cohort.
Through  its  observational,  non-interventional  nature, this  study provides 
valuable  insights  into  the  treatment  of the  epilepsies,  which  for  both 
doctors and patients,  involves a long-term commitment to various drugs 
and  drug  regimens.  Increasingly,  modern  epilepsy  treatment  moves 
towards  standardisation  and  rationalisation  of  therapies  and  without 
specialist  intervention  or  supervision,  many  patients  are  at  risk  of 
inadequate  or  inappropriate  treatments.  The  National  General  Practice 
Study of Epilepsy is invaluable in its potential to reflect current practices
13and  provides  an  accurate  representation  of the  dynamics  of treatment 
changes in the long term. There is particularly interesting information on 
20-30% of patients with treatment resistant epilepsy who are most likely 
to require ongoing treatment intervention.
The  purpose  of the  studies  detailed  in  this  thesis  was  to  analyse  and 
describe mortality in the long term and its various aspects, in a community 
based  population  with  epilepsy;  further,  it  was  to  describe  in  a 
longitudinal  and  observational  fashion,  the  modem  day  treatment  of 
epilepsy in the United Kingdom.
The study on mortality confirms in a prospective fashion what large-scale 
retrospective  studies  have  suggested;  that  the  mortality  of epilepsy  is 
elevated  in  the  long-term  even  in  community  based  populations  with 
epilepsy.  The  multivariate  analysis  and  the  time  dependent  co-variate 
analysis are novel analyses. The Cox model multivariate analysis confirms 
what uni-variate analyses in previous studies have shown; that older age at 
diagnosis,  cerebrovascular  disease,  alcohol,  tumours  and  congenital 
neurological  deficits  are  associated  with  increased  mortality.  The  time 
dependent  co-variate  analysis  examining  dynamic  variables  shows  that 
seizure  recurrence  and  drug  treatment  in  epilepsy  do  not  influence 
mortality in a community based cohort with epilepsy.
The study on treatment makes observations on antiepileptic drug therapy 
in a community-based cohort in the UK for the first time. It reveals that a 
substantial  proportion  of patients  do  not  have their  medication  changed 
despite  continuing  seizures,  suggesting  room  for  improvement  in  the 
management  of  epilepsy  in  the  community.  It  also  confirms  the 
observation  that  lack  of response  to  initial  medication  due  to  lack  of 
efficacy can predict poor response to further medication changes although 
the  significance  of  this  finding  in  this  purely  observational,  non­
interventional study is limited.
14AIMS OF THE STUDIES
MORTALITY
The aim of the study of mortality was:-
•  To determine whether mortality in patients with epilepsy is elevated in the 
long term
•  To determine mortality rates according to age,  aetiological  classification, 
cause,  seizure  type,  time  since  diagnosis  and  seizure  frequency  before 
index seizure
•  To  perform  a  Cox  proportional  hazards  model  multi-variate  analysis  of 
mortality using baseline variables
•  To  perform  a  time  dependent  co-variate  analysis  of  mortality  using 
baseline and dynamic variables
TREATMENT
The aim of the study of treatment was:-
•  To  determine  the  number  of patients  that  receive  treatment  for  newly 
diagnosed epilepsy in the general population
•  To  make  observations  on  treatment  patterns  and  the  dynamics  of the 
treatment of epilepsy over time
•  To determine current trends in the community treatment of epilepsy in the 
United Kingdom.
15A CRITICAL REVIEW OF THE LITERATURE
1.1  METHODOLOGICAL CONSIDERATIONS
Methodology  is  an  important  issue  and  requires  proper  attention  in  all 
epidemiological  studies.  As with  many  other  disease  conditions,  lack  of 
standardisation  in  many  studies  of epilepsy  renders  their  interpretation 
difficult.
1.1.1  The definition of epilepsy
The diagnosis of epilepsy, by definition, is made only after a two or more 
unprovoked  epileptic  seizures,  although  it  is  becoming  increasingly 
evident  that the  majority  of patients  with  single  seizures go  on  to  have 
more.  “Epilepsy”  encompasses  a  wide  range  of  conditions  in  which 
seizures are a manifestation. The use of the term “epilepsies” is therefore, 
preferable to “epilepsy” (Sander JWAS  1993).  Single,  acute symptomatic 
seizures  and  childhood  febrile  convulsions  are  not  considered  to  be 
epilepsy in most studies.  (Acute symptomatic seizures have been variably 
defined as seizures occurring within a week [Hauser, and others  1982], to 
three months [Sander, and others 1990] of a causative insult)
The study of the prognosis of epilepsy is rendered difficult by the diversity 
of  underlying  diagnoses  of  which  epilepsy  is  a  symptom.  Potential 
aetiologies  range  from  those  well  known  to  those  that  are  unknown 
(cryptogenic).
1.1.2  Diagnostic difficulties
Diagnosing  epilepsy  can  be  a  complex  task,  especially  since  a  good 
witnessed account of the seizure is crucial. For a variety of reasons, this is 
often difficult to obtain.  Seizures may be nocturnal  or occur in the early
16morning  and  thus  may  be  un-witnessed;  some,  such  as  minor  complex 
partial  seizures and absence attacks, may be brief, and may not appear as 
abnormal  to  the  unpractised  eye.  Poor  observation  in  describing  the 
seizure,  and inaccuracy of second-hand accounts are common  sources of 
error. Some, such as the elderly, those with learning difficulties, and those 
with infrequent seizures may not be able to provide an eloquent account of 
events.  There  may  also  be  significant  variability  in  the  way  clinicians 
interpret  information.  In  some  reports up  to  26%  of patients  referred to 
specialist  epilepsy  clinics  are  diagnosed  as  not  having  epilepsy  (Betts 
1983;  Lesser  R  1996;  Scheepers  1998;  Smith  1999).  Inter-  observer 
reliability  has been  found to  be  as  low as  a kappa value  of 0.58  in  one 
study (van-Donselaar, and others 1991). In the Rochester study, time from 
first seizure to diagnosis took over 6 months in 50% of patients and over 2 
years in 30% (Hauser and Kurland  1975). This lag time means that, when 
studies  exclude  patients  without  a  definite  diagnosis,  considerable  bias 
may  occur.  Most  studies,  apart  from  the  NGPSE,  do  not  address  this 
important  clinical  issue (Annegers,  and others  1986;  Blom  S,  and others 
1978; Cleland PG, and others 1981; Goodridge and Shorvon 1983b).
There  is  no  single  test  or  set  of investigations  that  is  definitive  in  the 
diagnosis of seizure disorders.  Thus,  adding to the difficulty of diagnosis 
are  other  paroxysmal  conditions,  the  presentation  of  which  may  be 
confused with epileptic seizures,  such as syncope, vertigo, panic disorder, 
hyperventilation  syndrome,  night  terrors,  sleep-walking,  benign  sleep 
myoclonus,  cardiac  dysrhythmias,  transient  ischaemic  attacks,  non­
epileptic  seizures,  panic  attacks,  hypoglycaemia,  hypoxia,  confusional 
migraine  and  cataplexy  (Commission  on  Classification  and  Terminology 
of the International League against Epilepsy 1989).
Acute symptomatic seizures,  such as those that occur during a metabolic 
disturbance or an acute illness, are not considered epilepsy. This is because 
they  are  deemed to be caused by transient pathological  processes,  which 
when removed, cannot provoke further seizures, and a continuing tendency 
to  seizure  activity  does  not  occur.  The  distinction  is,  however,
17conventional  and  not the result  of a clear-cut physiological  demarcation. 
For example,  alcohol can provoke seizures, both when taken in excess as 
well  as  during  withdrawal  in  alcohol  dependence;  it  can  also  however, 
precipitate seizures in juvenile myoclonic epilepsy for example and thus it 
would be incorrect putatively to label all  seizures associated with alcohol 
as being acute symptomatic in aetiology.
It  is  important that  studies  take the  issue  of diagnosis  seriously,  so  that 
there  is  a  necessary  level  of standardisation that renders the  outcome  of 
such studies meaningful and useful.
1.1.3  Limitations of the classification of epilepsy
A comprehensive syndromic classification was commissioned by the ILAE 
(Commission  on  Classification  and  Terminology  of  the  International 
League  against  Epilepsy  1989)  with  the  stated  intention  of  having  a 
reliable  clinical  tool  for  the  classification  of  epilepsy  and  to  allow 
comparison  between  studies.  Unfortunately,  it  has  its  limitations  and 
substantial  numbers  of patients  are  unclassifiable  (Manford,  and  others 
1992).
Whilst  this  classification  incorporates  EEG  and,  in  certain  cases,  MRI 
findings, it does not make allowances for the recent advent of the genetics 
of the epilepsies, advances that will undoubtedly hasten the reclassification 
of  seizure  syndromes  (Everitt  and  Sander  1999;  Johnson  and  Sander 
2001).
In most reliable studies,  only half of the cases are classified.  In children, 
classification poses greater problems  and  one way  of handling  data is to 
group “disputable events”  separately -  when using such a demarcation it 
was  found  that  these  children  with  such  events  had  a  10%  chance  of 
seizure  recurrence  versus  54%  overall  (Stroink  H,  and  others  1998) 
suggesting that many may not have had epilepsy at all..
181.1.4 Demographic considerations
Population based  studies are a sine qua non in epidemiology and are the 
only means of providing a comprehensive representation of the epilepsies. 
This is because some patients may never be referred for specialist opinion 
and the choice of specialist is wide (The Research Committee of the Royal 
College  of General  Practitioners  1960;  Hart  and  Shorvon  1995).  Clinic- 
based studies are influenced by referral patterns, patient characteristics and 
seizure  severity;  however,  many  studies  are  clinic  based  (Sato  S  1964; 
Lindsay J,  and others  1979; Loiseau,  and others  1983; Turnbull DM,  and 
others  1982;  Cavazutti  GB,  and  others  1984;  Camfield  PR,  and  others 
1985; Munson JF  1910; Beghi and Tognoni G 1988; Collaborative Group 
for the Study of Epilepsy  1992; Tinuper P, and others  1996;  Sato S  1964; 
Hadjipanayis A, and others 1997)
The  community  studied will  also  influence  findings.  In Rochester,  USA 
for example, the population is homogeneous, white, relatively affluent and 
of northern European descent (Hauser and Kurland  1975;  Annegers,  and 
others 1979).
1.1.5  Criteria for inclusion and exclusion
Criteria for inclusion and exclusion in epidemiological  studies are central 
to  determining  standardisation.  The  exclusion  of  people  with  single 
seizures  excludes  those  patients  with  a  lower  tendency  to  recur,  thus 
apparently  lowering  remission  rates  in  studies  of epilepsy  (Hauser  and 
Kurland  1975; Annegers, and others  1979; Ross, and others  1980; Elwes, 
and  others  1988).  Conversely,  the  exclusion  of patients  who  experience 
early recurrence in studies of single seizures seems likely to improve the 
overall  prognosis.  (Sander  1993)  Similarly,  an  atypical  population  with 
more severe epilepsy is selected if only patients taking AEDs are included 
(Collaborative Group for the Study of Epilepsy 1992). Another bias that is 
difficult to interpret is added if only patients who had an EEG are included 
(Shafer SQ, and others  1988). In one study, childhood febrile convulsions
19were not excluded but grouped together with other seizure types (Thurston 
JH, and others 1982).  Some studies have excluded patients with abnormal 
neurology before the seizure (Loiseau, and others 1983).
1.1.6 Temporal aspects
Patients should be followed from the same point in their illness -  whether 
this is a first or second seizure presentation.  If this policy is not pursued, 
there is a tendency to find poor outcome because of a bias towards those 
with ongoing seizures and more severe epilepsy (Shorvon  1984; Faxen N 
1935;  Sander JWAS  1993).  This underlies the poor prognosis of epilepsy 
reported in older studies (Rodin EA 1968; Gowers WR 1885).
Most  patients go  into  remission  early  in  the  course  of their  illness.  For 
example,  in the Rochester study the net probability of entering remission 
was 65% over 10 years but, if remission had not been achieved by 5 years, 
chances  of subsequent  remission  were  only  35%  (Annegers,  and  others 
1979).
1.1.7  Definition of remission
The  problem  of  the  definition  of  remission,  otherwise  hitherto  a 
considerable stumbling block in the interpretation of study outcomes,  has 
been  addressed to  a large  extent by the  ILAE,.  Remission  has  varied  in 
description between  1-5  years (Brorson LO and Wranne L  1987; Casetta, 
and others  1997; Hauser and Kurland  1975; Munson JF  1910; Stroink H, 
and  others  1998).  Studies  have  not  always  clarified  whether  terminal 
remission  or  any  period  of  remission  is  considered  (Goodridge  and 
Shorvon 1983b; Goodridge and Shorvon 1983a); and whether remission is 
on  or  off medication  (Hauser  and  Kurland  1975;  Annegers,  and  others 
1979).  Generally however,  medication status is not considered part of the 
definition  of remission,  and  many  studies  report both terminal  and  non­
terminal remission rates.
201.1.8 Study design
Retrospective studies have considerable limitations in their design and are 
liable  to  incorporate  significant  bias,  so  that  their  results  need  to  be 
interpreted with a degree of caution. Properly designed prospective studies 
avoid bias and yield appreciably better data quality although the logistical 
considerations  inherent  in  such  undertakings  are  often  mammoth,  and 
require considerable resources.
In particular  in  patients with  seizure  disorders  associated with  cognitive 
difficulties due to  medication  or as  part  of their  condition,  retrospective 
biases  may  be  induced  by  inaccuracies  of seizure counts,  chronology of 
medication,  reporting  of adverse  events  and  other  morbidity.  Length  of 
follow-up is central to the prognosis of a chronic relapsing and remitting 
condition, and the further back a retrospective study delves the more bias 
must enter the study.  Some of Rochester data go back to  1935 (Annegers, 
and others  1979); this is the same year that Faxen wrote a critique of the 
definition of epilepsy, which seems so far removed from current concepts 
of seizure disorders (Faxen N 1935).
1.1.9  Follow-up
Between 20  and  30%  of patients with  epilepsy  may  go  on to  develop  a 
chronic  disorder  and  thus  the  lengthier  the  follow-up  period,  the  more 
meaningful  a  study’s  conclusions  are  likely  to  be.  Studies  of  newly 
diagnosed patients followed for lor 2 years find remission rates as high as 
80% (Turnbull DM, and others  1982; Beghi and Tognoni G  1988; Stroink 
H,  and others  1998).  The term remission  is only  meaningful  however,  if 
remission  periods  are  lengthy,  thus  necessitating  prolonged  follow-up. 
Some prospectively designed studies are now reporting decades of follow- 
up data (Annegers, and others 1979; Kurtz, and others 1998; Sillanpaa, and 
others 1998).
211.1.10 Loss to follow-up
Loss to follow-up can damage the validity of a study because it cannot be 
assumed  that  those  lost  are  identical  or  even  similar  to  the  rest  of the 
group.  Despite  the  statistical  tenet  that  the  non-responder  does  not 
resemble the responders, many groups have ignored this problem (Casetta, 
and others 1997).
An alternative way of handling those lost to follow-up in actuarial analysis 
is to  assume that they  have  not  remitted,  which will  decrease  remission 
rates and give a pessimistic view of outcome.
1.1.11  Statistical analysis
Early in the course of their epilepsy, most patients will go into remission; 
fewer do so with the passage of time. For this reason, it is inappropriate to 
give the  proportion  of patients  going  into  remission  if the  cohort  is  not 
being followed from the same point in the illness.
Life-table  analysis  can  handle  only  a  single  end-point  but,  in  epilepsy, 
patients  may  go  in  and  out  of remission  and  may  therefore  need  more 
sophisticated statistical analysis. If both cumulative and terminal remission 
are calculated, this can, to some extent, be accounted for. As only  12% of 
patients  have  this  intermittent  pattern,  the  bias  may  not  be  excessive 
(Goodridge and Shorvon 1983a).
In  the  statistical  analysis  of  prognostic  factors,  the  use  of uni-variate 
analysis  has  confounded  many  studies.  Uni-factorial  models  are  not 
appropriate  for  a  multifactorial  disease.  Coupled  with  the  cut-off  for 
statistical analysis of  p =0.05, which means that one in twenty factors is 
found to be significant by chance alone, inevitably studies will not always 
agree.  A  Cox  proportional  hazards  method  is  multifactorial;  the 
multivariable  analysis  enables  the  identification  of  dominant  factors 
(which is not possible in single variate or Kaplan-Meier techniques).  This
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others 1998)and has been used in the NGPSE (MacDonald BK, and others 
2000)
1.1.12 Treatment and remission
Most  studies  of prognosis  and  remission  in  epilepsy  do  not  address the 
effect  of treatment on  seizure  outcome  very  well.  There  are few  studies 
that have randomised treatment at the population level, which would be a 
requirement for assessing this issue to any meaningful extent.  (Placencia, 
and others 1994; Feksi, and others 1991; Pal, and others 1998)
Interventional  studies  have  demonstrated  that  most  patients  presenting 
with  epilepsy  entered  long-term  remission when  treated.  (Turnbull  DM, 
and others  1982; Shorvon, and others  1978;  Shorvon and Reynolds  1982; 
Elwes,  and others  1984; Beghi and Tognoni G  1988; Okuno et al.,  1989; 
Collaborative Group for the Study of Epilepsy  1992; Mattson,  and others 
1996). The studies that found a good prognosis for patients presenting with 
seizures were interpreted as causal -  good prognosis was seen as a product 
of appropriate  early  intervention.  It  was  argued  by  most  authors  at that 
time that treatment improved prognosis although there is little evidence to 
uphold  this  view,  and  gathering  evidence  from  interventional  and 
epidemiological studies to refute it.
A  study  examining  the  effect  of  treating  patients  after  their  first 
generalised tonic-clonic seizures showed no difference in long-term (1 or 2 
years)  remission  rates  (Musicco,  and  others  1997).  Drug  withdrawal, 
however,  is  an  important  cause  of  seizure  relapse  (Medical  Research 
Council Antiepileptic Drug Withdrawal Study Group 1991).
1.1.13 Mortality
The  calculation  of mortality  statistics  has been  a  source of error in past 
studies of the mortality of epilepsy.  The use of the average age of death,
23and the life expectancy of a patient, are not useful measures and serve little 
purpose in the  investigation  of the  mortality  of any  condition,  including 
epilepsy (Bradford-Hill  A  1984).  One  commonly  used  measure of death 
rates  that  can  be  used  to  compare  rates  in  different  populations  is  the 
standardised  mortality ratio  (SMR).  The  SMR  is  a proportional  rate  and 
adjusts for age and sex. However, with low numbers of expected deaths in 
different strata of analysis, this can be misleading as assumptions about the 
normal  distribution  of SMRs  and  their  confidence  limits  are  not  valid 
(Kahn HA and Sempos CT 1989).
Discovering  the  cause  of  death  in  patients  with  epilepsy  is  difficult. 
Determining a single cause of death for each patient based on data from 
death certificates is the commonest method, because of the accessibility of 
this information in most countries. Death certificates used alone, however, 
are  inaccurate  sources  of information,  and  between  11%  and  29%  of 
patients  with  epilepsy  do  not  have  epilepsy  included  on  the  death 
certificate  (SilfVenius  H  and  Olivecrona  M  1988;  Massey  EW  and 
Schoenberg  1985).  Death  certificate  information  is  often  supplemented 
with data from  post-mortems,  hospital  records  and  other  sources,  where 
available,  leading to a selection bias towards younger patients with more 
unusual causes of death.
Selection of patients is critical. The majority of studies have not mentioned 
the  criteria  which  define  epilepsy.  Inclusion  or  exclusion  of potentially 
benign  or malignant  categories,  such  as  isolated  single  seizures  or  acute 
symptomatic  seizures,  will  result  in  major  bias.  Hauser,  for  instance, 
defined epilepsy as the state of having two or more seizures (Hauser, and 
others  1980),  but  this  is  not  uniform  practice.  Studies  employing 
proportional  mortality  rates  calculated  from  death  certificates  (Krohn  W 
1963;  Schwade E and Otto O  1954) are biased for the reason mentioned 
above, i.e., that epilepsy is often not put on the death certificate of patients 
with fewer seizures or seizures in the more distant past. There have been a 
number of studies  on the  death rates in  populations  of epileptics  looked 
after  in  special  epilepsy  institutions  or  clinics  (Klenerman,  and  others
241993;  Henriksen  PB,  and  others  1967;  White  SJ,  and  others  1979; 
Birnbach CD, and others 1991; Hashimoto K, and others 1989; Iivanainen 
M and Lehtinen J 1979) or in populations of insured patients with epilepsy 
(Lewis JA  1978).  The highly selected nature of these cohorts means that 
results are not directly applicable to the wider epilepsy population .
The  general  population  is  the  most  desirable  source  of information  on 
death rates of patients with epilepsy as all patients regardless of cause will 
be included (Zielinski JJ  1974a; Hauser,  and others  1980;  Satishchandra, 
and others 1988). However, the studies to date have been retrospective and 
so have a tendency to exclude patients with less severe seizures in whom 
the diagnosis may never have been finalised,  or who may have gone into 
remission and become lost to medical surveillance.
251.2 Mortality in Epilepsy
It is often not appreciated that epilepsy may be a life threatening condition. 
Although some of the early studies found that patients with epilepsy had a 
normal life expectancy (Livingston S  1963; Schwade E and Otto O  1954), 
it  is  now  generally  accepted  that  patients  with  epilepsy  have  a  higher 
standardised death rate than the general population (Annegers,  and others 
1984; Hauser, and others  1980; Klenerman, and others  1993; Massey EW 
and Schoenberg 1985; Zielinski JJ 1974a).
1.2.1  Historical perspective
Gowers  in  his  observations  of patients  at  the  National  Hospital  for the 
Paralysed  and  Epileptic  opined  that  “the  danger to  life  of patients  with 
epilepsy  was  not  great”  and  that  the  main  risk  was  one  of drowning 
(Gowers WR 1885). Rodin, in his influential monograph on the prognosis 
of epilepsy in  1968, (Rodin EA  1968) was somewhat more ambiguous in 
his  comments  on  mortality.  Whilst  stating  that  “general  statements 
covering all epileptics are likely to be an oversimplification”, he also said 
that  it  was  “quite  obvious  that  the  life  expectancy  of  the  epileptic 
individual does not reach that of the average person”.  He based the latter 
assumption  on  a  review  of  literature  that  dealt  almost  solely  with 
institutionalised patients who had chronic and refractory epilepsy in whom 
mortality  has always been reported to be high.  Munson in  1910 reported 
on patients from the Craig Colony where, of 2,732 patients,  582 had died 
in  the  institution  (Munson  JF  1910).  The  mean  age  at  death  was  30.08 
years  and  30%  deaths  were  related  to  epilepsy.  Studies  done  at  the 
Chalfont Centre for epilepsy  have  shown that this trend  has not changed 
overtime (O'Donoghue and Sander 1997; Klenerman, and others 1993).
261.2.1  Mortality rates in patients with epilepsy
In  the  past  there  has  been  a  conspicuous  dearth  of  comprehensive, 
population  based  studies  of the  issues  involved  although  more  selected 
groups of patients  have been  studied.  The  fact that  as  many  as 20%  of 
patients  with  epilepsy  may  not  seek  medical  advice  (Miller  FJW,  and 
others 1960) emphasizes the importance of proper, representative studies. 
In  their  review  of  death  certificates  in  Wisconsin  for  the  year  1953, 
Schwade  and  Otto  appeared  to  confirm  that  risks  of  mortality  were 
insignificant (Schwade E and Otto O  1954) although we now know that 
this method is notoriously unreliable for any meaningful analysis (Hauser, 
and  others  1980;  Hopkins  and  Scrambler  G  1977;  Zielinski  JJ  1974a). 
Alstroem’s study of outpatients in  1950 also stressed the absence of risk 
in patients who had no known cause for their epilepsy and were mentally 
normal. (Zielinski JJ 1974a; Alstroem CH  1950) Livingston, in  1963 was 
quite  categorical  about the  essentially  benign  nature  of the  disease  and 
said that there was “no reason why an epileptic should not live as long as 
he would if he did not have epilepsy”. (Zielinski JJ 1974a)This conclusion 
was gleaned from his experience with  15000 patients with epilepsy on an 
insurance  register.  Henriksen  in  1967  then reported  an  excess  mortality 
from epilepsy in  a large clinic population despite excluding people with 
cerebral tumors and cerebrovascular disease from  his  study in which he 
found SMRs to be elevated up to 3 .5 times that of the general population 
(Zielinski  JJ  1974a;  Henriksen  PB,  and  others  1967).  His  figures, 
however, were compared with Danish life insurance statistics based on an 
insured population that would necessarily have been vetted and healthier, 
and this may have exaggerated the comparison.
Since then,  three major population based  studies have made it clear that 
there  is  indeed  a  significant  elevation  of  SMRs  in  epilepsy.  In  1974 
Zielinski found that the overall  SMR was  1.8  in  a cohort of all epileptic 
patients in Warsaw, and 3.5 when only patients under the age of 50 were 
considered (Zielinski JJ 1974a; Henriksen PB, and others 1967). Epilepsy 
was  the  commonest  cause  of death,  being  responsible  for  14%  of all
27deaths in patients with epilepsy. This figure rose to 24% when people with 
cerebrovascular  disease  and  brain  tumors  were  excluded  from  the 
analysis. Hauser in 1980 described mortality in a retrospectively identified 
cohort of 618 patients from Rochester, Minnesota that had been followed 
up  for more than  8000  patient  years  (Hauser,  and  others  1980).  Febrile 
convulsions, single seizure and acute symptomatic seizures were excluded 
from the study. The overall SMR was highly significantly raised at 2.3 (Cl 
1.9-2.6) indicating substantial mortality in epilepsy.  The SMR in the first 
two  years  was  3.8  and  remained  elevated  for  the  first  decade.  It 
subsequently  dropped  below  significance  and  became  elevated  again  in 
the third decade,  indicating prominent early and late mortality.  The early 
increased mortality was mainly due to underlying pathologies rather than 
the epilepsy itself, but the late increase in mortality was thought to be due 
to epilepsy itself.  The NGPSE reported on mortality in  1994  in the first 
prospectively followed up, population-based cohort of 1091  patients (564 
with  definite  epilepsy,  228  patients  with  possible  epilepsy  and  220 
patients  with  febrile  convulsions  (Cockerell,  and  others  1994a).  There 
were  161  deaths in 7500 person years of follow up and none died in the 
group with febrile convulsions. Some deaths were directly due to seizures. 
The SMR was 6.6 in the first year for patients with definite epilepsy and
5.1  when those with both definite and possible epilepsy were combined. 
SMRs dropped below significant levels during the fifth year and remained 
so for the remainder of the 9-year follow up  period.  This early trend  in 
mortality was reminiscent of the Rochester study and was attributed to the 
high  death  rates  due to  the  underlying  cause  of epilepsy  such  as  brain 
tumors  and  cerebrovascular  disease.  With  continued  follow-up,  a  later 
increase in mortality related to refractory epilepsy had been anticipated in 
the 20-30% of patients who were likely to be in this group.
In  1997, Nilsson described a Swedish cohort study of 9000 patients who 
had  once  been  hospitalized  for  epilepsy  (Nilsson  L,  and  others  1997). 
Cases were retrospectively gathered from a discharge register and causes 
of death were obtained from death certificates. 4000 deaths were reported 
and  an  SMR  of  3.6  (Cl  3.5-3.7)  was  noted  for  the  whole  cohort,
28confirming  the  high  standardized  mortality  of  epilepsy.  However,  the 
study was not truly representative with its bias towards hospital admitted 
patients and no conclusions were drawn on epilepsy related deaths due to 
the usual unreliability of death certificates.
1.2.3  Cause specific mortality in epilepsy
1.2.3.1  Cancer
There has been concern that there is an increased risk of cancer in patients 
with  epilepsy.  Many  AEDs  have  a  liver  enzyme  inducing  effect,  and 
phenobarbital  in  particular  has  been  shown  to  cause  liver  tumours  in 
rodents  when  fed  in  high  enough  dosage  (International  Agency  for 
Research on Cancer,  1974). Against this is the fact that induction of liver 
enzymes  may  actually  protect  against  carcinogenesis  by  diverting  any 
harmful metabolites down safer metabolic pathways (White SJ, and others
1979).  There  are  anecdotal  reports  of  an  association  between 
neuroblastoma  and  phenytoin  therapy  (Pendergrass  JW  and  Nanson  JW 
1976),  and  an  increased risk of brain tumours  in  children of mothers on 
long term  AEDs  (Gold E,  and  others  1978).  Also,  the  lymphadenopathy 
syndrome produced by phenytoin may  be a precursor of lymphoma,  and 
one  retrospective  study  of all  patients  dying  of lymphoma  in  a  hospital 
population reported a ten-fold increase in the lymphoma rate; 4 out of the 
85  patients  were  on  long-term  phenytoin  (Anthony  V  1970).  Hauser 
reported an SMR for all  neoplasms,  excluding cerebral neoplasms of 1.8, 
but interestingly most of this excess was accounted for by a diagnosis of 
malignancy before the diagnosis of epilepsy was made (Hauser, and others
1980). In patients resident in institutions, such as the Chalfont Centre, two 
studies have reported an increased  SMR from cancer,  1.4  and 2.0 for all 
types of cancer,  excluding brain (White SJ,  and others  1979; Klenerman, 
and others  1993). One study from Denmark in an analysis of 9136 patients 
with epilepsy admitted to a specialist centre did not confirm this increased 
rate  (Munson  JF  1910;  Clemmensen  J  1974)  and  neither  did  a  much 
smaller  sample  of  300  people  with  epilepsy  in  a  hospital  for  mental
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different  types  of malignancy  in  epilepsy  patients  does  not  confirm  the 
possible higher risks of liver cancer that was a particular concern (White 
SJ, and others 1979; Klenerman, and others 1993; Hauser 1992). However, 
lung tumours (Friedman GD  1981) and gut malignancies (Klenerman, and 
others  1993)  are  over  represented,  although  no  reason  for this  has been 
forthcoming.  It  should be noted that no  study  has allowed  for other risk 
factors such as diet or smoking habits,  which may have profound effects 
on the risk of developing cancer.
An  increased  mortality  rate  from  cerebral  malignancy  is  not  surprising 
considering  the  association  with  the  aetiology  of  many  patients  with 
epilepsy.  More  sophisticated  investigation  of patients  performed  before, 
and  after,  death  will  tend  to  raise  the  known  incidence  of intracranial 
malignancy  (Iivanainen M  and  Lehtinen J  1979).  A better prognosis  for 
those patients with gliomas who develop epilepsy has been reported, and 
must  reflect  earlier  diagnosis,  rather than  any  beneficial  effect  (Scott & 
Gibberd,  1980).  There does not  seem to be any evidence of an increased 
rate of cerebral tumours in patients on long term AEDs (Hauser, and others 
1980).
1.2.3.2  Ischaemic heart disease (IHD)
There  are  a  number  of reasons  why  the  mortality  rate  due  to  IHD  in 
patients with epilepsy may be different from that of the general population. 
Phenytoin has an anti-arrhythmic effect and a reduced mortality rate might 
be  expected  in  patients  on  long  term  AEDs,  and  this  is  supported  by 
anecdotal evidence (Munson JF 1910; Linden V 1975). Also, all the AEDs 
reduce  serum  high  density  lipoproteins,  and  may  thus  reduce  the 
accumulation  of atherosclerosis  (Munson  JF  1910;  Berlit  P,  and  others 
1982).  Most  studies  have  not been  able to  support this  hypothesis,  with 
SMR rates of 0.8 to  1.4 reported (Munson JF  1910; Annegers, and others 
1984; Klenerman, and others  1993). The higher rates are found in patients 
with  symptomatic  seizures  and  probably  represent  increased  deaths 
associated  with  strokes,  which  are  a  common  cause  of epilepsy  in  the
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1978-80  in patients with epilepsy  registered with  an  insurance  company 
against age and sex matched controls (Munson JF  1910; Muuronen A, and 
others 1985). Of the 1399 deaths in patients with epilepsy, 258 were due to 
IHD compared with 382 in the control group, indicating a 29% lower risk 
for patients with epilepsy.
1.2.3.3 Cerebrovascular disease
Cerebrovascular disease accounts for 5% of all epilepsy in the community 
(Hauser,  and  others  1980) and  so  a higher mortality  from  strokes would 
not be unexpected.  The rate of stroke deaths is  about twice the expected 
rate (Hauser,  and others  1980; Klenerman,  and others  1993) (Zielinski JJ 
1974a).  In  one  study,  once  the  symptomatic  cases  of  epilepsy  were 
removed  the  rate  of strokes  in  the  idiopathic  group  was  about  normal 
(Klenerman, and others 1993).
1.2.3.4 Bronchopneumonia
An  increased  bronchopneumonia  death  rate  has  been  a  feature  of most 
mortality  studies  in  epilepsy  since  Munson’s  original  description  that 
“pulmonary  conditions  are  peculiarly  dangerous  to  him”  (Munson  JF 
1910).  Pneumonia  is  a  frequent  end  point  of  many  illnesses  and  is  a 
frequent  death certificate recourse,  when there  is  a lack  of other data to 
support  another  cause.  It  is  also  difficult  to  delineate  those  cases  of 
pneumonia  that  occur  de  novo  and  those  cases  that  follow  aspiration 
during  a  seizure  (Munson  JF  1910;  Karalus  MC,  and  others  1991),  or 
prolonged inactivity secondary to the cause of epilepsy,  such as  strokes, 
brain tumours, or congenital deficits, or to AED intoxication. In support of 
this is the high rate of pneumonia rates in institutionalised patients who are 
more  likely  to  have  frequent  seizures,  and  associated  mental  handicap 
(Iivanainen M  and Lehtinen J  1979;  Krohn W  1963) Penning,  Muller & 
Ciompi  1969; (Munson JF  1910; White  SJ,  and  others  1979; Zielinski JJ 
1974a)  compared  to  the  lower  rates  in  population  studies  (Hauser,  and 
others  1980).  Death  rates  from  pneumonia  are  also  more  likely  to  be
31higher in institutions because of facilitation of spread of viral and bacterial 
infections.  In spite of lower rates in community  studies,  these are still in 
excess of those expected, and are still  significant in the group of patients 
with idiopathic epilepsy (Hauser,  and others  1980).  It has been suggested 
that there is an increase in the rate of pulmonary fibrosis due to long term 
phenytoin  therapy  (Moore,  1959),  but  a  link  with  a  susceptibility  to 
infection has not been established.
1.2.3.5 Psychiatric causes
Gowers was the first to note a high rate of suicide in patients with epilepsy 
(Gowers,  1885).  Psychiatric  morbidity  is  common  in  the  epilepsy 
population, and many studies have found high rates of attempted self harm 
(Hawton,  Fagg  &  Marsack,  1980),  and  suicide  (Barraclough,  1987, 
Hashimoto  et  al.,  1989;  Krohn  W  1963;  Wolfersdorf &  Froscher  1987; 
Zielinski JJ 1974a). There are a number of theoretical reasons why patients 
with  epilepsy  should  have  a  higher  suicide  rate.  Neurological  handicap 
may  result  in  social  isolation  and  depression,  and  various  causes  of 
epilepsy such as temporal lobe abnormalities and alcohol abuse, as well as 
sedative AEDs will all increase the suicide risk (Barraclough,  1987). There 
is  a  greater  risk  in  patients  with  temporal  lobe  epilepsy,  related  to  the 
degree of severity  of the  seizures (Lindsay,  Ounsted & Richards,  1979), 
and in those patients who have undergone surgery.
1.2.3.6 Epilepsy related deaths
The concept of epilepsy-related death (ERD) is finding increasing usage. 
ERD  refers to  death  that  arises  as  a  direct  consequence  of the  epilepsy 
rather  than  the  underlying  cause  of the  epilepsy.  The  causes  of ERD 
include  accidents,  seizures  themselves,  status  epilepticus,  and  sudden 
unexpected death (SUDEP).
321.2.3.7 Accidents
The chance of a patient dying of an accident is higher than in the general 
population  (Iivanainen  M  and  Lehtinen  J  1979;  Klenerman  and  others 
1993; Krohn W  1963;  Schwade E and Otto O  1954; Zielinski  JJ  1974a). 
The  usual  cause  is  the  occurrence  of  a  seizure  whilst  swimming,  or 
bathing, and death rates from these causes are higher in epilepsy hospitals 
near lakes or the  sea,  or sites remote from attendants (Iivanainen M and 
Lehtinen J  1979; Quan, Gore, Wentz, Allen & Novack,  1989). The safety 
of the environment and the level of supervision are significant factors in 
reducing the mortality in certain institutionalised patients (Klenerman, and 
others 1993).
1.2.3.8 Status epilepticus
This condition is a significant cause of death in patients with epilepsy with 
a  mortality  of 8.3%  with  the  first  episode  (Aicardi,  1986;  Maytal,  and 
others  1989;  Oxbury  &  Whitty,  1971)  and  up  to  43%  in the  long-term. 
(Chin RF, and others 2004). This is largely accounted for by patients with 
underlying lethal conditions such as frontal lobe gliomas, and degenerative 
conditions.  Older  studies  have  found  higher  mortality  rates  of  status 
compared  to  more  recent  studies,  which  is  probably  due  to  advances  in 
status treatment (Klenerman, and others 1993; Krohn W 1963; Zielinski JJ 
1974a).
1.2.3.9 Antiepileptic drug toxicity
As well as the risk of malignancy discussed above, there are other hazards 
of AEDs.  For  instance  valproate  is  associated  with  acute  and  chronic 
hepato-toxicity (Dreifuss FE, and others 1989; Suchy FJ, and others 1979). 
These  and  other  idiosyncratic  drug  reactions,  however,  are  rare  and  are 
unlikely to be major causes of death.
331.2.3.10 Death due to an isolated seizure
Apart  from  death  due  to  status,  accidents,  or  asphyxiation,  an  isolated 
seizure  itself  may  immediately  precede  death.  The  reason  for  this  is 
discussed with the aetiology of SUDEP below. Whether this is aetiological 
or coincidental is unknown. In any event it is a rare phenomenon, 6 out of 
113  deaths being recorded from Chalfont over  10 years (Klenerman,  and 
others 1993).
1.2.3.11 Sudden Unexpected Death (SUDEP)
In  1910,  Munson  reported  on  mortality  from  the  Craig  Colony  for 
Epileptics  in  New  York  where  patients  with  chronic  and  intractable 
epilepsy  resided  and  found  that  99  out  of 582  deaths  were  “sudden” 
(Munson JF  1910).  Though several were what we would now refer to as 
seizure related accidental deaths, the remainder occurred in patients found 
mysteriously  dead  in  bed  by  their  carers.  He  concluded,  not  entirely 
incorrectly, that these deaths had occurred in the midst of a seizure, noting 
that “these deaths occur very rapidly at times -  seizures not infrequently 
take place  silently”.  Since then,  there has  always  been  somewhat  of an 
acceptance, grudgingly at times, of a small but probably significant risk of 
death  directly  attributable  to  seizures,  and  sudden  death  has  appeared 
sporadically through the decades in several mortality series as a cause of 
death (Gowers WR  1885).  With present day knowledge of increased all 
cause  mortality  in  epilepsy,  (Cockerell,  and  others  1994a;  Hauser,  and 
others  1980) there has been  increasing  interest  in the  enigma of sudden 
unexpected death in epilepsy or “SUDEP” and several  studies have been 
conducted in the last few decades in an attempt to quantify risk, to identify 
risk  factors  and  to  determine  it’s  phenomenology.  It  has  become 
increasingly  clear  that  SUDEP  is  a  very  real  problem  and  perhaps  the 
commonest cause of seizure related death in patients with chronic epilepsy 
(Nashef L and Sander JWAS  1996).
34The National  Sentinel  Clinical  Audit of Epilepsy-Related Death (Hanna 
NJ  et  al  2002)  investigated  2412  deaths  reported  with  epilepsy  on the 
death certificate. A large proportion of deaths (39% of adults and 59% of 
children)  were  found  to  have  been  potentially  preventable  and 
recommendations were made at both primary as well  as secondary  level 
care to improve the existing quality of service provision.
1.2.3.11.1  Incidence studies of SUDEP
The  true  incidence  of  SUDEP  is  unknown  and  there  are  no  truly 
community based, prospective incidence studies though observations have 
been made about the phenomenon in  some cohort  studies.  The National 
GP  Study of Epilepsy in the United Kingdom (Sander,  and others  1990) 
has had one confirmed SUDEP death in a community based, prospective 
cohort  of  564  patients  with  definite  epilepsy  followed  up  for 
approximately  8000  person  years.  The  MRC  Antiepileptic  drug 
withdrawal study had two deaths attributable to SUDEP after 5000 person 
years  of  follow  up  (Medical  Research  Council  Antiepileptic  Drug 
Withdrawal  Study Group  1991).  These figures may be misleadingly low 
as  in  the  NGPSE,  almost  70%  of  the  cohort  had  achieved  5-year 
remission, a significant number of patients suffered early mortality due to 
symptomatic seizures and only a minority (55 out of an original 564 when 
last followed up) continue to have epilepsy. (Cockerell, and others 1997b) 
Similarly, the majority of the MRC study population was in remission and 
there  is  strong evidence that  SUDEP  is  mainly  a problem  in the patient 
with chronic and intractable epilepsy.
Case ascertainment methods have varied  in different  studies,  but can be 
broadly  categorised  into  studies  that  have  used  death  certificates  and 
coroner’s  registers,  (Leestma  JE,  and  others  1984;  Leestma,  and  others 
1989; Terrence CF, and others  1975)studies that have used treatment data 
-  medical,  (Derby  LE,  and  others  1996;  Jick  SS,  and  others  1992; 
Leestma,  and  others  1997;  Tennis,  and  others  1995)  surgical  (Dasheiff
351991;  Sperling  MR,  and  others  1996;  Vickery  BG  1997)or  palliative 
(Annegers, and others 1998), and those that have been based on data from 
epilepsy clinics or institutions. (Klenerman, and others  1993; Lip GY and 
Brodie  1992;  Nashef,  and  others  1995a;  Timmings  PL  1993)  Coroner 
based studies have been both retrospective (Klenerman, and others  1993; 
Leestma JE,  and others  1984; Terrence CF,  and  others  1975) as well  as 
prospective  (Leestma,  and  others  1989)  and  have  shown  incidences 
varying between  1:525  to  1:2100 and  1:370 to  1:1100 respectively.  The 
higher incidence in prospective studies may be attributable to better case 
ascertainment methods. However, these studies are fundamentally flawed 
due  to  the  fact  that  death  certificates  are  notoriously  unreliable  and 
because  the  presumed  prevalent  epilepsy  population  is  used  as 
denominator  -  a  figure  prone  to  variation  and  inaccuracy.  (Zielinski  JJ 
1974a)
SUDEP  incidence  rates  of up  to  1:200  have  been  reported  by  several 
studies based on epilepsy clinic data; (Lip GY and Brodie 1992; Nashef L, 
and others 1995a; Timmings PL 1993) these figures are much higher than 
those  from  studies  based  on  coroners’  registers.  Slightly  higher  figures 
have  been reported from institutionalised  patients who  share features of 
seizure intractability and chronicity with clinic subjects (Klenerman,  and 
others 1993; Nashef, and others 1995b). Walczak et al pooled prospective 
data from three epilepsy centres and  followed patients for  16,463  years. 
They  found  an  incidence  of  1.21/1000  patient  years  for  SUDEP, 
1.45/1000 among women and 0.98/1000 among men (Walczak and others 
2001).
Several  studies  have  used  antiepileptic  drug  therapy  lists  for  case 
ascertainment  and  individual  methodologies  have  varied  within  this 
group.  Some  have  excluded  symptomatic  cases,  (Jick  SS,  and  others
1992)  others have used patients on more than 2 antiepileptic drugs (Derby 
LE, and others 1996) and others have considered patients on drug therapy 
for more than 2 years (Tennis, and others 1995). More recent studies have 
been  based  on  newer  antiepileptic  drug  registers  such  as  those  on
36lamotrigine  (Leestma,  and  others  1997).  There  have  also  been  some 
studies  based  on  surgical  data  which  have  shown  particularly  high 
incidences of sudden death,  especially in post surgical  patients in whom 
the  operative  procedure  has  not  been  successful  in  containing  seizures 
(Dasheiff 1991;  Sperling MR,  and others  1996).  A more recent study of 
791  patients who  had  received  vagal  nerve  stimulation  system  implants 
and  were  followed  up  for  1335  person  years  showed  an  incidence  of 
definite  or  probable  SUDEP  of 4.5  /1000  person  years  of  follow  up 
(Annegers, and others  1998). The high mortality and incidence figures in 
most  of these  studies  reflect  the  severity  and  intractability  of epilepsy 
suffered by patients in these study populations and therefore is not truly 
representative of the population at large with epilepsy.
1.2.3.11.2  Important  factors implicated in SUDEP
Seizure status
It is obvious from most studies that seizure status is vitally important in 
the mortality statistics of SUDEP and incidence figures are considerably 
higher  in  studies  of  cohorts  of  patients  with  refractory  and  chronic 
seizures  than  in  studies  that  are  more  community  based.  One  surgical 
study  found  a  particularly  high  incidence  of  SUDEP  in  patients 
unsuccessfully  treated  surgically  for  their  epilepsy,  with  mortality 
approaching 1:50 when such patients were considered in contrast to 1:150 
when  both  pre  and  post  surgical  candidates  were  analysed  together 
(Dasheiff 1991;  Sperling MR,  and others  1996).  In contrast, the NGPSE 
and MRC Drug Withdrawal  studies have both shown very low incidence 
figures for sudden death.  A recent study has shown that a cohort of post­
surgery  patients  in  long-term  remission  has  a risk  of sudden  death that 
approaches that of the general population. Thus active epilepsy appears to 
pose  a  significant  risk  (Sperling  MR,  and  others  1999;  Nilsson  L  and 
others 1999; Walczak and others 2001).
37Medication
Non-compliance  with  prescribed  antiepileptic  medication  has  been 
implicated  in  the  occurrence  of sudden  death  and  several  patients  have 
been found to have sub-therapeutic serum levels of antiepileptic drugs at 
post  mortem  (Leestma,  and  others  1989;  Vickery  BG  1997).  The 
significance  of drug  levels,  however,  is  arguable  as  patients  may  have 
well-controlled  epilepsy  despite  low  drug  levels  and  vice  versa. 
Conversely, there are reported instances of patients experiencing sudden 
arrhythmic  deaths  possibly  due  to  the  cardiac  side  effects  of 
carbamazepine (Boesen F,  and others  1983) though this is obviously not 
the case in the majority of SUDEP cases.
Neurological status
A  higher  incidence  of  SUDEP  has  been  found  in  patients  with 
neurological  deficits  and  learning  difficulties  (Klenerman,  and  others
1993).  This  may be  attributed to the  severity  of epilepsy that  is usually 
present in these patient groups and the higher all cause mortality generally 
found in such patients.
Alcohol abuse
Alcohol abuse  has also been implicated in  some patients,  (Leestma,  and 
others 1989) as have psychotropic drugs (Tennis, and others 1995).
1.2.4  Other  factors  affecting  the  mortality  rate  in  patients  with 
epilepsy
1.2.4.1  Age at diagnosis
Age has a critical affect on death rate, and it is important to adjust for this, 
such  as  by  using  the  SMR.  Most  studies  have  found  that  the  SMR  is 
highest  in  younger  patients  (Munson  JF  1910;  Kurokawa  T,  and  others
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decline,  in spite of the increased percentage of patients dying at an older 
age, with the lowest  SMR in the over 65  age groups (Hauser,  and others 
1980)  (Zielinski  JJ  1974a).  Epilepsy  in  the  first  year  of life  has  a  high 
mortality because of associated neurological dysfunction in many of these 
patients (Brorson LO and Wranne L  1987; Munson JF  1910; Munson JF 
1910; Chevrie JJ and Aicardi J 2003), so that in older patients the high-risk 
patients have already been selected out. As discussed above, patients in the 
middle years between  15  and  50,  are  most  likely to  suffer  SUDEP,  and 
other  ERD.  Later  the  mortality  due  to  strokes  and  tumours  increases 
(Hauser, and others 1980) (Luhdorf K, and others 1987).
1.2.4.2 Sex
There  are  small  differences  between  the  mortality  rates  for  men  and 
women.  Zielinski found the SMR to be the same until the fourth decade, 
when  men  started  to  have  a  higher  SMR  (Zielinski  JJ  1974a).  Hauser 
found that the SMR of idiopathic epilepsy for men was 2.1 and women 1.6 
(Hauser, and others 1980).
1.2.4.3 Time from diagnosis
This  has  only  been  examined  in  two  studies  (Hauser,  and  others  1980; 
Luhdorf K,  and  others  1987).  The  death  rates  for  the  first  years  after 
diagnosis are far higher than in subsequent years.  In Rochester the  SMR 
was 2.5  in year 0-1  declining to  1.7 in the year after (Hauser,  and others
1980).  The high  SMR in years 25-29  is a function of the small  numbers 
followed up for this length of time, as discussed above in the misuse of the 
SMR.  The high  earlier rates can be accounted for by the poor prognosis 
from lethal causes such as tumours.  All patients in the Danish study with 
cerebral tumours died in the first year (Luhdorf K, and others 1987).
391.2.4.4 Type of epilepsy and type of  seizures
Because of variation in classification of epilepsy and seizures in mortality 
studies,  there  is  sparse  evidence  for  an  effect  of these  variables  on  the 
mortality  rate  of  epilepsy.  There  is  some  evidence  that  patients  with 
idiopathic epilepsy have a lower mortality and that patients with absence 
seizures,  or  partial  seizures  only,  in  the  younger  ages,  do  not  have  an 
increased  risk  of  dying  (Hauser,  and  others  1980).  Patients  with 
generalised  tonic  clonic  seizures  were  found  to  be  an  independent  risk 
factor for SUDEP in one study (Walczak and others 2001).
1.2.4.5  Seizure  frequency
Patients with more frequent seizures might be expected to have a higher 
mortality because of the deleterious effect of the seizures,  increased risks 
of accidents,  and  increased  incidence  of status  epilepticus  as  well  as  an 
association  with  more  lethal  causes  of epilepsy.  However,  this  has  not 
been examined in detail apart from the risk of SUD with respect to seizure 
frequency  already  mentioned.  In  relation  to  this,  Hauser  still  found  a 
higher  SMR  in  patients  in  prolonged  seizure  remission,  and  in  patients 
who had only suffered one seizure (Hauser, and  others  1980), suggesting 
an independent risk of having epilepsy apart from frequent seizures.
401.3  THE DYNAMICS OF THE TREATMENT OF EPILEPSY
The most widely  followed  model  of epilepsy  management  in the United 
Kingdom is one of referral from primary care to hospital clinics followed 
by investigation, treatment and follow-up at primary, secondary or shared 
care levels.  A description of the evolution  of therapy in this model  over 
time  at  a  population  level  should  provide  important  data  for  knowing 
where  to  target  treatment  improvements  and  for the  planning  of health 
care.  In  a  hospital  setting,  the  various  facets  of this  model  are  easily 
studied, but the bias towards more complicated cases is likely to present a 
distorted  picture  (Sander  JWAS  and  Shorvon  SD  1996).  Unselected, 
population based studies provide a more accurate picture of the generality 
of  therapy,  in  a  representative  patient  sample,  although  the  potential 
logistical  difficulties  involved  have  resulted  in  a  considerable  dearth  of 
such  studies  (Sander  JWAS  and  Shorvon  SD  1996).  In  particular there 
have  been  no  previous  prospective,  long-term  studies  of  treatment 
dynamics in a population-based cohort with epilepsy,  although treatment 
characteristics  in  a  community  based  prevalent  population  have  been 
reported on before (Hart YM and Shorvon SD 1995).
Several  questions  remain  unanswered.  How  many  patients  with  newly 
diagnosed epileptic seizures receive treatment and who initiates therapy? 
How  many  patients  change  treatment,  and  when,  in  the  course  of the 
epilepsy? What are the reasons for drug change and which drugs and drug 
combinations  are  used  initially  and  how  often  is  treatment  switched  or 
added? Is there uniformity in the choice of antiepileptic drugs for different 
seizure types? How often were the  newer antiepileptic drugs used by  an 
unselected  population  with  epilepsy?  To  what  extent  were  seizures 
controlled by drug changes in patients with uncontrolled epilepsy?
411.3.1  Medical services for people with epilepsy
1.3.1.1  Government reports about services for people with epilepsy
Between  1953  and  1999  there  were  six  government-sponsored  reports 
assessing  service  provision  for  people  with  epilepsy  and  making 
recommendations about their care.
The  1953  report “National  Assistance Act  1948: Welfare of handicapped 
persons: the special welfare needs of epileptics and spastics” (Ministry of 
Health  1953) evaluated service provision at the local authority level.  The 
Cohen Report (Central Health Services Council  1956) emphasised the role 
of GPs, and the need for them to be regularly updated in epilepsy care, but 
also examined hospital services.  It recommended regional  diagnostic and 
treatment clinics although this was not implemented.
In  1969, the Central Health Services Council published its report “People 
with Epilepsy:  Report of a joint  sub-committee  of the  standing  medical 
advisory committee and the advisory committee on the health and welfare 
of  handicapped  persons”  (The  Reid  Report;  Central  Health  Services 
Council  1969).  This reviewed the existing services and recommended the 
establishment of specialist epilepsy clinics. All patients with epilepsy were 
to be referred for evaluation by a multidisciplinary team at a district level, 
and  a  minority  requiring  more  detailed  investigation  would  go  on  to 
tertiary units with specialist neurological and neurosurgical investigational 
facilities.  The  Reid  Report  envisaged  clinics  on  the  lines  of  diabetic 
clinics, where patients with chronic conditions avoided being followed up 
by inexperienced junior doctors on short-term contracts.
In  1987 the Bennet Report (Kurtz Z and Morgan JD  1987) was completed 
and  evaluated the response to the recommendations  of the  Reid Report. 
Unsurprisingly,  it  found  that  regional  conferences  had  not  responded 
positively:  for  example,  nine  conferences  had  disapproved  of epilepsy 
clinics,  and  three  had  not  indicated  their  views,  whilst  only  four  had
42approved.  Health  authorities  were  similarly  reticent;  23  approved  of 
epilepsy clinics,  31  did  not and 42  abstained  from  comment.  The report 
recognised the inadequacies of existing facilities and the lack of continuity 
of care.  Again,  it recommended the establishment of specialist clinics for 
people with chronic epilepsy.
The Winterton Report (Department of Health and Social Security 1986), in 
contrast to the Reid Report, concluded that patients could be managed by 
neurologists or specialists,  rather than by a multidisciplinary team.  It felt 
that  epilepsy  clinics  should  be  established  for  people  with  intractable 
epilepsy  and  suggested  specialist  pilot  clinics.  They  again  noted  the 
existing  problems  of appointments,  follow-ups  and  the  shortcomings  of 
existing investigational facilities.
The Reid Report suggested the establishment of five or six supra-regional 
centres for patients with disabling epilepsy. Such centres were evaluated in 
the  Bennett  Report  as  being  beneficial  and  were  recommended  by  the 
DHSS Working Group (Department of Health and Social Security 1986).
The DHSS Working Group  1986 also recommended that medical care for 
children  should  be  of the  same  standard  as  for  adults,  with  specialist 
referral  for  evaluation  and  recommendation  of  the  appropriate 
management.  The general  practitioner was to  provide ongoing  care.  The 
consensus of the Welfare Report (Ministry of Health 1953) and the Cohen 
and  Reid  Reports was that there  was  a  need  for  accurate  diagnosis  and 
careful review of children with epilepsy,  and for communication between 
school  medical  services,  teachers  and  general  practitioners.  This  was 
further reiterated in the 1981 Education Act (Education Act 1981).
The Clinical Standards Advisory Group (CSAG)  1999 (Clinical Standards 
Advisory Group 1999), set out to determine the organisation, configuration 
and standards of clinical care for epilepsy in the UK.  This used evidence 
from a variety of published sources,  professional  and lay experts,  as well 
as data from primary research with service providers and users.  It looked
43at patient as well as clinician, perspectives and identified the special needs 
of children and adolescents,  women of reproductive age,  the elderly,  and 
people with learning disability.  Various recommendations were made,  as 
in  previous reports.  In  addition,  the  setting  up  of a network of Epilepsy 
Centres was recommended that would support primary care for epilepsy in 
the  local  population  and  provide  comprehensive  secondary  care  of 
epilepsy.  The special  care of specific groups such as children, women of 
reproductive age, the elderly and people with learning disability was made. 
The  setting  up  of  Regional  Epilepsy  Implementation  Groups  was 
recommended to develop care standards at regional levels.
A further report in 2002, The National Sentinel Clinical Audit of Epilepsy- 
Related Death  (Hanna NJ et  al  2002)  investigated the pathology behind 
sudden deaths in epilepsy along with primary and secondary care prior to 
death.  During  the  study  period,  there  were  2412  deaths  reported  with 
epilepsy  somewhere  on  the  death  certificate.  1023  were  subjected  to 
autopsy  and  the  audit  examined  43%  of these  autopsies.  A  further  156 
deaths not  subjected to  post mortem were  also  studied.  In  812,  epilepsy 
was  identified  as  the  primary  cause  of  death.  Access  to  appropriate 
specialist  care,  record  keeping,  provision  of support  and  the  sharing  of 
information  regarding  the  hazards  of epilepsy,  drug  treatments  and  the 
importance  of  adherence  to  drug  regimens  were  all  identified  as 
inadequate.  A  large  proportion  of  deaths  (39%  of adults  and  59%  of 
children)  were  found  to  have  been  potentially  preventable  and 
recommendations were made at both primary  as well  as  secondary  level 
care to improve the existing quality of service provision.
1.3.1.2  Problems associated with studies
1.3.1.2.1  Selection bias and case ascertainment in studies of medical care 
for people with epilepsy.
As  with  many  population  studies,  selection  bias  is  a  potential  hazard. 
Patients  at  opposite  ends  of the  spectrum  of severity  often  encountered
44with the epilepsies will have different degrees of social problems and will 
require varying levels of input from healthcare facilities.
There  is  tremendous  variability  in  surveys;  some  have  included  people 
who  have  had  single  seizures  whilst  others  have  concentrated  on  those 
with “active” epilepsy. This is usually defined as those having had at least 
one seizure in the past two years, with more than one afebrile seizure ever, 
and those taking antiepileptic drugs.
Disease registers are a relatively new phenomenon in many practices and 
those that exist may be inaccurate. Mant and Tulloch (Mant D and Tulloch 
A  1987)  showed  that  only  56%  of patients  with  chronic  diseases  were 
recorded. Thus, many studies have surveyed patients presenting for repeat 
prescriptions  of antiepileptic  medication.  Nevertheless,  this  method  has 
drawbacks because many patients with epilepsy will not be on medication 
for  various  reasons.  Goodridge  and  Shorvon  (Goodridge  and  Shorvon 
1983b)  in  their  general  practice  study  found  that  44%  of patients  with 
active epilepsy were not taking antiepileptic drugs, and Zielinski (Zielinski 
JJ 1974b) found that almost one quarter of patients with epilepsy known to 
specialist facilities and two thirds of those identified during a field survey 
were on no medication.  Although not all had active epilepsy,  more than 
one  third  of those  identified  form  the  field  survey  had  never  received 
medication. This group may be less severely afflicted by their epilepsy. On 
the other hand, it might include patients who have failed to derive benefit 
from medical care, and those who have recently ceased medication but are 
still at significant risk of seizures.  Nevertheless, unless a well maintained 
disease  register  is  available,  identifying  patients  with  epilepsy  through 
AED prescriptions may be the only means possible, short of extensive case 
records scrutiny.  The latter method is labour-intensive and not practicable 
for  large-scale  surveys;  it  would  itself  be  liable  to  bias,  such  as 
participating GPs having a particular interest in epilepsy.
Information about medical  services for people with epilepsy  needs to be 
obtained from a community base,  since only a small proportion of people
45with  epilepsy  attend  hospital  for  long-term  follow-up  (Lloyd  Jones  A 
1980; Goodridge and Shorvon 1983b; Taylor MP  1987). Some small scale 
audits of care within the community have been performed (Lloyd Jones A 
1980;  Goodman  I  1983;  Taylor  MP  1987),  but  information  is  required 
from  throughout  the  country  to  take  into  account  such  variables  as  the 
availability  of resources,  difference  in  numbers  of neurologists  and  the 
lengths  of outpatient  waiting  lists.  Various  studies  have  done  this  with 
varying success. The Research Committee of the Royal College of General 
Practitioners  (Crombie  DL,  and  others  1960)  collected  details  from  67 
practices  in England  and  Wales,  and  Cooper and  Huitson’s (Cooper GL 
and  Huitson  A  1986)  study  involved  30  practices  throughout  the  UK. 
There have been no recent large scale studies addressing these issues.
Most  surveys during the past 30 years have dealt only with people with 
active  epilepsy;  some  have  included  only  those  taking  anticonvulsant 
drugs.  The  prevalence  varies  from  2.3/1000  for  people  with  epilepsy 
undergoing  treatment  in  one  practice  (Munson  JF  1910;  White  PT  and 
Buckley  EG  1981),  to  10.5/1000  with  active  epilepsy  and/or  taking 
medication in another (Goodridge and Shorvon  1983b), where cases were 
identified  by  scrutiny  of case  records.  The  prevalence  in  most  studies 
ranges from 3.4-6.1/1000, regardless of method.
1.3.1.2.2  Accuracy of information
Assessing epilepsy severity on a community basis is similarly fraught with 
difficulty. As has been discussed, the frequency and intensity of a patient’s 
seizures have considerable bearing on the requirement of medical services. 
Knowledge  of seizure  frequency  and  classification  is  thus  important  in 
assessing optimum management, but this is often difficult to obtain even in 
a hospital setting. Patients’ seizure disorders can render seizure counts and 
accounts  inaccurate  since  alteration  of consciousness  is  often  integral to 
these. Patient literacy and communication problems are further obstacles. 
Finally,  on  a  practical  note,  where  surveys  are  undertaken  by  patient 
questionnaire,  respondents  may  be  unwilling  to  report  aspects  of care
46about which they  are unhappy  if they  suspect the  questionnaire  may be 
seen  by  those  involved  in  their  care.  A  number  of studies  have  been 
undertaken.  With  the  exception  of Zander  et  al  (Zander  LI,  and  others 
1979),  there  is  considerable  agreement  about  the  deficits  in  the  care  of 
people with epilepsy.
1.3.1.2.3  Severity of epilepsy and the control of  seizures
As above, the situation is often complex:  Taylor (Taylor MP  1987) found 
that  many  patients  only  reported  tonic  clonic  convulsions  when  asked 
about  attacks.  The  proportion  of  patients  with  partial  seizures  varies 
between  studies,  the  issue  being  complicated  by  the  use  of  different 
classifications, with stated values between 18% and 61%. Different criteria 
for  assessing  seizure  frequency  also  make  comparison  between  studies 
difficult.
Lloyd Jones (1980) found that 71% of patients taking antiepileptic drugs 
had less than 3 seizures per year, and Cooper and Huitson (Cooper GL and 
Huitson  A  1986)  reported  that  68%  had  less  than  one  seizure  in  three 
months.  Taylor (Taylor MP  1987)  found that  33%  of patients had  more 
than 3 fits per year (all of these having complex partial seizures) and in the 
study of Hopkins and Scambler (Hopkins and Scambler G  1977), 66% of 
patients with partial seizures and 27% of those classified as having grand 
mal attacks had had seizures in the past 2 months.
A less optimistic view of the likelihood of seizure control  in  epilepsy  is 
seen in studies in which only cases of active or treated epilepsy have been 
included.  The  proportion  of patients  seizure-free  for  1   year ranges  from 
30%  in  a  study  in  which  patients  were  identified  as  they  presented  for 
repeat prescription (McCluggage JR, and others  1984), to 76% of those in 
a group with “active” epilepsy (Zander LI, and others  1979). Most studies 
suggest values of around 40%; e.g. 42% of patients with treated or active 
epilepsy in the  study of the research  committee of the Royal  College of 
General  Practitioners  (Crombie  DL,  and  others  1960),  41%  of Taylor’s
471987  study  (Taylor MP  1987),  and  42%  in  White  and  Buckley’s  study 
(White PT and Buckley EG 1981). In the three studies quoting figures for 
patients  having  more than one  seizure per  month  (Lloyd  Jones  A  1980; 
Cooper GL and Huitson A 1986; Taylor MP  1987) 18-20% of patients fell 
into this category.
1.3.1.2.4  Hospital referrals and consultation rates
The  DHSS  report  (Department  of  Health  and  Social  Security  1986) 
recommended  that  people with  new  onset  seizures  should  be  seen  by  a 
hospital  doctor  for  initial  evaluation  and  treatment.  Follow-up  for  the 
majority in whom seizures are easily controlled should then devolve to the 
GP.  Patients with intractable epilepsy  should continue to be followed up 
by a specialist, preferably in an epilepsy clinic.
Most studies suggest that the figure for patients ever attending a hospital 
for their seizures is around 90% (Hopkins and  Scambler G  1977; Zander 
LI, and others 1979; Lloyd Jones A 1980; Munson JF 1910; White PT and 
Buckley  EG  1981)  (Taylor  MP  1987),  although  some  are  seen  by 
consultants  other than  neurologists  or  paediatricians  (Munson  JF  1910; 
White PT  and  Buckley EG  1981)  (Goodridge  and  Shorvon  1983b).  The 
percentage under continued follow-up is much smaller, ranging from  10% 
of patients who have ever had a seizure in Goodridge and Shorvon’s study 
(1983) to 58% in practice A of White and Buckley’s study (1981), but was 
around  10-30% in most surveys (Hopkins and  Scambler G  1977; Zander 
LI, and others 1979; Lloyd Jones A 1980) (Taylor MP 1987).
The CSAG study found that 81% of respondents with controlled epilepsy 
had not seen their GP in the past year; 30% with new onset epilepsy and 
35% with established epilepsy had not done so either (Clinical  Standards 
Advisory Group  1999).  Patients tended to  make  contact only when they 
deemed it necessary because of problems that may have arisen. Only 30% 
had attended hospital in the last 12 months. Attendance appeared linked to
48severity; 57% with severe epilepsy had attended as opposed to  16% with 
mild epilepsy.
Several studies have found that most patients had seen a doctor within the 
last  year  (85%  in  the  study  of Hopkins  ands  Scambler  (Hopkins  and 
Scambler  G  1977),  and  92%  in  Taylor’s  study  (Taylor  MP  1987). 
However, there was considerable variation. In Lloyd Jones’  study in  1980 
(Lloyd  Jones  A  1980),  60%  of patients  had  not  seen  a  doctor  in  the 
preceding year,  and 9% had apparently  not seen a doctor to discuss their 
seizures during the past 10 years. Nine out of 17 patients having problems 
with  fit  control  or  antiepileptic  medication  were  not  being  followed  up 
regularly by any doctor. 25% of patients in the study by McCluggage et al 
had  not  seen  a  doctor  for  more  than  1   year  and  50%  of these  were 
continuing to have seizures (McCluggage JR,  and others  1984).  Hopkins 
and  Scambler  also  reported  little  correlation  between  the  severity  of 
epilepsy and the frequency of follow-up (Hopkins and Scambler G 1977).
1.3.1.2.5  Patterns of  follow-up in patients with epilepsy
Several  investigators  have  commented  on  the  quality  of  follow-up 
amongst  patients  with  epilepsy.  Hopkins  and  Scambler  (Hopkins  and 
Scambler G 1977) noted that in small units the patient would usually see 
the  consultant,  whereas  in  large  units  this  would  be  unlikely,  and 
Goodman (Goodman I  1983) commented that “...  most of the follow-up 
was performed by junior hospital doctors.”
1.3.1.2.6 Medication
In the last 15 years, there has been a huge change in the manner and range 
of prescribing  in the United Kingdom.  Thus data from  older studies has 
less relevance today. In McCluggage’s study (McCluggage JR, and others 
1984), 59% of patients had been treated for epilepsy for 10 years or more
49and 30% for 20 years or more, and in White and Buckley’s study 73% had 
been treated for epilepsy for at least  5  years (White PT and Buckley EG
1981).  Most studies quote phenobarbital  and phenytoin as being the two 
most  widely  prescribed  drugs,  either  alone  or  in  combination  (Crombie 
DL,  and  others  1960;  Taylor  MP  1987),  with  80-90%  of  those  on 
medication taking these drugs in several studies (Hopkins and Scambler G 
1977;  Goodridge and  Shorvon  1983b;  Cooper GL  and Huitson  A  1986; 
Taylor MP 1987).
The proportion  of patients taking medication who were on monotherapy 
ranged from 33% in Goodman’s study (1983) to 68% in that of Goodridge 
and  Shorvon (1983), with the proportion on three or more drugs ranging 
from  2-14%.  With  the  exception  of Taylor’s  studies  (Taylor MP  1983; 
Taylor MP  1980; Taylor MP  1987) in which an active effort was made to 
decrease  polytherapy,  there  was  little  evidence  of  monotherapy  being 
commoner  in  the  most  recent  surveys.  This  is  despite  the  finding  by 
Shorvon et al (1979) that 76-88% of newly diagnosed, untreated patients 
can  be  completely  controlled  with  a  single  drug  (phenytoin  or 
carbamazepine) (Shorvon and Reynolds 1977).
1.3.2  Treatment of the first seizure
1.3.2.1  Drug treatment of the first seizure
Treatment  of  the  first  seizure  and  its  influence  on  recurrence  is  a 
controversial  issue.  In  the  UK,  current  guidelines  suggest  initiation  of 
treatment in first seizures in specific situations. These include patients with 
congenital neurological deficits, patients with brain imaging abnormalities, 
patients  with  unequivocal  epileptiform  discharges  and  patients  with 
previously unrecognised  absences,  myoclonic jerks  or partial  seizures as 
the  risk  of seizure  recurrence  is  high  in  these  groups  (NICE  guidelines 
2004;  SIGN  guidelines  2003).  These  guidelines  also  include 
recommendations for commencing treatment in first seizure patients who 
deem the risk of subsequent  seizures to be unacceptable.  Approximately 
70% of first seizure patients in the USA are given drug treatment (Hauser,
50and others  1982); the corresponding figure in the UK is largely unknown. 
An inherent bias in most studies examining this has been the tendency for 
the physician to prescribe antiepileptic medication to patients they deem to 
be at risk of recurrence.  (Annegers,  and  others  1986;  Hauser,  and others 
1982; Hopkins,  and others  1988) Two randomised,  controlled trials have 
suggested that there is a significant reduction in the risk of recurrence in 
patients treated after the first seizure (Musicco, and others 1997; Camfield 
P,  and  others  1989)  although  one  study  included  only  31  patients 
(Camfield P,  and  others  1989)  and  the  other  included  only  tonic  clonic 
seizures  (Musicco,  and  others  1997).  Undoubtedly,  further  trials  are 
needed to clarify the influence of treatment in preventing recurrences.  An 
MRC study group (MESS -  The Multi-centre Study of Early Epilepsy and 
Single  Seizures)  is currently  carrying  out  a controlled trial,  randomising 
patients  with  seizures  at  the  time  of  a  first  epileptic  attack  to  either 
treatment or delayed treatment. It is hoped that the results of this study will 
shed light on the role of treatment in the long-term prognosis of epilepsy. 
This  study  randomised  1443  patients  to  immediate  therapy  or  deferred 
therapy  and  the  outcomes  to  be  examined  will  be  both  the  short-term 
prevention  of seizures  and  the  proportion  of patients  in  the  two  groups 
achieving long-term remission.
1.3.3  Treatment of epilepsy with conventional antiepileptic drugs
Drugs such as carbamazepine, phenytoin, valproate and phenobarbital are 
loosely  grouped  under  the  rubric  of “conventional”  AEDs,  largely  by 
virtue of their long-established  presence  and efficacy  in the antiepileptic 
armamentarium.  They  are  licensed  for  use  as  monotherapy  and  where 
indicated  also  serve as  effective  adjunctive therapy  for about half of all 
patients with  seizures  not controlled  by a  single  drug.  Over the last few 
decades, carbamazepine and valproate have established themselves as first 
line therapy  for partial  and generalised  seizures  respectively whereas  an 
unfavourable pharmaco-kinetic  and  adverse  event  profile  has  resulted  in 
the relegation of phenytoin to a more secondary role (Table I).
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phenytoin or phenobarbital, either singly or in combination (Crombie DL, 
and others  1960; Taylor MP  1987). In several studies,  80-90% of patients 
taking medication were  on these  drugs  (Hopkins  and  Scambler G  1977; 
Goodridge and Shorvon  1983b).  Phenobarbital,  due to its sedative effects 
and  its propensity to  cause behavioural  disturbances  in  children,  is  now 
rarely prescribed as a first line drug for any type of seizure.  Both drugs, 
however, have a prominent role as parenteral therapy for status epilepticus.
TABLE I. Choice of Antiepileptic Drugs
First-line  Second-line
Generalized epilepsy 
Idiopathic
Simple absence  VPA  ESM, LTG, BZPs
Juvenile myoclonic  VPA  LTG, TPM
Tonic clonic  VPA  LTG, TPM, LVT, CBZ,
PHB, PHT
Symptomatic
Partial epilepsy  CBZ, VPA  LTG, GBP, TPM, LVT,
OXC, TGB, VGB
Generalised epilepsy  VPA, CBZ  LTG, TPM, LVT, OXC,
VGB
Unclassified epilepsy  VPA, CBZ  LTG, GBP, TPM, LVT,
TGB, OXC, VGB
Note:  VPA,  sodium  valproate;  CBZ,  carbamazepine;  OXC,  oxcarbazepine;  PHT, 
phenytoin;  PHB,  phenobarbital;  ESM,  ethosuximide;  BZPs,  benzodiazepines;  LTG, 
lamotrigine,  GBP,  gabapentin;  TPM,  topiramate;  LVT,  levetiracetam;  VGB, vigabatrin 
(used only as a last resort); TGB, tiagabine
1.3.3.1  Treatment with carbamazepine
Carbamazepine is the first choice drug for partial  seizures with or without 
secondary generalisation. It may also be used in the tonic-clonic variety of
52idiopathic  generalised  epilepsy  in  which  valproate  is  ineffective  or 
contraindicated. However,  it is contraindicated in absence and myoclonic 
seizures,  both of which may be  aggravated by  its use  and  it is therefore 
important to  exclude the presence of these  seizure types in patients who 
have primary generalised epilepsy. It can also be used in various childhood 
epilepsy syndromes.
Most of the common adverse events with carbamazepine therapy are CNS 
related.  These  consist  of drowsiness,  unsteadiness,  dizziness  and  visual 
disturbances.  Cognitive dysfunction  is not uncommon although this  may 
be less frequent than with phenytoin or phenobarbital.  Skin reactions are 
also frequently seen and may be life threatening in a minority. Fulminant 
liver failure has been reported although minor elevations in liver enzymes 
are much more common due to enzyme induction.
1.3  .3 .2 Treatment with sodium valproate
Valproate is the drug of choice for primary generalised epilepsy, including 
absence  and  myoclonic  seizures.  It  is  also  effective  therapy  in  partial 
seizures and has a wide spectrum of activity.
CNS-related adverse events such as sedation and cognitive dysfunction are 
uncommon  but  may  occur.  Small  elevations  in  ammonia  levels  maybe 
seen  quite  frequently  in  normal  individuals  however  but  symptomatic 
hyperammonemia  is  rare.  Hepatotoxicity,  although  a  well  publicised 
adverse event, is uncommon and occurs in less than 1   in 37000 patients on 
monotherapy.  However,  in  children  with  neurological  handicaps  on 
polytherapy under the age of 2 years, the incidence may be nearer 1  in 500.
More  common  and  less  serious  adverse  events  are weight gain,  postural 
tremor,  hair  loss  and  gastrointestinal  upsets.  There  have  been  recent 
reports  of polycystic  ovarian  disease  due  to  valproate  therapy  and  this 
should be mentioned to young female patients before initiating therapy.
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many other antiepileptic drugs. This includes neural tube defects and more 
uncommonly, the foetal valproate syndrome. There is some suggestion that 
valproate  exposure  in  utero  may  affect  neuropsychological  outcomes  in 
offspring  although  this  has  not  been  ascertained  in  a  prospective, 
controlled fashion.
1.3.3.3 Treatment with phenytoin
Phenytoin  is  effective  in  a wide  variety  of seizure types  and  syndromes 
although its adverse event profile has resulted in it mainly being used as 
second  line  or adjunctive therapy where  carbamazepine  or valproate  are 
ineffective  or  have  caused treatment  limiting  side  effects.  In  convulsive 
status epilepticus, however, it is still considered a drug of first choice. Like 
carbamazepine,  it has no role in the treatment of absence and myoclonic 
seizures.
PHT has both acute as well  as chronic side effects.  The former are often 
dose  related  and  usually  occur  above  the  therapeutic  range  of  10- 
30mcg/ml.  Nystagmus  and  ataxia  occur  at  levels  above  30mcg/ml, 
drowsiness  and  dysarthria  between  30-40mcg/ml  and  stupor  at  levels 
above  40-60mcg/ml.  Also  common  as  early  side  effects  are 
hypersensitivity  reactions  such  as  rash,  fever,  lymphadenopathy,  blood 
dyscrasias  and  renal  failure.  Several  chronic  side  effects  have  also  been 
described, gum hyperplasia probably being the best known of these. Folate 
deficiency  megaloblastic  anemia  is  also  occasionally  seen,  as  is 
osteomalacia.  Other  side  effects  include hirsutism,  facial  coarsening  and 
pigmentation, and acne. Teratogenicity can occur with phenytoin therapy.
1.3 .3 .4 Treatment with phenobarbital
Phenobarbital  was  commonly  used  as  first  line  therapy  for  a  variety  of 
partial  and generalised  seizures as well  as  many  neonatal  and  childhood
54seizure disorders.  Its role in the long-term treatment of the epilepsies has 
now become somewhat limited in developed countries due to the advent of 
equally  or  more  efficacious  drugs  with  better  adverse  event  profiles, 
although  it  remains  a  cheap  and  effective  therapy  in  many  developing 
countries. In the treatment of status epilepticus, however, it still occupies a 
prominent position in parenteral form and is used as a drug of first choice 
by many specialists in this situation.
The side effects that have primarily been responsible for the decline in its 
use  are  impaired  cognition  and  behavioural  problems,  particularly  in 
children.  Drowsiness  and  sedation  are  most  often  dose-related,  although 
habituation  with  continued  therapy  can  occur  in  some  patients.  Higher 
doses can have prominent depressive effects on the CNS and phenobarbital 
overdoses can be fatal without prompt remedial action. Hyperactivity and 
irritability can be especially irksome in children.  Other acute side effects 
such  as  ocular  and  gait  disturbances  may  also  occur  although  non-dose 
related  hypersensitivity  reactions  such  as  skin  rashes  and  hepatitis  are 
uncommon. Like phenytoin, it can also cause folate deficiency anemia and 
osteomalacia.
1.3.3.5  Treatment with ethosuximide
Ethosuximide is primarily used as therapy in absence epilepsy although it 
can  also  be  used  as  sole  or  adjunctive  therapy  in  juvenile  myoclonic 
epilepsy  where  valproate  has  been  ineffective  or  is  contraindicated.  A 
related compound,  methsuximide has similar indications for use although 
it can also be used as adjunctive therapy in partial seizures.
Gastrointestinal adverse events are common with ethosuximide and consist 
mainly of nausea, abdominal discomfort and hiccups.  These uncommonly 
culminate in termination of therapy.  Sedation may be observed at higher 
doses  although  it  has  a  minimum  of  cognitive  side  effects. 
Neuropsychiatric  disturbances  such  as  anxiety,  depression  and  acute 
psychosis  have  also  been  described.  Skin  reactions  such  as  rashes  and
55erythema  multiforme  have  been  noted  to  be  common  occurrences. 
Potentially  fatal  adverse  events  such  as  Steven Johnson’s  syndrome  and 
blood dyscrasias have also been reported.
1.3  .4 Treatment with new antiepileptic drugs
Several  new  AEDs  are  now  available  for  the  treatment  of  refractory 
epilepsy.  Apart from  lamotrigine  and topiramate,  which  are  licensed  for 
use  as  monotherapy,  all the others  are used  as  adjunctive therapy in the 
treatment of partial seizures with or without secondary generalisation. New 
drugs however,  produce long-term seizure remission in less than  15% of 
patients  with  chronic  epilepsy  and  less  than  a  third  of  such  patients 
continue with new drugs such as lamotrigine, topiramate, gabapentin and 
levetiracetam beyond 5  years despite lack of seizure remission (Krakow, 
and others 2001; Lhatoo, and others 2000)
An overriding worry about the new AEDs has been the possibility of the 
occurrence of long-term side effects. A considerably longer study period is 
required  than  those  currently  utilised  in  clinical  trials,  to  allow  the 
discovery  of uncommon  though  serious  side  effects.  Fulminant  hepatic 
failure  and  aplastic  anemia  were  found  to  be  potentially  fatal  adverse 
events  due  to  felbamate  therapy  long  after  it  was  approved  for  use  in 
patients with epilepsy.  Similarly,  the discovery  of serious  impairment of 
vision due to visual field defects with vigabatrin therapy has considerably 
restricted its use and is now only prescribed when absolutely necessary. In 
addition,  clinical  trials  do  not recruit  elderly  and  very young  patients  or 
female patients on inadequate contraception; thus inadequate information 
exists for whole sections of the patient population.
At  the  current  time,  topiramate,  levetiracetam,  gabapentin,  vigabatrin, 
tiagabine, and lamotrigine are available for use as adjunctive therapy in the 
treatment of partial epilepsy with or without secondary generalisation, the 
latter also for use in primary generalised epilepsy and as monotherapy.
561.3.4.1 Gabapentin
Gabapentin is a mild to moderate efficacy antiepileptic drug useful as add­
on treatment of refractory partial seizures. Clinical trials showed that 22% 
of patients with partial seizures will experience at least a 50% reduction in 
seizure frequency.  Gabapentin is not effective for treatment of idiopathic 
generalized  epilepsy.  As  with  standard  antiepileptic  drugs,  secondarily 
generalized  tonic-clonic  seizures  may  respond  better  than  simple  or 
complex partial  seizures.  The  side effects of gabapentin are usually mild 
and  include  diplopia,  ataxia,  fatigue,  and  headache.  Male rats  developed 
acinar  pancreatic  tumors  in  a  dose-related  fashion,  and  gabapentin  has 
therefore been  termed  a potential  human  carcinogen  with  an  acceptable 
low risk.  An advantage of Gabapentin is its lack of interaction with other 
drugs,  which makes plasma drug monitoring unnecessary.  It is however, 
known to cause seizure exacerbation in some cases and is not particularly 
effective in patients with severe epilepsy.
1.3.4.2  Lamotrigine
Lamotrigine can be  effective as monotherapy in  newly diagnosed partial 
seizures and generalized tonic-clonic seizures,  and as add-on treatment of 
refractory  partial  seizures.  Clinical  trials  showed  a  reduction  of at  least 
50% in about 24% of patients, with up to 5% of patients becoming seizure- 
free  at  doses  of  100-300  mg/day.  Lamotrigine  is  of mild  to  moderate 
efficacy  as  add-on  treatment  of  refractory  generalized  epilepsy  with 
atypical absences, atonic seizures, and myoclonic seizures. Lamotrigine is 
a  triazine  derivative  and,  like  phenytoin  or  carbamazepine,  causes  an 
extended  inactivation  of  neuronal  membrane  sodium  channels,  thus 
inhibiting repetitive discharges in  experimental  models.  The pathological 
release of glutamate,  a major excitatory neurotransmitter in human brain, 
is also blocked.  The elimination of lamotrigine is accelerated by enzyme- 
inducing  antiepileptic  drugs,  such  as  carbamazepine,  phenytoin,  and 
phenobarbital,  and  inhibited  by  valproate.  Even  in  monotherapy,  the 
initiation of lamotrigine therapy should be at a very low dose (25 mg/day)
57to avoid the development of a rash in  up to  5% of patients,  particularly 
younger age groups and those on concurrent valproate.  The rash may be 
severe,  amounting  in  some  cases to  a  Stevens-Johnson  syndrome.  Other 
side effects include sedation,  dizziness,  diplopia,  and ataxia but generally 
the drug is well tolerated.
1.3.4.3 Levetiracetam
Levetiracetam  is  the  most  recently  marketed  anti epileptic  drug,  a 
pyrrolidone derivative whose mode of action remains unknown (Shorvon 
SD 2000). It is well tolerated and the most frequent central nervous system 
adverse  events  in  trials  were  dizziness,  asthenia  and  somnolence.  An 
increased frequency of upper respiratory tract “infections4 4  were noted but 
these were  not treatment  limiting.  Placebo  controlled  trials  in  refractory 
partial  epilepsy  have  shown  50%  seizure  reduction  in  up  to  33%  on 
lOOOmg  and  40%  on  3000mg  compared  to  11%  in the  placebo  groups. 
There  are  no  formal  trials  examining  its  usefulness  in  the  primary 
generalised  epilepsies  although  it  has  been  shown  to  be  effective  in 
eliminating  photoparoxysmal  responses  on  EEG,  and  has  been 
successfully used in juvenile myoclonic epilepsy and myoclonic jerks. It is 
useful in the treatment of refractory epilepsy.
1.3.4.4 Oxcarbazepine
Oxcarbazepine was developed as a structural variant of carbamazepine. It 
is  a  pro-drug,  as  its  10-hydroxymetabolite  is  responsible  for  the 
antiepileptic effect. When compared to carbamazepine, oxcarbazepine has 
shown similar efficacy as an add-on drug for refractory partial seizures and 
as a first-line agent in previously untreated patients with tonic-clonic and 
partial  seizures.  Common  side  effects  include  drowsiness,  dizziness, 
ataxia,  headache,  and  hyponatremia.  The  hyponatremia  is  more  marked 
than with carbamazepine and occasionally leads to confusion and increase 
of seizures.  Other side effects include rashes,  diarrhea,  nausea,  vomiting, 
and anorexia.  The enzyme-inducing activity of oxcarbazepine is probably
58limited  to  the  P450  Ilia  isoenzyme  of the  cytochrome  P450  complex; 
nevertheless, interactions occur, for instance with oral contraceptives.
1.3.4.5 Tiagabine
Tiagabine is another new drug with mild to moderate efficacy in  seizure 
control. Its proposed mechanism of action is by inhibiting glial cell GABA 
reuptake. It is used as adjunctive therapy in partial seizures with or without 
secondary generalisation. Results from controlled trials have shown that up 
to one third  of patients on tiagabine achieve a  50% reduction in  seizure 
frequency,  although  complete  remission  from  seizures  is  an  infrequent 
occurrence.  The commonest adverse events related to therapy are central 
nervous system related and consist of sedation,  tremor,  headache,  mental 
slowing,  tiredness  and  dizziness.  Confusion,  irritability  and  depression 
may occur. Increases in seizure frequency and episodes of non-convulsive 
status  have  also  been  reported.  So  far,  no  life-threatening  idiosyncratic 
reactions  have been encountered.  Use in pregnancy  is not recommended 
although no teratogenicity has been reported in humans.
1.3.4.6 Topiramate
Topiramate  is  a  sulfamate-substituted  D-fructose,  a  naturally  occurring 
monosaccharide. Its antiepileptic action was discovered during a search for 
antidiabetic  drugs.  It  has  a  variety  of mechanisms  of action,  the  major 
being  its  effect  on  the  voltage-dependent  Na  channels  in  the  neuronal 
membrane.  It affects glutaminergic (via the AMP A receptor) and GABA- 
ergic  (at  the  GABA  receptor)  transmission.  The  drug  also  has  carbonic 
anhydrase  action.  Animal  experimentation  showed  topiramate  to  be 
effective against a wide variety of experimental epilepsy models,  and the 
experimental  profile  suggests  a  wide  spectrum  of  activity  in  human 
epilepsy.  Animal toxicology showed  only  mild effects,  but the drug was 
shown  to  have  teratogenicity  at  high  doses.  The  drug  has  excellent 
pharmacokinetic  properties  and  there  are  no  active  metabolites.  In
59randomized  clinical  trials,  topiramate  has  been  shown  to  be  effective 
against partial and secondarily generalized seizures. Topiramate can cause 
predominately neurological side effects, particularly at high dosage and if 
titrated  too  fast.  These  adverse  effects  include  headache,  sedation, 
asthenia,  and  confusion.  Loss  of weight  is  common,  and  the  drug  also 
causes  renal  stones  in  less  than  2%  of patients.  There  are  no  serious 
recorded idiosyncratic reactions, and there is no hematological toxicity. To 
lessen the  incidence  of treatment limiting  side  effects,  drug  intitiation at 
low doses and slow upward titration is necessary.
1.3.4.7  Vigabatrin
Vigabatrin is effective as add-on treatment of refractory partial seizures. In 
clinical  trials,  the  addition  of 1-3  g/day  led  in  about  46%  of cases to  a 
reduction  of at  least  50%,  with  5%  of patients  becoming  seizure-free. 
Vigabatrin is not effective in patients with idiopathic generalized epilepsy. 
The antiepileptic effect of vigabatrin is due to the irreversible inhibition of 
GABA-transaminase that leads to a permanent severalfold rise in GABA, 
the major inhibitory neurotransmitter in human brain.  The most common 
side  effects  are  transient  drowsiness  and  weight  gain,  which  may  be 
unacceptable  in  some  patients,  and  less  often,  depression  and  manic- 
depressive  disorder,  confusion,  and  psychotic  episodes.  Recent,  well 
documented  descriptions  of visual  field  defects  in patients  on  long-term 
therapy  with  the  drug  have  drastically  limited  its  use.  The  visual  field 
defects,  which  may  be  asymptomatic,  may  occur  in  upto  half  of  all 
patients,  and  are  thought  to  be  as  a  result  of GABA  mediated  retinal 
toxicity.  It  can  lead to blindness  and  when  vigabatrin  is used,  therefore, 
visual fields need to be carefully monitored. Rare cases of encephalopathy 
with stupor and an increase in seizures have been reported.
1.3  .5 Duotherapy in newly diagnosed epilepsy
Therapy with more than one drug for newly diagnosed epilepsy has been 
recommended  in  the  past  (Yahr  MD,  and  others  1952),  and  until  two
60decades ago, this was common practice.  The lack of evidence supporting 
this has been pointed out (Shorvon,  and others  1978) and it is no longer 
considered acceptable or safe practice to consider this.  Whilst there is no 
convincing basis to support the hypothesis that drugs with differing modes 
of action are likely to have synergistic actions in epilepsy treatment,  it is 
difficult to endorse duotherapy.  It is no longer common practice and it is 
unusual in newly diagnosed epilepsy.
1.3  .6 Treatment changes in epilepsy
There are no studies which have longitudinally assessed treatment changes 
in the community treatment of epilepsy. We know that 70-80% of patients 
with epilepsy achieve long term remission from seizures, usually with one 
antiepileptic drug and a further 10-15% may be able to achieve long term 
remission with two or more drugs (Sander JWAS  1993). In the remaining, 
seizure  control  is  difficult  and  requires  the  addition  or  replacement  of 
drugs  with  each  new  antiepileptic  drug  in  turn  in  the  hope  of attaining 
seizure  remission.  A  proportion  of  patients  (0.33-1.33%)  with  newly 
diagnosed epilepsy are said to eventually require epilepsy surgery for the 
treatment of refractory epilepsy (Engel  1996).
In the work of Kwan et al,  where the  study population consisted  of 525 
patients with newly diagnosed epilepsy, 92% of whom were referred to the 
epilepsy clinic by general practitioners, 470 patients had never previously 
received  treatment  for  seizures.  In  222  of 470  patients  (47%),  seizure 
control was achieved with the first drug, whereas with drug changes, only 
13%  and  4%  became  seizure  free  with  the  second  and  third  (or  more) 
drugs respectively.  This suggested that failure to respond to the first drug 
was a good predictor of subsequently refractory epilepsy. If the initial drug 
change was  because of lack of efficacy  rather than  side  effects,  a  much 
smaller  percentage  of patients  became  seizure  free  (11%  compared  to 
41%).  (Kwan  and  Brodie  2000)  This  is  a  hospital-based  study  in  most 
respects and patient enrolment took place between 1984 and 1997.
61622.  METHODS
2.1 The United Kingdom General Practice Study of Epilepsy
The NGPSE began by identifying 1200 patients newly diagnosed by their 
general  practitioners  as  having  epilepsy.  Diagnosis  was  confirmed  by 
means of an expert panel after a period of time (6 months) that sufficiently 
allowed for any change or evolution of the initial diagnosis, and the cohort 
was then monitored in a prospective manner by means of yearly follow-up 
questionnaires.
The initial aims of the study were to assess the demographics of the cohort 
with  confirmed  epilepsy  and  make  observations  of  the  clinical 
phenomenology of their seizures, to follow up this cohort prospectively to 
assess  the  risk  of recurrence  following  the  first  seizure,  and  finally  to 
assess the  prognosis of epilepsy,  including  remission  from  seizures and 
the mortality of epilepsy.
2.1.1 Ethical considerations
The Joint Ethics Committee of the Institute of Neurology and the National 
Hospital  for  Neurology  and  Neurosurgery  at  Queen  Square,  London 
approved  the  study.  The  Research  Committee  of the  Royal  College  of 
General  Practitioners  recommended  participation  to  its  members.  Strict 
confidentiality  was  maintained  at  all  times,  in  keeping  with  the  Data 
Protection Act and all patients were assigned code numbers.  The study is 
registered with the Office of National Statistics and the Office of the Data 
Protection Registrar.
2.1.2 Identification of the incident cohort
2.1.2.1  Community base
63Participation  in  the  study  was  encouraged  through  widely  publicised 
notices  in  medical journals  and  periodicals  as well  as through  personal 
contact  with  general  practitioners.  A  total  of  275  individual  general 
practitioners  throughout the  United  Kingdom  volunteered  for the  study 
and reported all newly diagnosed cases of epilepsy to the study panel.
2.1.2.2 Study design and registration
2.1.2.2.1 Inclusion criteria
All patients newly diagnosed with, or suspected as having, epilepsy were 
recruited  into the study and this included childhood febrile convulsions, 
single seizures and seizures associated with acute illnesses.
2.1.2.2.2 Exclusion criteria
All patients with a suspected previous diagnosis of epilepsy and patients 
with neonatal seizures were excluded because these types of seizures have 
a  distinct  clinical  picture  and  prognoses  that  are  well  defined  and 
documented.
2.1.3  Initial registration
GPs  were  provided  with  patient  registration  forms  and  throughout  the 
patient  recruitment  period,  which  began  in  June  1984  and  lasted  until 
October  1987,  contact  with  each  GP  was  scrupulously  maintained  to 
ensure that  every  single patient  appropriate for the  study was recruited. 
This active surveillance ensured a complete and unselected cohort. Each 
patient was flagged at the NHS Central Register. This allowed tracing of 
any patient who changed GP and the study was automatically informed of 
any deaths in the cohort, and provided with a copy of the death certificate.
642.1.4 Prevention of bias
2.1.4.1 Random selection
Patients were  recruited  from  both  rural  and  urban  practices to  reflect  a 
balanced mix of cases. As patients do not choose their GPs in anticipation 
of a seizure, choice of GP did not bias the study.  Equally,  since reported 
cases  were  those  with  suspected  newly  diagnosed  epilepsy  rather  than 
those with established epilepsy, a diminution of ascertainment bias, if any, 
was expected.
2.1.4.2 Completeness of case ascertainment
To  avoid  the  main  shortcoming  of  many  epidemiological  studies  of 
epilepsy,  GPs  were  asked  to  consider  all  patients  with  symptoms 
attributable to  seizures for recruitment.  This was to  ensure that patients 
with milder symptoms would also be ascertained.  This ensured sensitivity 
but  resulted  in  a  potential  compromise  of  specificity  during  the 
recruitment period.
2.1.5  Initial data collection
Demographic  and  clinical  details  were  collected,  together  with 
characteristics  of  the  index  seizure.  The  study  offices  located  at  the 
Institute of Neurology and the Chalfont Centre for Epilepsy received all 
the  registration  forms  and,  with  the  available  information,  case  folders 
were created. A coded, computerized database was designed, with GP and 
patient  records  linked  together  for  convenience.  Patient  details  with 
registration numbers and codes were sent back to the GPs with a ‘green 
card’  to  be  inserted  in  the  practice  notes  that  detailed  the  patient’s 
involvement in the study. This was designed to inform the new GP in case 
the patient changed practices. The seizure that resulted in the patient being 
registered  in the  study was  designated the  index  seizure which was  not 
necessarily the same as the first seizure.  This was because,  in retrospect,
65there were several  patients newly recruited who had suffered seizures in 
the past without a diagnosis of epilepsy having been made.
2.1.6 Follow-up
At  6  months,  further  information  was  collected  from the  GP  through  a 
detailed questionnaire; details of seizures and treatment were requested, as 
well as neurological, medical and psychological developments. If no reply 
was received within 3 months, a follow-up letter and further questionnaire 
were  sent;  if this produced  no  response,  the  GP  was telephoned  by the 
study co-ordinator and the questionnaire filled out.  Frequent changes of 
GP practice in a minority of patients,  and retirement or changes of GPs 
themselves were anticipated problems.
2.1.7 Hospital enquiry
Six  months  after  registration,  letters  and  forms  were  sent  to  hospital 
consultants for details regarding all patients who had been seen in hospital 
clinics  or  had  been  admitted  to  hospital  with  suspected  or  definite 
seizures. Confirmation of the diagnosis was sought and specific questions 
on  seizure  classification,  results  of neuro-imaging  and  EEG,  nature  of 
treatment given and details of follow-up were asked. Where no responses 
were obtained,  personal  inquiry,  examination of copies of hospital notes 
and examination of GP’s copies of hospital correspondence followed up 
requests.
2.1.8 Change of GP
When  patients  changed  GP,  the  new  GP  would  be  alerted  to  their 
involvement  in the  study by the card that  had  been put  in the  patient’s 
notes at registration.  The card asked that the new GP inform the study of 
the patient’s new general practice. If this failed to occur, the patient could 
be traced  using  the  individual’s NHS  number,  via the NHSCR  and  the
66Family Health  Service Authority.  Follow-up forms were then sent to the 
new GP.
2.1.9 Classification of patients
All  the  information  gathered  from  the  registration  forms,  the  6-month 
follow-up forms and the hospital enquiry were used by the study panel to 
classify the patient.
2.1.10 Study panel
The study was co-ordinated by a panel based at the Chalfont Centre for 
Epilepsy.  This  reflected  the  appropriate  specialities  to  the  community 
study of epilepsy  comprising three  neurologists,  a paediatrician with an 
interest in epilepsy, two general practitioners and a statistician.
2.1.11 Seizure classification
On  the  basis  of  all  the  information  available  at  6  months,  the  panel 
classified seizures and epilepsy after the index seizure into the four groups 
of  definite  epilepsy,  probable  epilepsy,  febrile  convulsions  and  non­
epileptic episodes.  The probable group  comprised those cases in which, 
even at 6  months,  a definite diagnosis of epilepsy was not possible,  but 
remained in question.
Children  aged  between  1   month  and  6  years,  who  experienced  a  first 
seizure during an episode of fever but not in the context of CNS infection, 
were identified as having had a febrile convulsion.
Seizure  classification  was  based  on  the  International  Classification  of 
seizures (1981) with adaptation for the fact that not all cases had an EEG.
672.1.12 Aetiological classification
The cases were further classified in to the following groups:
1.  Idiopathic/Cryptogenic -  no identified underlying cause
2.  Remote symptomatic -  postnatal CNS lesions
3.  Acute symptomatic -  seizures starting within 3  months of a CNS 
insult
4.  Seizures  associated  with  congenital  or  perinatal  neurological 
abnormality
This classification is similar to that used in other large community based 
studies,  which  allows comparison (Hauser,  and  others  1982).  The  study 
classification  predated  the  ILAE’s  aetiological  classification  of  the 
epilepsies.  Those  cases  classified  as  symptomatic  were  further  divided 
into aetiological groups.
1.  Vascular  -   where  there  was  clear  evidence  of vascular  or  embolic 
disease
2.  Tumour -  either radiological or an otherwise clear clinical picture of 
an expanding lesion
3.  Trauma -  definite history of head injury with loss of consciousness of 
more than 1  hour
4.  Alcohol  -   where  seizures  occurred  during  withdrawal  or  due  to 
excessive intake
5.  Post-infective -  during or in the aftermath of a confirmed episode of 
encephalitis, bacterial meningitis or cerebral abscess
2.1.13 Sample size
A sample size of 1,200 patients was chosen in order to achieve 700 cases 
of probable and definite epileptic seizures.
682.1.14 Long-term follow-up
Regular active surveillance was chosen as the method to follow-up these 
patients.  This  ensures  that  data  collection  is  carried  out  at  reasonable 
intervals,  so that no information is lost.  It puts the responsibility of data 
collection  on  the  central  study  office,  removing  as  much  responsibility 
from  GPs  as  possible.  Active  surveillance  is  also  far  more  likely to  be 
accurate than systems that rely on passive reporting and is one of the great 
strengths of the NGPSE.
Each  year,  the  GP  was  sent  a  form  to  fill  in  details  of the  patient’s 
epilepsy,  medication  and  medical  developments.  In  1993,  a  second 
hospital follow-up was carried out.
In  1997,  the  Office  for  National  Statistics  took  on  responsibility  for 
mortality reporting and patient migration from the NHSCR.
2.3  Mortality in the long-term in epilepsy
2.3.1 Case ascertainment
All deaths were notified to the investigators, initially by the NHSCR and 
after  1997  by  the  Office  for National  Statistics.  All  notifications  were 
accompanied  by  the  patient’s  death  certificate  and  where  done,  by  the 
coroner’s  autopsy report.  In  some  cases,  deaths  were  also  notified with 
relevant details, by patients’ GPs.
2.3.2 Identification of exact cause of death
Cause  of death  was  noted  from  the  death  certificate  and  in  every  case, 
confirmatory  details  were  sought  from  hospital  specialists,  coroners  or 
from  the  certifying  doctor  before  being  assigned  an  International 
Classification  of  Diseases  (ICD-10)  classification  number.  Autopsy
69reports  were  obtained  for  all  cases  that  underwent  post-mortem 
examination.
2.3  .3 Statistical analysis
Three different methods of analysis were used.  As in the previous short­
term analysis of mortality in the NGPSE, SMRs were calculated using the 
person-years  method.  A Cox  model  analysis  and  a time  dependent  co- 
variate analysis were also carried out, both for the first time in the analysis 
of mortality in epilepsy.
2.3.3.1  The person years method
The  first  analysis  was  by  the  person  years  method  (Coleman  MP,  and 
others  1989)  and  summarised  by  standardised  mortality  ratios  (SMRs) 
with 95% confidence intervals (CIs) based on the Poisson distribution and 
two-tailed significance tests; it utilised all deaths in the NGPSE up to 31st 
December  1997.  Expected  numbers  of  deaths  were  calculated  for  all 
causes, and for specific causes of death, by sex, age (0,  1, 2, 3, 4, 5-9,  10-
14,.................85-89,  90-100  years)  and  year  (1984-1997)  for  the
population  of  England  and  Wales  (Registrar  General’s  Mortality 
Statistics).  SMRs were calculated (Coleman MP,  and others  1989) for the 
whole  cohort  as  well  as  individually  for  definite  epilepsy,  probable 
epilepsy and febrile seizures.  SMRs for individual causes of death and for 
aetiology of epilepsy were also calculated.
2 .3 .3 .2 The Cox proportional hazards analysis
Cox proportional hazards models were used in this analysis as well  as in 
analysis  3,  implemented  with  the  program  2L  from  the  BMDP  suite 
(Dixon WJ  1992). Baseline characteristics that influenced mortality up to 
31st December  1997,  including age at index seizure,  sex,  number of pre­
index  seizures,  aetiology,  seizure  type  and  seizure  classification
70(idiopathic/cryptogenic,  acute  symptomatic,  remote  symptomatic  and 
congenital neurological deficits) were assessed.
2.3.3.3  Time dependent co-variate analysis
The third analysis used time-dependent co-variates in the Cox model (in 
addition to the baseline characteristics),  to  assess the influence of events 
that occurred during follow-up.  The follow-up period from index seizure 
to death or censoring for each patient was divided into contiguous 3-month 
intervals. During each of these intervals, the recurrence of seizures and use 
of AEDs were noted. Seven time-dependent co-variates were derived:
(i)  any  recurrence  of seizures  in  each  3  month  interval  of follow-up  was 
coded  as  a  step  function,  as  shown  for a typical  patient  in Fig. 1;  in the 
figure,  the step function is equal to zero throughout any 3  month period 
during which there are no seizures (the 1st, 3rd, 6th, 7th and 8th), and equal to 
one throughout any 3 month period during which a seizure occurs (the 2nd, 
4th and 5th).
(ii)  use  of  AEDs  was  similarly  coded  as  a  step  function  where  the  step
function equalled zero throughout any 3month period when no treatment 
was received and equal to one where treatment was received;
(iii)  for  each  3-month  interval,  the  cumulative  number  of 3-month  intervals
during which a seizure occurred (for the patient whose seizure recurrence 
is  illustrated  in  Fig.  1,  the  values  of this  time-dependent  co-variate  are 
0,1,1,2,3,3,3  and  3  for  the  first  eight  3-month  intervals  respectively 
[Fig.2]);
(iv)  a similar time-dependent co-variate for cumulative use of AEDs;
(v)  a  step  function  as  in  (i)  equal  to  one  when  the  two  preceding  3-month
intervals were seizure-free (i.e. patient in 6 month remission from seizures) 
and zero otherwise (for the patient in Fig.l,  the values  of this co-variate 
are zero for the first seven 3-month intervals and one for the eighth); and 
are similar to (v) but indicate 1-year and 2-year remission respectively.
71Deaths in the 3-month interval following the index seizure were excluded 
since  complete  information  about  the  time-dependent  co-variates  was 
unobtainable.  This  removes  the  potential  bias  of early  mortality  in  co- 
variate analysis in patients who had few seizures but nevertheless died due 
to  serious underlying pathologies.  Further,  for some patients information 
about seizures and use of AEDs was not available up to the date of death; 
for these patients, follow-up was censored at the end of the last complete 
3-month interval.
72Fig.l  Example  of seizure  recurrence  as  a  time-dependent  co-variate 
during each 3-month follow-up period.
1
1 2 3 4 5 6 7 8  quarters
3- monthly time periods (quarters) from index seizure
1= one or more seizures in a 3 month interval.
0= no seizures during a 3-month interval.
Fig.2 Example of cumulative seizure  recurrence as a time-dependent 
co-variate during each  3-month follow-up period.
8  quarters
3- monthly time periods (quarters) from index seizure
1= one or more seizures in a 3 month interval.
0= no seizures during a 3-month interval
732.3  THE DYNAMICS OF TREATMENT IN EPILEPSY
2.3.1 Case ascertainment
Treatment  patterns  were  analysed  in  the  564  patients  with  definite 
epilepsy.  Data recorded included  age,  sex,  date of index seizure,  date of 
onset  of  seizures  if  different  from  index  seizure,  seizure  type  (The 
Commission on classification and terminology of the International League 
Against Epilepsy,  1981),  person prescribing initial treatment,  duration of 
treatment, number of treatment changes, reasons and types of changes, use 
of newer antiepileptic drugs and seizure status.
2.4.2 Statistical Methods
Kaplan Meier survival analyses were carried out using SPSS version 7.5.1, 
to estimate the time taken to change treatment for the first time, by either 
adding a drug  or  substituting  a drug.  The time taken to  first change for 
individual drugs and the percentage of patients continuing on a particular 
drug  was  also  calculated  using  the  same  method.  Life  table  survival 
analyses  were  carried  out  to  estimate  the  total  number  of  patients 
continuing on medication at the end of the follow-up period.
743.  RESULTS
3.1 THE MORTALITY OF EPILEPSY
3.1.1 Follow-up period
Median  (25th,  75th  centiles)  follow-up  of patients  was  11.8  (10.6,12.7) 
years,  equivalent  to  11,400  person  years.  17  (2%)  patients  were 
untraceable  at  last  follow-up.  A  total  of 214  deaths  (106  males,  108 
females)  occurred  in  the  entire  cohort  (SMR  1.9[95% 
CI=1.6,2.2;p<0.001])  suggesting increased  long term mortality twice that 
of the general population (Table 2).
Table 2.  All cause mortality for whole cohort and specific subgroups
Number at Risk Number of Deaths
Males Females Totals
Obs Exp Obs Exp Obs Exp SMR (Cl 95%)i  P*
Definite epilepsy  564  79 33.0 70 25.3 149 58.3 2.6 (2.1, 3.0) <0.001
Probable epilepsy 228  21 13.7 29 22.8 50 36.5 1.4 (1.0, 1.8) <0.04
Sub-total 792 100 46.7 99 48.1 199 94.8 2.1 (1.8, 2.4) <0.001
Not epilepsy 79 6 6.5 9 7.9 15 14.4 1.0 (0.5, 1.7) 0.94
Febrile seizures 220 0 1.3 0 0.6 0 1.9 0 (0, 1.9) 0.72
Total 1091 106 54.5 108 56.6 214 111.1 1.9 (1.6, 2.2) <0.001
♦Significance test based on Poisson distribution for SMR different from 1  (2-sided)
753 .1.2  Analysis 1 —  the person years method
3.1.2.1 Overall mortality
Patients  with  definite  epilepsy  had  an  SMR  of  2.6  [95%
CI=2.1,3.0;p<0.001]  whilst those with probable epilepsy  had an  SMR of 
borderline significance (1.4[95% CI=1.0,1.8;p<0.04]).  Combined analysis 
of the definite and probable groups, to allow for possible under-diagnosis 
of epilepsy in the cohort confirmed significantly elevated mortality (SMR
2.1  [95% CI=1.8,2.4;p<0.001]).
3 .1.2.2 Age-specific mortality
Analysis of age-specific mortality (Table 3) showed significant increases 
in all age bands. In the group with definite epilepsy this was highest in the 
50-59 years (SMR 8.4 [95% 0=5.3,12.7]) and 0-49 years (SMR 5.4 [95% 
CI=3.2,8.4]) age bands, and lowest in the 70-79 years age band (SMR 1.7 
[95% CI=1.1,2.4]). An identical pattern was seen when those with definite 
and probable epilepsy were combined.
Idiopathic/cryptogenic  epilepsy  was  analysed  separately  because  of the 
inclusion of patients in this group with primary generalised epilepsies in 
which the seizure disorder typically starts in the first two decades of life. 
No significant elevations of SMRs were noted (Table 3).
76Table 3 -  All cause mortality by age group in the combined group with definite 
and  probable  epilepsy,  patients  with  definite  epilepsy  and  the  subgroup  with 
idiopathic/cryptogenic epilepsy.
Age (years)
Number of Deaths 
Obs Exp SMR (95%CI)
Definite and probable epilepsy (n=792)
0-49 20 4.8 4.2 (2.5, 6.4)
50-59 25 3.8 6.6 (4.2, 9.7)
60-69 32 11.9 2.7 (1.8, 3.8)
70-79 48 27.5 1.7 (1.2, 2.3)
>80 74 46.8 1.6 (1.2, 2.0)
Definite epilepsy (n=564)
0-49 19 3.5 5.4 (3.2, 8.4)
50-59 22 2.6 8.4 (5.3, 12.7)
60-69 26 8.5 3.1 (2.0, 4.5)
70-79 35 20.6 1.7 (1.1, 2.4)
>80 47 23.0 2.0 (1.5, 2.7)
Idiopathic/cryptogenic epilepsy  (n=346)
0-49 5 2.3 2.2 (0.7, 5.1)
50-59 3 1.5 2.0 (0.4, 6.0)
60-69 5 5.3 1.0 (0.3, 2.2)
70-79 9 9.6 0.9 (0.4, 1.8)
>80 12 7.1 1.7 (0.4, 2.9)
773.1.2.3 Mortality according to aetiology
Analysis of mortality according to aetiology is shown in Table 4. There was 
some suggestion of excess mortality in the idiopathic/cryptogenic epilepsy 
group,  though  this  was  not  statistically  significant  (SMR 
1.3[95%CI=0.9,1.9)].  Mortality was however,  significantly elevated in the 
remote  symptomatic group  (SMR 3.7  [95%  CI=2.9,4.6])  and in the acute 
symptomatic group (SMR 3.0 [95%CI=2.0,4.3]).
Table  4.  All  cause  mortality  in  patients  with  definite  epilepsy  according  to 
aetiology.
Aetiology At risk Number of deaths
Obs Exp SMR (CI95%)
Idiopathic/cryptogenic 346 34 25.8 1.3 (0.9, 1.9)
Remote Symptomatic 119 81 22.1 3.7 (2.9, 4.6)
Acute symptomatic 83 31 10.3 3.0 (2.0, 4.3)
Congenital deficit 16 3 0.1 25 (5.1, 73)
The commonest causes of death in patients under the age of 50 years were 
primary brain  tumours,  neoplasms other than primary brain tumours and 
lung  neoplasms.  Ischaemic  heart  disease,  cerebrovascular  disease  and 
pneumonia  accounted  for  most  deaths  in  people  over  the  age  of  50 
although SMRs were not significant in the ischaemic heart disease group. 
In the definite seizures group, cause specific SMRs were higher with wider 
CIs than the  combined group  (Table  5).  Mortality  from  all  causes  other 
than  malignant  neoplasms,  cerebrovascular  disease  and  pneumonia  was 
still  higher than  in the  standard  population  (SMR  1.2;  95%CI=0.96-1.6; 
p=0.097) but the slightly higher risk was confined to women even in those
78with definite epilepsy (women SMR  1.9  [95%CI=1.2-2.7], men SMR 1.1 
[95%CI=0.6-1.7]).  There  was  one  death  consistent  with  the  criteria  for 
sudden unexpected death in epilepsy (SUDEP) and one death due to status 
epilepticus.  Bums  sustained during a seizure (1),  a bathtub drowning (1) 
and  a  fall  resulting  in  a  broken  neck  (1)  were  other  causes  of seizure 
related mortality. One patient committed suicide.
79Table 5. Selected causes of death for the combined group with definite and probable epilepsy, 
patients with definite epilepsy and the subgroup with idiopathic/cryptogenic epilepsy.
Number of Deaths
In first 7 years  In second 7 years  Overall -  14 yrs
Cause of Death_______Obs  Exp  SMR(95%CI)  Obs  Exp  SMR(95%CI)  Obs  Exp  SMR(95%CI)
Definite and probable epilepsy (n=792)
Malignant Neoplasms 
including primary brain 
tumour
47 13.5 3.5 (2.5,4.6) 9 7.8 1.2 (0.5,2.2) 56 21.3 2.6 (1.9,3.4)
Malignant Neoplasms 
excluding primary brain 
tumour
33 13.3 2.5 (1.7,3.5) 6 7.5 0.8 (0.3,1.8) 39 20.7 1.9 (1.3,2.6)
Neoplasms of Lung 10 3.3 3.0 (1.4,5.5) 4 1.8 2.3 (0.6,5.8) 14 5.1 2.7 (1.5,4.6)
Ischaemic Heart Disease 16 15.6 1.0 (0.5,1.7) 9 7.8 1.2 (0.5,2.2) 25 23.4 1.1 (0.7,1.6)
Cerebrovascular disease 28 7.5 3.7 (2-4,5.4) 7 3.6 1.9 (0.8,4.0) 35 11.1 3.2 (2.2,4.4)
Pneumonia 25 3.5 7.2 (4.6,10.7) 14 3.2 4.4 (2.4,7.4) 39 6.6 5.9 (4.1,8.0)
Other* 34 20.6 1.7(1.1,2.3) 10 11.8 0.9 (0.4,1.6) 44 32.4 1.4 (0.9,1.8)
Definite epilepsy (n=564)
Malignant Neoplasms 
including primary brain 
tumour
43 8.9 4.8 (3.4,6.5)
Malignant Neoplasms 
excluding primary brain 
tumour
30 8.8 3.4 (2.3,4.9)
Neoplasms of Lung 10 2.3 4.3 (2.0,7.9)
Ischaemic Heart Disease 10 9.9 1.0 (0.4,1.9)
Cerebrovascular Disease 19 5.0 4.4 (2.6,6.8)
Pneumonia 18 1.9 9.6 (5.6,15.1)
Other* 24 12.2 2.0 (1.2,2.9)
7 5.3 1.3 (0.5,2.7) 50  14.3 3.5 (2.6,4.6)
4 5.1
0
0
o
’ (0.2,2.0) 34  13.9 2.4 (1.7,3.4)
2 1.3 1.6 (0.2,5.7) 12 3.6 3.3 (1.7,5.8)
6 5.2 1.2 (0.4,2.5) 16 15.1 1.1 (0.6,1.7)
5 2.2 2.3 (0.7,5.4) 24 6.5 3.7 (2.3,5.5)
9 1.8 5.0 (2.3,9.5) 27 3.7 7.3 (4.8,10.6)
8 1.2 1.2 (0.5,2.4) 32 13.4 1.7 (1.1,2.4)
Idiopathic/cryptogenic epilepsy (n=346)
Malignant Neoplasms  8  3.9  2.0  (0.8,4.0) 1 3.0 0.3 (0.0,1.9) 9 7.0 1.3 (0.6,2.5)
including primary brain 
tumour
Malignant Neoplasms 5 3.8 1.3  (0.4,3.0) 1 2.9 0.3 (0.0,1.9) 6 6.8 1.3 (0.3,1.9)
excluding primary brain 
tumour
Neoplasms of Lung 0 1.0 0  (0.0,3.6) 1 0.7 1.4 (0.0,7.8) 1 1.8 0.6 (0.0,3.2)
Ischaemic Heart Disease 1 3.9 0.3  (0.0,1.4) 3 2.8 1.1 (0.2,3.2) 4 6.7 0.6 (0.1,1.5)
Cerebrovascular disease 1 1.5 0.6  (0.0,3.6) 2 1.1 1.8 (0.2,6.5) 3 2.7 1.1 (0.2,3.3)
Pneumonia 6 0.6 10.1 (3.6,21.8) 2 0.9 2.3 (0.2,8.2) 8 1.5 5.4 (2.3,10.7)
Other* 8 4.6 1.7  (0.7,3.4) 2 3.3 0.6 (0.0,2.2) 10 8.0 1.3 (0.6,2.3)
80*Causes of death other than those listed above. These included ruptured aortic 
aneurysm,  pneumoconiosis,  accident,  old  age,  duodenal  ulcer, 
cardiomyopathy,  cirrhosis,  septicaemia,  fracture neck  of femur,  Alzheimer’s 
disease  and  not  known  (1).  There  were  5  directly  epilepsy  related  deaths 
(Sudden  unexpected  death  in  epilepsy  or  SUDEP=1,  status  epilepticus=l, 
burns=l, cervical fracture=l, drowning=l).
3.1.2.4 Mortality according to time since diagnosis
Mortality  for  each  year  of follow-up  is  shown  in  Table  VI.  SMR  was 
highest in patients with definite epilepsy (SMR 6.6 [95%CI=4.8,8.7]), and 
slightly lower in the combined probable and definite epilepsy group (SMR 
5.01[95%CI=3.7,6.4])  during  the  first  year  of  follow-up.  This  halved 
during the subsequent 3 years, and then halved again after 3 further years. 
Excess mortality fell below significant levels after 4 years from the index 
seizure but then  increased  again to  significant levels after 9 years (SMR
1.6  [95%CI=1.1,2.2]).
Similar results were obtained with period of exposure to seizures (defined 
as  the  interval  from  the  first  seizure).  Among  those  with  a  history  of 
seizures  for  less than 2  years,  the  SMR was  5.0  (95%CI=3.9,6.3).  It then 
declined to 2.2 (95%CI=1.5,3 .1) in those having a history of between 2 and 
4 years of seizures,  and to  1.4 (95%CI=1.1,1.7) in those with a history of 
more than 4 years of seizures.
81Table  6.  Mortality  for  each  year  of  follow-up  from  index  seizure  in  the 
combined  group  with  definite  and  probable  epilepsy,  patients  with  definite 
epilepsy and patients with idiopathic/cryptogenic epilepsy.
Yrs after index seizure  No. at risk  No. of  Deaths
Obs Exp SMR  (CI95%)
Definite and probable epilepsy (n=792)
0-1 792 59 11.9 5.0 (3.7,6.4)
1-2 733 24 9.9 2.4 (1.5,3.6)
2-3 709 18 8.8 2.1 (1.2,3.2)
3-4 691 20 8.1 2.5 (1.5,3.9)
4-9 671 46 35.8 1.3 (0.9,1.7)
9-14 625 32 20.4 1.6 (1.1,2.2)
Definite epilepsy (n=564)
0-1 564 49 7.4 6.6 (4.8,8.7)
1-2 515 16 6.1 2.6 (1.5,4.2)
2-3 499 13 5.7 2.3 (1.2,3.9)
3-4 486 16 5.1 3.1 (1.8,5.1)
4-9 470 33 21.6 1.5 (1.0,2.1)
9-14 437 22 12.3 1.8 (1.1,2.7)
Idiopathic/cryptogenic epilepsy (n=346)
0-1 346 6 2.8 2.2 (0.8,4.7)
1-2 340 3 2.5 1.2 (0.2,3.5)
2-3 337 5 2.3 2.2 (0.7,5.2)
3-4 332 5 1.9 2.7 (0.8,6.3)
4-9 327 11 9.4 1.2 (0.6,2.1)
9-14 316 4 7.0 0.6 (0.1,1.5)
823.1.3  The Cox proportional hazards analysis
The  Cox  model  was  used  to  examine  the  possible  influence  of baseline 
characteristics on mortality.  In view of the expected influence of age and 
sex  on  mortality,  these  two  variables  were  entered  into  the  initial  Cox 
model,  and  the  remaining  variables  then  selected  stepwise  (p to  enter = 
0.10; p to remove = 0.15). Enhanced mortality was associated with older 
age  at  index  seizure,  cerebrovascular  disease,  alcohol-related  seizures, 
malignant  neoplasms and congenital  neurological  deficits (Table 7).  One 
or more  seizures before the index seizure appeared to be associated with 
reduced mortality.
When patients with idiopathic/cryptogenic (no known cause) epilepsy with 
generalised tonic clonic seizures were analysed separately, they were found 
to have a significantly increased risk of mortality,  although the confidence 
intervals were wide (hazard ratio 6.2 [95%CI=1.4-27.7; p=0.049]).
83Table 7. Cox  model analysis of mortality in definite and probable epilepsy.
n (%)  Hazard ratios (95%CI)  p (n=792)
Age at index seizure(per decade) 1.9 (1.7,2.0) <0.001
Aetiology of epilepsy
Cerebrovascular disease 111  (14) 2.4 (1.7,3.4) <0.001
Alcohol 38  (5) 2.9 (1.5,5.7) =0.004
Tumour 40  (5) 12.0 (7.9,18.2) <0.001
Congenital neurological deficits 16  (2) 10.9(3.2,36.1) =0.003
Number of seizures before index seizure
One or more 428  (54) 0.6(0.4,0.8) <0.001
A hazard ratio >1.0 indicates enhanced risk of mortality for a patient with 
the  associated  risk  factor by comparison with  one without  it.  The  hazard 
ratio of 0.6 indicates a reduction in the risk of mortality for a patient with 
one or more seizures prior to the index seizure by comparison with a patient 
for whom the index seizure is the first.
843 . 1.4  Time-dependent co-variate analysis
The Cox  model with time-dependent co-variates was used to examine the 
influence of events that occurred  during the follow-up period.  The time- 
dependent co-variates were those described earlier (and presented in Table 
8); each has been adjusted for the baseline characteristics listed in Table 6.
As  is  evident  from  Table  VIII,  neither  seizure  recurrence  nor  AED 
treatment  appeared  to  be  associated  with  mortality.  The  analysis  of 
cumulative  seizures  and  cumulative  AED  treatment  in  particular,  gives  a 
tight confidence interval around a hazard ratio of one. (The hazard ratios are 
unchanged whether the time  dependent  co-variates are  analysed  singly or 
together).
There was also a suggestion that the achievement of remission (particularly 
short  term)  may  enhance  survival  though  these  results  do  not  reach 
significance at p=0.05 and the confidence intervals are wide. In an analysis 
restricted to patients with primary or secondary generalised seizures tonic 
clonic seizures,  seizure recurrence was associated with increased mortality 
although this did not reach significant levels (hazard ratio 1.79 [95%CI 0.98 
-3.06]).
85Table 8. Effect of seizure recurrence and AED treatment during follow-up 
(time-dependent  co-variates)  in  patients  with  both  definite  and  probable 
epilepsy adjusted for the characteristics in Table 6.
♦Time dependent co-variates
Hazard ratios (95% Cl)
Seizure recurrence (yes/no) 1.30 (0.84,2.01)
Cumulative seizures 1.02 (0.99,1.05)
AED Treatment (yes/no) 0.97 (0.67,1.38)
Cumulative AEDs 1.00 (0.98,1.02)
6 month remission 0.70 (0.46,1.07)
*for definitions see methods section.
This analysis excludes deaths during the first 3 months of follow up.
863.2  THE DYNAMICS OF THE TREATMENT OF EPILEPSY
3.2.1 Follow-up
Out of 564 patients with newly diagnosed definite epilepsy, only  17 were 
lost to follow-up at the end of the study in 1997 (the median follow-up was
th   tli
11.8  years  [25  and 75  centiles  10.6 and  12.7 years respectively] a total 
of 11,400 person years). The causes of loss to follow-up in these 17 cases 
were  emigration  (4),  entry  into  the  armed  forces  (5;  medical  details  of 
serving  personnel  are  not  made  available  by  government  decree), 
withdrawal of consent (3) and unknown (5).
3.2.2 Overall treatment
433  (77%) were started on drug treatment.  Of the  131  (23%) who did not 
start therapy,  41  had suffered acute symptomatic seizures; 42 died within 
the first 6 months due to underlying pathologies.
3 .2.3 Treatment of the first seizure
Of the 252 cases in whom the index seizure was also the first seizure, only 
38  (15%) were prescribed  medication after the first seizure.  Due to  high 
rate  of seizure  recurrence  in  these  patients  however,  almost  70%  were 
eventually treated. Initial therapy was prescribed by a hospital physician in 
303  (70%) cases whilst a GP initiated therapy in the remainder (although 
often on the advice of a specialist).
3 .2.4 Choice of antiepileptic drug
433  (77%) patients were started on therapy. Phenytoin was started in  161 
(29%), carbamazepine in  154 (27%), valproate in 84 (15%), phenobarbital 
in 14 (2%) and other drugs including benzodiazepines and ethosuximide in 
20 (4%).
873 .2.5 Duotherapy
Of these,  426  (98%)  were  started  on  single  drug  therapy  and  7  (2%) 
patients were started on duotherapy,  3  with phenytoin and phenobarbital, 
and 4 patients with phenytoin and carbamazepine.
3.2.6  Treatment according to seizure type
Of  292  patients  with  partial  seizures  with  or  without  secondary 
generalisation, 236 (81%) received treatment. Of these,  105 (45%) patients 
were prescribed carbamazepine,  90 (38%) phenytoin,  27 (11%) valproate 
and  14  (6%)  received  other  drugs.  Of the  160  out  of 221  patients  with 
generalised  seizures  who  received  treatment,  phenytoin  was  the  most 
frequently preferred drug in 59 (37%) patients followed by valproate in 48 
(30%),  carbamazepine  in  44  (28%)  and  other  drugs  in  9  (5%). 
Carbamazepine  was  prescribed  initially  in  9  patients  who  had  absence 
and/or myoclonic seizures in addition to generalised tonic-clonic seizures. 
Of  36  patients  with  unclassified  seizures,  phenytoin  was  the  most 
frequently  preferred  drug  (36%)  followed  by  valproate  (25%), 
carbamazepine (19.5%) and other drugs (19.5%).
3 .2.7 Treatment changes and treatment retention
A  life  table  survival  analysis  (Fig.4)  of  patients  shows  that  patients 
changing  therapy  usually  do  so  early  in  the  course  of their history.  The 
sequence of treatment events is illustrated in Fig.3. 91/564 (16%) patients 
changed medication for the first time because of lack of efficacy. Of these 
91, 29 (32%) patients have now achieved 2 year terminal remission and 21 
(23%)  have  achieved  5  year terminal  remission.  5%  (30)  of all  patients 
went on to change medication for the second time for the same reason, and 
of this group 9 patients (30%) achieved 2 year terminal remission and only 
5  (17%)  have  achieved  5  year terminal  remission.  Of the  50/564  (9%) 
patients who changed for the first time due to adverse events, only 4 did so
88again for the same reason.  39/564 patients (7%) have not switched to any 
other  drug  despite failure to  attain  even 2-year terminal  remission  from 
seizures.
89Fig.3 Treatment dynamics over 11-14 years (median 11.8 years) in a community based cohort with newly 
diagnosed epilepsy.
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903  .2.8   The use of new antiepileptic drugs
A  new  antiepileptic  drug  such  as  gabapentin,  lamotrigine,  vigabatrin  or 
topiramate was used  in  only  25  (11%)  treatment  changes  in  17  patients 
with  recurrent  seizures,  out  of a  total  of 221  treatment  changes  in  the 
whole  cohort  (11%).  The  most  commonly  used  new  antiepileptic  drugs 
were lamotrigine and vigabatrin (11 patients each), followed by gabapentin 
(2 patients) and topiramate (1 patient).
3 .3 .9 The time course of treatment changes
Kaplan  Meier  survival  analysis  estimated  the  time  course  of treatment 
changes  (addition  or  substitution  of  antiepileptic  drugs)  in  the  cohort 
(Fig.4) Of the 433 treated patients,  15% changed their initially prescribed 
medication for the first time within 2 years and a further 20% did so in the 
next  12  years.  Approximately  18%  of  patients  on  phenytoin  and 
carbamazepine changed medication in the first 2 years compared to 7% on 
valproate (Fig.4).
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923.3.10 Current cohort characteristics
209/564 patients (37%) were on drug therapy for epilepsy at the time of 
last follow-up.  168/564 patients (30%) stayed continuously on medication 
and another 41/564 patients (7%) restarted drug therapy because of seizure 
recurrence, having withdrawn medication. 42/564 (7%) were on combined 
therapy with  2  drugs  and  only  15/564  (3%)  patients were  on  3  or more 
drugs simultaneously at the time of last follow-up.  98/564 (17%) of those 
on treatment are known to be in 5-year terminal remission.
3 .3 .11 Treatment changes and seizure remission
111/564  patients  (20%)  had  not  achieved  5-year  terminal  remission. 
39/564  patients  (7%)  had  not  had  any  drug  switches  despite  lack  of 
remission and continued on their originally prescribed medication.  31/564 
patients (5%) continued to have frequent (one or more a week) seizures.
9/31 patients (29%) with frequent seizures had changed drug doses but had 
not  switched  to  any  other  drug.  2/31  (6%)  patients  had  changed  their 
initially prescribed drug once,  6/31  (19%) had done so twice and another 
7/31  (23%) had done so thrice.  Only 7/31  patients (23%) had changed 4 
times or more.  Thus,  only 22 out of 31  patients with frequent seizures at 
the time  of follow-up  (4%  of the  study population)  changed  medication 
more than once in order to achieve better seizure control.
934. DISCUSSION
Despite its strengths, the NGPSE has been criticised for its methodology. 
An  important criticism  is the  inclusion of first  seizures,  a feature of this 
study that runs contrary to the definition of epilepsy with its requirement 
for “recurrent”  seizures.  This argument is largely based on older, hospital 
based studies where seizure recurrence rates for first seizures are low.  In 
community-based  studies,  the  majority  of  first  seizures  recur  (Sander 
1993).  We  have  argued  that  single  seizures  are  not  likely  to  be  a 
biologically distinct entity and probably represent one end of the spectrum 
of disease severity.  The inclusion of acute symptomatic seizures has been 
similarly  criticised  because  of the  significant proportion of patients with 
alcohol  related  seizures.  Analyses  of  data  with  and  without  acute 
symptomatic  seizures  in  the  prognosis  (Cockerell  and  others,  1997)  and 
seizure remission studies (Hart and others,  1994) in the NGPSE show no 
significant differences.
The epilepsies  are a heterogeneous group of disorders.  Whilst inferences 
can  be  drawn  for  several  broad  categories  in  epilepsy,  such  as  with 
aetiological  classes,  numbers  are  insufficient  for  deriving  meaningful 
information  on  individual  epilepsy  syndromes  or  aetiologies.  Moreover, 
the  NGPSE  was  designed  before  the  International  Classification  of 
Epilepsies, Epilepsy Syndromes and Related Disorders was proposed.
A major difficulty with the continuation of the NGPSE has ironically been 
its  longevity.  Ethics  approval  obtained  in  1983  at the conception  of this 
study  is  no  longer  deemed  sufficient  in  many  general  practices  and 
obtaining  approval  with  a  vast  number  of  individual  local  ethics 
committees  is  not  practical.  This  was  becoming  increasingly  evident  in 
1997  and  1998  during  the  collection  of data  for  this  thesis  and  in  the 
subsequent years has resulted in the cessation of all data collection.
944.1 MORTALITY
Although  recent  reports  on  the  long-term  prognosis  of seizure  disorders 
have  made  observations  on  mortality  (Sillanpaa,  and  others  1998),  there 
have been no  specific,  long-term community based studies of mortality in 
epilepsy since the Mayo Clinic study in 1980 (Hauser, and others 1980) and 
certainly none that have been prospectively reported in patients with newly 
diagnosed  epilepsy.  Recent  retrospective,  long-term  mortality  studies 
(Nilsson  L,  and  others  1997;  Shackleton  DP,  and  others  1999)  have 
included large numbers of patients but their focus on hospital populations is 
likely  to  exaggerate  mortality  in  general  and  epilepsy  related  deaths  in 
particular  (Nashef  L  and  Shorvon  SD  1997).  The  limitations  of  older 
studies based  on cohorts derived  from insurance registers,  hospital clinics 
and institutions are well  recognised (Cockerell,  and others  1994a; Hauser, 
and  others  1980).  Many  previous  studies  have  suffered  from  the 
unreliability of death certificates used to ascertain causes of death,  a large 
proportion  of which  do  not  mention  epilepsy  as  cause  or  contributor to 
mortality (Zielinski JJ  1974a; Hauser,  and others  1980). The design of the 
NGPSE (Hart YM, and others 1989; Sander, and others 1990), large patient 
database (1091  patients), cohort characteristics similar to that of an incident 
population with epilepsy (Cockerell, and others 1997b), long follow-up and 
efficient system of data collection (2% lost to follow up),  provides an ideal 
opportunity to  study  mortality in epilepsy.  It is also representative of the 
current  population  of  a  developed  country,  in  which  significant 
demographic changes in the incidence of epilepsy have occurred in the last 
few decades (Everitt and Sander 1998). The category of “probable seizures” 
recognises initial difficulty in the diagnosis of some epileptic disorders and 
allows analyses that would otherwise not account for patients who later turn 
out to have seizure disorders (Hart YM, and others 1989; Sander, and others 
1990).
954.1.1 Overall mortality
All cause mortality in the whole cohort analysed up to  14 years from index 
seizure was significantly elevated to twice that of the age-matched general 
population.  This finding is similar to that noted at 8 years (Cockerell, and 
others  1994a)  and  in  other  studies  (Hauser,  and  others  1980;  Zielinski  JJ 
1974a) although expectedly lower than those noted in recent, more hospital 
based populations (Nilsson L,  and others  1997;  Shackleton DP, and others 
1999).  It  confirms  previously  made  observations  that  mortality  is 
significantly elevated above that of the general population in patients who 
suffer from epilepsy.
4.1.2  Mortality and time trends
Initial mortality in the cohort was very high but halved over the subsequent 
3  years  and  dropped  below  significant  levels  after  4  years.  A  late, 
significant rise  in  mortality  occurred  again  after 9 years.  Epilepsy related 
deaths were few and the late increase in mortality is not easily explained. In 
an earlier community based study, a late increase in mortality, thought to be 
directly  caused by epilepsy,  occurred  only in the  3rd decade (Hauser,  and 
others  1980).  In this cohort, further follow-up beyond  15 years is required 
to confirm this trend.
The  cause  of the  initial  high  mortality  is  a  consequence  of underlying 
serious brain pathologies such as primary and  secondary brain tumours as 
well  as  major  cerebrovascular  events.  The  seizures  were  thus  agonal 
seizures arising as a direct consequence of these pathologies, and the raised 
mortality probably reflects the mortality inherently associated.
The  late  rise  in  mortality  in  this  cohort  is  not  explainable  and  may  be 
artefactual.  The late increase seen in the Mayo report (Hauser,  and others 
1980)  encouraged  speculation  that  this  reflected  direct  epilepsy  related 
deaths  although,  in  this  cohort,  there  were  only  5  deaths  attributable  to 
epilepsy throughout the period of follow-up, two of which occurred early.
964.1.3 SUDEP and epilepsy related mortality
Three epilepsy related deaths were noted in the second decade of follow-up 
in addition to the two (one burns death and one death due to a fall) reported 
in  the  first  8  years  of  follow-up  (Cockerell,  and  others  1994a).  These 
included  one  death  consistent  with  sudden  death  in  epilepsy  (SUDEP) 
(Lhatoo SD, and others  1999), one due to convulsive status epilepticus in a 
patient with brain tumour, and one drowning after a seizure. Data from this 
study  suggests that  SUDEP is an infrequent occurrence in the community 
with  only  one  death  having  occurred  in  11,400  person  years  of patient 
follow-up.  This compares with one death per 2500 person years of patient 
follow-up  in  another  community  based  study  (Medical  Research  Council 
Antiepileptic Drug Withdrawal  Study Group  1991) and up to  1   death per 
200 patients in a tertiary referral centre. (Nashef, and others 1995a)
4.1.4 Mortality and seizure duration
Mortality was  significantly elevated in patients who had  suffered  seizures 
for  more  than  4  years,  was  even  higher  in  patients  who  had  suffered 
seizures for 2-4 years and highest in patients who had suffered seizures for 
less than 2  years.  This  is consistent with mortality trends in other studies 
(Hauser, and others 1980; Shackleton DP, and others 1999) and reflects the 
greater  representation  of people  with  epilepsy  due to  serious  pathologies 
such  as  tumours  and  cerebrovascular  disease  who  tend to  die  soon  after 
presentation.
4.1.5 Multi-variate analysis of mortality
Cox  regression  analysis  of  baseline  variables  showed  that  older  age, 
cerebrovascular  disease,  alcohol,  malignant  neoplasms  and  congenital 
neurological deficits were associated with significantly increased mortality 
in patients with newly diagnosed seizures.  The occurrence of one or more 
seizures  before  the  index  seizure,  however,  was  associated  with  a 
significantly decreased mortality. This is partly explained by the presence in
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seizures  and  cryptogenic  partial  seizures  that  come  to  medical  attention 
later.  These  seizure  disorders  may  not  be  associated  with  increased 
mortality (Hauser, and others 1980; Nilsson L, and others 1997).
4.1.6  Time dependent co-variate analysis -
4.1.6.1  The effects of  seizure recurrence
Neither recurrent seizures or cumulative  seizure recurrence were found to 
be  significant  factors  in cohort mortality.  Reports that frequent,  recurrent 
seizures  are  an  independent  risk  factor  (Hendriksen B,  and  others  1970; 
Sperling  MR,  and  others  1999)  for  mortality  may  not  hold  true  in 
unselected  populations  with  epilepsy.  Seizure  recurrence  may  not 
significantly  influence  mortality  in  a community-based  cohort  due to the 
inclusion  of absence  seizures  and  mild  cryptogenic  partial  seizures,  for 
example,  which  may  not  have  an  increased  risk  of  mortality  even  if 
occurring  frequently  in  patients.  Seizure  recurrence  may  have  a  more 
serious  connotation  in  a  hospital-based  cohort  in  which  patients  tend  to 
have  more  disabling  epilepsy,  as  is  evident  from the high  SMR obtained 
from  a recent  comparison  of patients with  seizure remission and patients 
with  continuing,  frequent  seizures  in  a  post-epilepsy  surgery  cohort 
(Sperling MR, and others 1999). Similarly, high mortality has been noted in 
an outpatient cohort with refractory, disabling seizures in a tertiary referral 
centre  (Nashef L,  and  others  1995a).  The  relative  non-homogeneity  of 
seizure  types  and  epilepsy  syndromes  with  different  prognoses  in  a 
community-based  cohort  may  be  masked  in  analysis,  thus  creating  the 
impression that seizure frequency is unimportant in mortality analysis. This 
is partly  confirmed  in this cohort by the observation that  in patients with 
primary or secondary generalised tonic clonic  seizures,  seizure recurrence 
appeared to increase mortality although not significantly so.  Larger studies 
could potentially  surmount these differences to provide a more discerning 
picture of mortality in individual epilepsy syndromes although the logistical 
implications  are  considerable.  Despite  the  exclusion  of  33  deaths  that
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likely to have occurred due to underlying pathologies, mortality in the first 
year was  high.  Seizure remission,  and  short term remission  in  particular, 
was  associated  with  decreased  mortality,  although  this  did  not  reach 
significance.
4.1.6.2  The effects of  antiepileptic drug treatment
AED treatment was also found not to influence mortality. High mortality in 
the  1st  year may  have  influenced this  finding as patients dying  of serious 
underlying pathologies would not be expected to have their risk of mortality 
improved by AEDs. Conversely, there is no evidence to suggest that AEDs 
worsen mortality risks either. These findings are consistent with studies that 
have  suggested  a  seemingly  ambiguous  role  played  by  AEDs  in  the 
prognosis of epilepsy in other community-based populations (Sander JWAS 
and Sillanpaa 1997).
4.1.7 Mortality and age
Mortality was most marked in the 50-59 year age group and this reflected 
the  high  incidence  of both  CNS  and  non-CNS  neoplasias.  SMRs  were 
significantly raised,  although comparatively much lower in the >70 years 
age group despite a high absolute number of deaths due to increased age- 
related mortality in the corresponding age bands in the general population.
4.1.8 Mortality and idiopathic/cryptogenic generalised epilepsy
Idiopathic/cryptogenic epilepsy, a category that included all epilepsies with 
no obvious cause as well as idiopathic generalised epilepsy had a slight but 
not  significantly  increased  long-term  mortality.  When  patients  with 
generalised tonic clonic  seizures  in the idiopathic/cryptogenic group were 
analysed however, mortality was significantly increased. This suggests that 
tonic clonic seizures may be an independent risk factor for mortality.
994.1.9 Mortality and aetiology
Epilepsy due to acute symptomatic causes was significantly more likely to 
be associated with increased mortality and this reflects the large number of 
patients who  died  in the  first  2  years  after entry  due to  acute underlying 
conditions.  Mortality was most marked in the remote symptomatic group, 
which had a high proportion of primary brain tumours and cerebrovascular 
disease.  In  patients  with  symptomatic  epilepsy,  acute  or  remote,  the 
increased  mortality  almost  certainly  reflects  serious underlying  causes  of 
epilepsy  rather  than  the  epilepsy  itself.  Patients  with  congenital 
neurological  deficits  causing  epilepsy  also  had  comparatively  high 
mortality rates although confidence intervals were very wide.
Pneumonia  had the  highest  cause-specific  mortality  rates  in patients with 
definite epilepsy as well as in the combined definite and probable group, as 
noted  previously  (Cockerell,  and  others  1994a).  This  is  more  likely  to 
reflect overrepresentation of pneumonia as a terminal  event in the elderly 
during  hospital  admissions for concurrent illnesses rather than the seizure 
disorder itself or antiepileptic drug treatment (Cockerell, and others 1994a). 
Cancer  related  mortality  was  also  significantly  elevated  and  whilst  more 
readily  explained  in the group with primary brain tumours,  it is not so in 
those  who  died  of lung  and  other  non-CNS  tumours.  Antiepileptic  drug 
treatment  has  been  implicated,  although  no  association  between  any 
particular  drug  and  neoplasia-related  mortality  was  noted  in  this  study. 
Mortality  due to  cerebrovascular diseases was significantly elevated.  This 
does  not  directly  implicate  epilepsy  as a  cause  of death  in these  patients 
who  had cerebrovascular disease although it may  imply that patients who 
have  cerebrovascular  disease  and  subsequent  seizures  have  a  worse 
prognosis than those without seizures.  This  may be  more true of patients 
with  acute  symptomatic  seizures  than  those  who  present  with  remote 
symptomatic seizures due to cerebrovascular disease.
100SUMMARY AND CONCLUSIONS
o  The  long-term  mortality  in  a  population  based  cohort  of patients  with  newly
diagnosed  epilepsy  was  found  to  be  twice  that  of  the  age-matched  general 
population.
o  Patients with  symptomatic  epilepsy  and  epilepsy  due to  congenital  neurological
deficits  had  significantly  increased  mortality  rates  whilst  patients  with 
idiopathic/cryptogenic epilepsy did not.
o  Patients with generalised tonic clonic seizures appeared to have an increased risk
of mortality although this did not reach significance.  Short-term remission on the 
other  hand  appeared  to  reduce  mortality  although  this  also  did  not  reach 
significance.
o  Baseline  factors that  significantly  enhanced  mortality were vascular and tumour 
etiologies,  congenital neurological deficits and older age at index seizure. On the 
other  hand,  one  or  more  seizures  before  index  seizure  significantly  reduced 
mortality, possibly suggesting milder epilepsy in such patients.
o  Seizure recurrence, cumulative seizure recurrence, AED treatment and cumulative
AED  treatment  had  no  effect  on  mortality,  a  possible  reflection  of  the 
heterogeneity of the different types of seizure disorders analysed in which frequent 
seizures do not always imply severe epilepsy.
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This  study provides a useful  overview of the dynamics of treatment and 
treatment changes, as they occur in routine practice throughout the United 
Kingdom.  This data is valuable for targeting health service provision and 
identifying areas for raising clinical  standards.  This analysis of treatment 
dynamics in the NGPSE reveals several interesting findings that provide a 
picture  of the patterns of treatment of epilepsy in the general population 
during the period 1984-1997, a pattern of treatment which is quite different 
from that observed from hospital clinics of chronic, often intractable cases. 
We found that 77% of patients receiving a diagnosis of epilepsy are started 
on  therapy.  The  hospital  physician  (clinic  and  accident  and  emergency) 
initiated therapy in  over 2/3rds of cases.  Furthermore,  it  is likely that in 
many of the cases in which therapy was started by the GP, the advice of 
the hospital  was taken.  This  appears to be a change in practice over the 
past decade (Hart YM and Shorvon  SD  1995),  and is an improvement in 
line with current guidelines, which emphasise the importance of obtaining 
specialist advice before initiating antiepileptic drug therapy.
4.2.1  Treatment changes and treatment retention
The study allowed us to track treatment over the  12-year period from the 
initiation  of therapy.  Overall,  about one third  of patients  continued  long 
term therapy (i.e.  were  still  on treatment  at the time of last follow-up,  a 
mean of 12 years). The yearly incidence of epilepsy is about 50/100,000 in 
the UK or 30,000 patients per year.  Thus,  about  11,000 newly diagnosed 
patients  each  year continue to  be  on medication  for a  mean  of 12  years 
after the  initiation  of therapy  (Fig.5).  Of these,  about  5000  continue  on 
drug therapy despite long-term remission from seizures whilst about 6000 
do  so because of unsatisfactory seizure control.  The majority of the latter 
group have infrequent seizures although approximately 1500 patients have 
seizures at least once a month. Of these, surprisingly, 400 patients will not 
have done so despite frequent seizures.  Of the patients having more than
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Only  about  400  patients  may  have  tried  4  or  more  drugs,  alone  or  in 
combination, in addition to the initial medication for seizure control. When 
one  considers  the  fact  that  these  are  annual,  recurring  figures  in  each 
year’s  incident population,  it is probable that there are large numbers of 
people in the prevalent “pool”  of chronic epilepsy patients who have not 
been  adequately treated.  The lack of change and the  slowness to  change 
are  an  indictment  of  current  practice,  and  suggest  that  too  often  an 
insouciant  attitude  is taken to  early  epilepsy.  How  many  of the 20%  of 
patients  with  continuing  epilepsy  would  have  benefited  from  a  more 
aggressive  approach  to  treatment  is  not  possible  to  say,  but  almost 
certainly some medical and social complications could have been avoided, 
and perhaps even mortality.
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1044.2.2 Treatment changes and seizure remission
The outcome of those who do make treatment switches is not necessarily 
good.  91  patients (16%)  switched medication because of poor control on 
the first drug of whom 38 (41%) failed to gain control on the second. This 
is  similar to the findings of Kwan and Brodie in which epilepsy was not 
controlled by first medication in 248 patients, of whom treatment was still 
ineffective  with  second  or  more  drug  changes  in  113  patients  (46%). 
(Kwan and Brodie 2000) Furthermore,  only  116th  of those who  switched 
because of poor control on the second drug obtained lasting control on the 
third. Whilst it is possible that alternative drug changes would have helped 
some  of these  patients,  the  majority  are  likely  to  be  resistant  to  all 
antiepileptics.  The  first  switch  was  usually  within  2  years  of initiating 
therapy.  These are the types of patients who develop chronic epilepsy. As 
the  first  drug  change  is  usually  in  the  first  2  years  after  diagnosis,  our 
findings imply that the patients at risk of chronicity can be identified early 
in the course of their epilepsy.  In most but not all patients, the failure of 
initial  monotherapy  is  predictive  of chronicity  as  has  been  noted before 
(Shorvon  1984). The identification of reliably predictive clinical factors at 
this stage would be of great importance, but to date none have been found. 
More research  is needed to identify these drug resistant cases earlier,  as 
more  aggressive therapy  or much  earlier  surgical  intervention  would  be 
appropriate in many.
4 .2.3 Treatment of the first seizure
About a quarter of patients with newly diagnosed epilepsy did not receive 
medication  for  their  seizures,  most  commonly  those  with  serious  or 
progressive  underlying  pathology.  Only  15%  of  patients  whose  index 
seizure  was  also  their  first  seizure  received  medication  after  the  first 
seizure.  This  reflects  a  more  conservative  approach  to  single  seizure
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in  the  USA  who  are  given  drug  treatment  (Hauser,  and  others  1982); 
which is the most appropriate approach is controversial. However, because 
of high rates  of subsequent  seizure recurrence,  the ultimate number who 
received  antiepileptic  medication  was  more  than  70%.  Preliminary 
analyses  in  the  MESS  study  suggest  that  there  are  significantly  fewer 
recurrences for patients immediately allocated to treatment.  (Hazard ratio 
1.4; 95% Cl 1.2-1.7) (Marson and others, 2004)
4.2.4  Duotherapy and polytherapy
The vast majority of patients were prescribed initial monotherapy.  This is 
in accord with current guidelines (NICE guidelines 2004; SIGN guidelines 
2003).  Therapy with  more than  one  drug  has  been  recommended  in the 
past (Yahr MD, and others 1952), although the lack of evidence supporting 
this  has  been  pointed  out  (Shorvon,  and  others  1978).  Duotherapy  no 
longer  appears  to  be  common  practice  as  only  7  patients  were 
simultaneously  started  on  2  drugs.  With  continued  drug  treatment, 
polytherapy was more common although less than 3% continued on 3  or 
more  drugs.  Less  than  a  tenth  of  all  patients  continued  on  2  drugs, 
suggesting  that  this  is  a  relatively  infrequent  practice  in  an  unselected 
population  with  epilepsy,  contrary  to  observations  in  more  selected 
populations with uncontrolled seizures (Mattson 1992).
4 .2 .5 Choice of treatment
The choice of drug for initial therapy in this study is a useful reflection on 
overall  practice  in  the  UK  between  1984-1987.  Phenytoin  and 
carbamazepine were the most frequently preferred first line drugs and were 
used in over a third each of the treated cohort; valproate was used in a fifth 
and phenobarbital in only a minority. The comparatively infrequent use of 
phenobarbital  is  probably  due  to  increased  awareness  of  its  frequent 
adverse events and the availability of better drugs, and this is a change in 
practice  from  that  a  decade  earlier.  Carbamazepine  was  the  most
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advice  (Sillanpaa  1996;  NICE  guidelines  2004;  SIGN guidelines  2003). 
Only  a  slightly  smaller  number  however,  were  prescribed  phenytoin, 
suggesting  this  is  also  a  popular  first  choice  drug.  In  the  case  of 
generalised seizures, phenytoin was most often prescribed.  Only a quarter 
of treated  patients  with  generalised  epilepsy  were  prescribed  valproate 
first,  contrary  to  its  current  status  as  first  line  therapy  (Bruni  J  1996; 
Mattson, and others  1992; NICE guidelines 2004; SIGN guidelines 2003). 
Furthermore,  carbamazepine  was  used  in  9  patients  who  had  idiopathic 
generalised  epilepsy  and  absence  and/or  myoclonic  seizures.  In  such 
situations,  carbamazepine  is  a  contraindication  because  of the  risk  of 
exacerbating  seizures  (Snead  OC  and  Hosey  LC  1985).  Almost  all  the 
patients  with  childhood  absence  epilepsy  were  prescribed  ethosuximide. 
Although  this  remains  effective  therapy  for  the  condition,  valproate  is 
probably a more favoured first line option by many specialists nowadays 
(Bruni J 1996).
4.2.6  Reasons for treatment changes
Most patients who change therapy due to adverse events or lack of efficacy 
appear to do so in the first 2 years (Fig.4). Valproate (7%) appeared to be 
less  commonly  discontinued  at  2  years  than  carbamazepine  (18%)  or 
phenytoin (19%) (Fig.4). Less than a tenth of the cohort patients changed 
medication for the first time because of adverse events, suggesting that this 
is not an overly frequent cause of failed drug retention (Fig.3). This figure 
is  similar to  another  study of drug therapy  in  newly  diagnosed  epilepsy 
although  only  hospital  referred  patients  with  2  or  more  seizures  were 
considered  over  a  3-year  period  (Heller  A,  and  others  1995).  Only  4 
patients subsequently changed therapy again because of adverse events to 
the second drug and repeated discontinuation of medication due to adverse 
events seems uncommon in the general population. Lack of efficacy is the 
commonest cause for change of therapy and  16% of the cohort did so for 
the first time for this reason.  A third of these patients went on to change 
therapy again for the same reason,  suggesting more refractory seizures in
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during the course of follow-up; in all  cases returning to the discontinued 
drug.  These  patients  were  not  considered  to  have  changed  medication 
during  analysis  if they  continued  on the  same  drug until  further  seizure 
remission, mortality or loss to follow-up.
Even  at  the  stage  of the  first  treatment  change,  several  patients  had 
medication  added  rather  than  substituted.  Substitution  however,  was  4 
times more frequent.  Current practice is to advise that monotherapy with 
the  conventional  antiepileptic  drugs  should  be  tried  sequentially  before 
trying combination therapy.
4.2.7 The use of new antiepileptic drugs
Only  11%  of  treatment  changes  involved  a  new  antiepileptic  drug 
(lamotrigine,  vigabatrin,  gabapentin and topiramate).  This is unsurprising 
as most drug changes took place in the first two years of entering into the 
study,  which was before these antiepileptic drugs were widely available. 
The situation is probably gradually changing now.
4.2.8 Treatment retention
38% of patients who continued on therapy did so despite 5 or more years 
of terminal  remission.  Driving  considerations,  fear of seizure recurrence 
and lack of specialist advice on drug discontinuation may account for this. 
Of the  111  patients not in 5 year terminal remission, 31  (28%) had one or 
more  seizures  a week  at the time  of last follow-up  and  although  a  high 
frequency  of drug changes would be  expected  in this group,  a third  had 
only tried a single drug. Only a quarter had changed their medication 4 or 
more times.  This may suggest poor specialist input in this group as more 
than  a  third  were  not  under  regular  hospital  follow-up  despite  frequent 
seizures.
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•  This study allows us to determine to what extent the pattern of therapy in 
the population follows accepted clinical guidelines. Practice in some areas 
is acceptable; for instance, the widespread use of initial monotherapy and 
substitution rather than  addition of the  second  drug;  hospital referral  for 
initial treatment advice; restriction of initial monotherapy to conventional 
cheaper  drugs;  and  a  general  reluctance  to treat the  first  seizure.  Other 
aspects  of practice  are below  acceptable  standards;  for  instance,  lack of 
change of medication in the face of continuing seizures; lack of specificity 
in  the  choice  of drugs;  reluctance  to  use  newer  antiepileptic  drugs  in 
patients with resistant epilepsy.
•  There  also  seems to be a lack of correlation between  seizure occurrence 
and the decision to continue or withdraw therapy.
•  Some  patients  may  have  benefited  from  the  newer  antiepileptic  drugs 
although  it  is  probable  that  only  a  small  proportion  of patients  in  the 
general  population  require these  drugs  and this  is  in  marked  contrast to 
those in hospital clinics.
•  These findings indicate that there is considerable scope for improving the 
care of patients with epilepsy, that treatment is not changed fast or often 
enough  in  those  with  continuing  seizures.  This  lack  of  urgency  will 
inevitably result in less good medical and social outcomes for people with 
epilepsy.  Whilst it is clear that some aspects of therapy are better than in 
previous surveys,  others are not,  and there is probably considerable room 
for improvement in the provision of epilepsy treatment in the UK.
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The International Classification of Epileptic Seizures 
I. PARTIAL SEIZURES ( seizures beginning locally )
A.  Simple partial seizures (consciousness not impaired)
1. With motor symptoms
2. With somatosensory and special sensory symptoms
3. With autonomic symptoms
4. With psychic symptoms
B.  Complex partial seizures (consciousness impaired)
1.  Beginning as simple partial seizures and progressing to impairment of consciousness
a. With no other features
b. With features as in A. (1-4)
c. With automatisms
2.  With impairment of consciousness at onset
a. With no other features
b. With features as in A.(1-4)
c. With automatisms
C.  Partial Seizures secondarily generalised
EL GENERALISED SEIZURES ( Bilaterally symmetrical and without focal onset)
A. Absence Seizures
1. Typical absence seizures
2. Atypical absence seizures
B Myoclonic Seizures
C. Clonic Seizures
D. Tonic Seizures
E. Tonic Clonic Seizures
F. Atonic Seizures
HL UNCLASSIFIED EPILEPTIC SEIZURES ( inadequate or incomplete data )
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INTERNATIONAL CLASSIFICATION OF EPILEPSIES. EPILEPTIC SYNDROMES AND
RELA TED DISORDERS
1.  LOCALISATION RELATED (focal, local, partial)
Idiopathic (Primary)
1.1  Benign childhood epilepsy with centro-temporal spikes 
Childhood epilepsy with occipital paroxysms 
Primary reading epilepsy
Symptomatic
1.2  Temporal lobe epilepsies 
Frontal lobe epilepsies 
Parietal lobe epilepsies 
Occipital lobe epilepsies
Chronic progressive epilepsia partialis continua of childhood 
Syndromes characterised by seizures with specific modes of precipitation
Cryptogenic
1.3  Defined by
Seizure type 
Clinical features 
Etiology
Anatomical Localisation
2.  GENERALISED
2.1  Benign neonatal familial convulsions 
Benign neonatal convulsions 
Benign myoclonic epilepsy in infancy 
Childhood absence epilepsy 
Juvenile absence epilepsy 
Juvenile myoclonic epilepsy
Epilepsies with grand mal epilepsy on awakening 
Other generalised idiopathic epilepsies
Epilepsies with seizures precipitated by specific modes of activation 
Cryptogenic or symptomatic
2.2  West syndrome 
Lennox Gastaut syndrome
Epilepsy with myoclonic-astatic seizures 
Epilepsy with myoclonic absences
2.3.1  Non specific etiology
Early myoclonic encephalopathy
Early infantile epileptic encephalopathy with suppression bursts 
Other symptomatic generalised epilepsies
2.3.2  Specific syndromes
Epileptic seizures complicating many disease states
1113.  UNDETERMINED EPILEPSIES
3.1  With both generalised and partial seizures
Neonatal seizures
Severe myoclonic epilepsy in infancy
Epilepsy with continuous spike waves during slow wave sleep
Acquired epileptic aphasia
Other undetermined epilepsies
3.2  Without unequivocal generalised or focal features
4.  SPECIAL SYNDROMES
4.1  Situation related seizures 
Febrile convulsions
Isolated seizures or isolated status epilepticus
Seizures occurring only when there is an acute or toxic event due to factors such as alcohol, 
drugs, eclampsia, 
non-ketotic hyperglycemia
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Some important studies of epilepsy treatment in the community 
Crombie et al, 1960.
A  survey of the  epilepsies in general practice:  a report hy the research 
committee of the College of General Practitioners.
1957-8  survey  of  patients  with  seizures  identified  hy  134  general 
practitioners from 67 practices.  182 patients with first seizures (including 
febrile  and  acute  symptomatic  seizures)  identified:  46%  of those  with 
“major” and 58% with  “other” seizures referred to hospital.  1209 with 
chronic epilepsy identified:  6% with  “major” fits and 10% with  “other” 
fits referred to hospital during study year, with 4% admitted  for treatment 
of epilepsy or respite care.  44% with chronic epilepsy with  “major” and 
32% with  “other” seizures completely controlled during study year.
Zielinski, 1974c.
Epileptics not in treatment.
Study of 2 groups with epilepsy:  (A) Random sample of 10% of people 
with  epilepsy  known  in  1969  to  specialty facilities,  re-examined 1971-3 
(312 patients),  (B)  98 patients  with  epilepsy found during field survey 
(structured interview  of 15000  Warsaw  residents subsequently examined 
by neurologists).  Epilepsy if >2 spontaneous seizures.  Convulsions with 
fever,  intoxication  or  hypoglycaemia  excluded.  Nearly  ] A  of patients 
known to specialist facilities,  and 2/3 of  patients identified in field survey 
were  on  no  medication.  Most  known  to  have  epilepsy  had themselves 
stopped treatment in 3 years preceding examination,  and 2/3 of those on 
medication had previously attempted withdrawal.  More than 1/3 identified 
in field survey had never received treatment.
113Hopkins and Scambler, 1977.
How doctors deal with epilepsy
Adults  with>l  non-febrile  seizure,  >=7  seizure  in  2  years preceding 
prevalence  day  and/or  on  continuing  anti-convulsants for  >1  previous 
non-febrile seizure,  and not in long-term institutional care identified  from 
lists of 17 general practitioners in 5 London group practices using Second 
National Morbidity Study records, diagnostic indices, or scrutiny of notes. 
94/108 (87%) interviewed.  Study population 42339, prevalence 3.4/1000. 
18%  unaware  they  had  epilepsy.  95%  referred  to  hospital  (86%  to 
hospital with consultant neurologist on staff) ; 86% of these had EEGs.  10 
(11%)  (5  with  <=1  generalised  seizure/year)  were  under  continued 
hospital surveillance.  32% of 74 patients questioned had seen GP in past 
month,  49%  in past 2  months,  65%  in past  6 months,  and 85%  in past 
year.  3 (4%) had not seen their doctor for >+2 years.  5/94 were taking 
no medication, a sixth was taking only oral diazepam.  Phenobarbital and 
phenytoin most  frequently used drugs.
Zander et al, 1979.
Audit of care for epileptics in a general practice.
Record review  of 64 patients with  epilepsy in general practice  of 8500 
identified from  morbidity register.  12  had died or  left practice,  giving 
prevalence  7.6/1000.  29 had active  epilepsy  (seizures or medication  in 
preceding 2 years),  4 were under regular hospital surveillance,  and 96% 
had hospital diagnosis (compared with 83% of 23 with inactive epilepsy). 
66% with active epilepsy,  and 48% with inactive epilepsy had had EEG. 
Only 3/21  with active epilepsy not under hospital surveillance,  and who 
were reviewed, had had  fit during previous year.  3 A attending hospital had 
intractable seizures, the fourth insisted on hospital  follow-up despite being 
fit-free 30 years.  Patient education or satisfaction not mentioned.
Lloyd Jones, 1980.
Medical audit of the care of  patients with epilepsy in one group practice. 
Audit of care given to 47 patients with epilepsy in group practice of 8607, 
prevalence 5.5/1000.  Patients identified through prescriptions over four
114months.  Untreated patients  excluded,  handling  of patients  with  single 
seizures unclear.  45/47 patients participated in structured interview and 
examination.  Most having <3 seizures/year.  29 (64%) remembered being 
given  diagnosis.  91%  had seen  hospital specialists,  all  these  had had 
EEG.  36%  continued to  attend hospital.  27  (60%)  had not seen  any 
doctor  during preceding year.  4  had not  seen  any  doctor  to  discuss 
seizures  within previous  10  years.  38%  were  on  monotherapy.  Few 
patients  advised  about  avoiding  potentially  dangerous  situations, 
management  of  seizures,  inheritance  of  epilepsy  or  British  Epilepsy 
Association.
Taylor, 1980.
A job half done.
Audit  of patients  with  epilepsy  in Doncaster practice  of 6498  in which 
efforts  made  to  improve  management  in previous year.  37 with  active 
epilepsy, prevalence  5.8/1000.  3  children aged <16.  Extent of hospital 
referral  not given.  70%  had had EEG,  92% had been seen  by doctor 
within previous year.  4 untreated,  17 on monotherapy.  21  (57%) were 
“seizure-free ” (duration not stated).  Only 2 were in long-term remission.
White and Buckley, 1981.
The management of epilepsy -  an audit of two practices.
Structured  interview  of patients  with  epilepsy  in  2  practices,  list  size 
20043,  identified  through  repeat  prescriptions.  Handling  of  single 
seizures not stated: untreated patients excluded.  38 in one practice and 26 
in  other,  prevalences  3.4/1000  (practice  A),  and 2.3/1000  (practice B). 
58%  in practice A  and 30%  in B  under hospital supervision;  >90%  in 
each practice seen in hospital at some time.  42% > had 2 or more seizures 
during year preceding  study,  while  42%  seizure-free  during  this  time. 
Patient education not mentioned.
115Fry, 1982.
Epilepsy.
96 patients with epilepsy or convulsions (including  febrile) identified  from 
general practice  1955-75 and still at practice assessed 1981  (cumulative 
incidence over 20 years 10.5/1000).  21/96 had  febrile convulsions (none 
developed epilepsy).  Prevalence  treated patients  1981  3/1000,  73%  of 
these  having  >=7  attack  in previous year.  80%  with  seizures  starting 
under age  1  seizure-free for 3 years at follow-up,  and 75% with attacks 
beginning aged 1-14.
Goodman, 1983.
Auditing care of epilepsy in a group practice.
36 patients  with  recurrent spontaneous afebrile  seizures  identified from 
practice morbidity register (list size 8743), prevalence 4/1000.  Extent of 
hospital referral  unclear,  but hospital care  described as  unsatisfactory, 
with lack of continuity of supervision:  “ patients saw a different doctor at 
each  attendance,  and  most  of the follow-up  was performed  by junior 
hospital doctors ”.  No  comment made about general practice follow-up. 
33% on monotherapy, 67% taking 2-3 drugs.  58% had <4 seizures/year.
Goodridge and Shorvon, 1983.
Epileptic seizures in a population of 6000
122 patients with history of definite seizures identified by scrutiny of 3000 
male,  3000 female  consecutive  records  in  Tonbridge  general practice. 
Single  and  acute  symptomatic  seizures  included.  71  (58%)  seen  by 
neurologist,  22  (18%)  by paediatrician.  73% known to have had EEG, 
result unknown in 18%.  8% had CT.  10% continuing to attend hospital 
clinic.  39%  of total were  receiving medication,  68%  monotherapy.  A 
further 40% had previously taken drugs.  Nearly half of those with active 
epilepsy  were  not  receiving  anti-convulsants,  others  were  receiving 
inadequate or inappropriate treatment unchanged despite continuing  fits.
Taylor, 1983.
Improving the outlook  for patients with epilepsy.
116Records from practice audited in 1980 were re-audited in 1981.  37 (95%) 
had history of tonic clonic seizures,  of whom 20% had evidence of  focal 
onset or associated partial seizures.  Only 10 had tonic clonic seizures in 
past year,  though 33% continued to have recurrent partial seizures.  46% 
were  seizure-free.  Polypharmacy  had been  reduced,  with 59% now  on 
monotherapy.
McCluggage et al, 1984.
Anticonvulsant  therapy  in  a  general practice  population  in  Northern 
Ireland.
Study  of 300  patients  with  epilepsy  (>1  non-febrile  seizure,  on  anti­
convulsants  at  time  of study,  over  6  months  old,  and living  at  home) 
identified through repeat prescriptions in 9 general practices, population 
75200,  in Belfast,  1979-81.  Prevalence of treated epilepsy 4/1000.  247 
participated,  of  whom  5  found  not  to  have  epilepsy  and  excluded. 
Proportion  referred to  hospital not stated.  EEG mentioned in practice 
records in 72%.  Approximately equal numbers ofpatients had partial and 
generalised seizures.  59% treated >=10years, and 36% for  >=20 years. 
30% seizure-free in preceding year.
Cooper and Huitson, 1986.
An  audit  of the  management  of patients with  epilepsy  in  thirty general 
practices.
Patients  aged  >=12  with  treated  epilepsy  on  lists  of  30  general 
practitioner members of research group (total list size 100,000) identified 
over  3  months  through  surgery  attendance  or  repeat prescription,  or 
sometimes by diagnostic register.  Patients interviewed by GP, and patient 
and doctor completed matching questionnaires, and were being compared. 
377  took part,  prevalence  3.8/1000.  Mean  age  46 years.  71% >  had 
generalised tonic clinic seizures.  69% had <1 seizure per three months. 
39%  saw  GP  at  less  than  three  monthly  intervals.  No  comment about 
hospital  referral.  54%  on  monotherapy.  Considerable  discrepancy 
between answers of doctors and patients, particularly regarding effect of 
epilepsy on patient’ s home life.
117Hall and Ross, 1986.
General practice study of the care of epileptic patients.
39 patients with epilepsy identified through repeat prescriptions over six 
months from  list of 8000, prevalence  4/1000.  32/39  interviewed.  Most 
had generalised tonic  clonic seizures only.  All knew  they had epilepsy, 
except one child whose parents did not want him told.  58% had seen GP 
within previous 6 months:  19% >1 year earlier. Except for advice about 
precipitating  factors, special risks, and driving, which were discussed with 
>  J A patients, patients ’ recollection of advice was sketchy.  No information 
given about hospital referral.
Taylor, 1987.
Epilepsy in a Doncaster practice:  audit and change over eight years.
The  same  Doncaster practice,  list  size  now  7500,  re-audited  in  1986. 
Patients with active epilepsy (seizures in past 2 years,  or previous seizures 
and current mediation)  identified from disease register,  checked through 
repeat prescriptions over 6 months.  Single and  febrile seizures excluded. 
Prevalence  of active  epilepsy  6.1/1000.  One  of original  37 patients 
excluded as having  febrile convulsions only; 2 recorded as having been in 
remission.  61% had seizures of  partial origin.  89% seen at early stage by 
specialist,  usually neurologist or paediatrician,  EEG performed on all of 
these.  CTperformed on 24% of  patients.  67%o under GP care alone, 22% 
“shared are”,  and 11% solely under specialist.  41% seizure-free,  15% 
had  <3  seizures/year.  67%  on  monotherapy  or  no  medication.  No 
comment made about patient education.
Clinical standards advisory group (CSAG) study into epilepsy services 
in the United Kingdom 1999.
The  CSAG  committee  was  commissioned  by  competitive  tender  as  a 
national research project to provide a comprehensive report on epilepsy 
services in the  UK and to make recommendations that would improve the 
care of  patients with epilepsy in the  United Kingdom. Evidence and data
118were  sought from  a postal  questionnaire  distributed  to  4620 patients 
(52%  responded),  another  to  731  clinicians  (72%  responded),  a  tape 
recorded  interview  of  79  patients,  consultations  with  professionals, 
patients and organisations,  telephone surveys of all UK Trusts and postal 
enquiries of neurosurgical and neurophysiological facilities. It was found 
that only 30% of  patients had attended hospital in the last 12 months. Half 
of those with severe epilepsy, for example had not attended hospital in the 
last year.  Access  and waiting  times for  consultation  and investigations 
were unduly long.  Various recommendations were made and the needfor 
patients  to expect the highest standards of care was emphasised.  In the 
same  vein,  recommendations for  the provision  of services and facilities 
were made at the primary, secondary and tertiary care levels.
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Selected Studies of mortality 
(Zelinski, 1974c)
An important study which was population based study and carried out in 
Warsaw.  Patients with epilepsy were ascertained as part of a wider study 
into the epidemiology of epilepsy in  Warsaw using patient record review 
and house to house survey.  218 patients with epilepsy died in 1969 giving 
an  SMR  of  1.8  which  was  much  higher  in  patients  under  50  years. 
Epilepsy was the cause of death in 14% of  patients and this was 20% in 
institutionalised patients.  Other important causes of death were cancer, 
pneumonia and heart disease.  The lot of the patient with epilepsy resident 
in Warsaw in 1969 is illustrated by a high suicide rate.
(Terrence Jr, Wisotzkey & Perper, 1975)
Thirty-seven cases o f unexpected,  unexplained death in epileptic patients 
were recorded by the Allegheny County Coroner’ s Office during the years 
1969 through 1973.  In no case was there anatomic or chemical evidence 
at  autopsy  sufficient  to  explain  death.  All patients  had a  duration  of 
epilepsy greater than a year.  All but two had less than one seizure per 
month.  Blood levels  of anticonvulsants at autopsy revealed only  three 
patients  with  therapeutic  levels  of the  drugs.  Almost 50 percent of the 
cases studied had no demonstrable anticonvulsant.  It was suggested that 
inadequate  levels  of  anticonvulsant  drugs  were  a  significant  factor 
associated with unexpected,  unexplained death in epileptic patients.
(Annegers, Elveback, Labarthe & Hauser, 1976)
The records of a cohort of  patients with epilepsy in Rochester, Minnesota 
were  reviewed to ascertain  their rates of occurrence of ischaemic heart 
disease.  The results did not show any relative decrease in the incidence of
120mortality rates due to ischaemic heart disease among men or women with 
epilepsy.  The number of ischaemic heart disease incidence and mortality 
cases  were  25  and  15,  respectively,  relative  to  corresponding expected 
values of 15.0 and 15.7 new and fatal events.  The use of anticonvulsant 
medications  did  not  appear  to  influence  the  rates  of ischaemic  heart 
disease  among  the  patients  with  epilepsy.  Subgroups  of the  epilepsy 
patients,  by aetiology and types of epilepsy, were not found to account  for 
a disproportionate share of the ischaemic heart disease.  The survivorship 
of epilepsy patients  after  the  initial  manifestations  of ischaemic  heart 
disease  was  comparable  to  that  expected  among  all  ischaemic  heart 
disease patients.
(Bowerman, Levisky, Urich & Wittenberg, 1978)
A  good  early  study  looking  at  the factors predictive  of SUD.  Eleven 
autopsy cases from a Colorado coroner ’ s service were presented in which 
post-mortem  levels  o f anticonvulsant drugs were  subtherapeutic.  Scene 
investigation or medical history,  or both,  revealed evidence of epilepsy in 
all  eleven  cases.  Five  of the  deaths  (three  drowning  and  two  with 
aspiration of gastric contents)  occurred during a suspected seizure.  The 
six remaining deaths were attributed to asphyxia associated with terminal 
seizures.  Because anatomic evidence of epilepsy is often minimal and non­
specific,  the authors though that levels of anticonvulsant drugs should be 
determined in cases of sudden unexpected death with a history of epilepsy, 
and  that  these  eleven  deaths  were  preventable  with  better  patient 
motivation and compliance with the physicians' orders.
(Chevrie & Aicardi, 1978)
Mortality and neurological and mental outcome were studied in infants 28 
days to 1 year of age with afebrile seizures not due to an acute postnatal 
injury.  Cases  were  divided into four  seizure  types:  infantile  spasms:
status  epilepticus;  and  “others”  (patients  without  spasms  or  status), 
generalised and partial.  Mortality was studied in 334 cases.  Mortality
121was higher and mental and neurological sequelae were more common in 
symptomatic than in cryptogenic cases.  The highest mortality and greatest 
number of neurological defects were in status epilepticus and in  “others ” 
partial groups.  Severely retarded subjects were more common in infantile 
spasms and “others ” partial.  The proportion of mentally normal patients, 
however,  was  no  different  according  to  ictal  type.  Mental  and 
neurological  prognosis  was  less  unfavourable  when  the  first  seizure 
occurred at or over 6 months.
(Iivanainen & Lehtinen, 1979)
An  interesting  paper  which  examined  the  causes  of  death  in 
institutionalised epilepsy patients at  the  Vaajasalo Hospital in Finland. 
During  the years  1900-1076,  179  inpatients  in  Vaajasalo Hospital had 
died;  12%  of all  inpatients.  The  most  common  causes  of death  were 
pneumonia  in  40  cases,  seizures  in  34  cases  (single  seizure  in  18  and 
status epileptics in 16), drowning in 29 cases, stroke in 10 cases and heart 
infarct  in  9  cases.  Chronic  intoxication  caused  by phenytoin  and/or 
phenobarbital was  a  common  supplementary factor leading to  death  in 
patients  who  died  of pneumonia  or  seizures.  Thirteen  deaths  were 
recorded  as  suicides  or  suspected suicides  (11  by  drowning and 2  by 
strangulation).  This study will be best remembered  for the large numbers 
of death by drowning which was due to the close proximity of a lake where 
the residents often bathed.
(White, McLean & Howland, 1979)
Over 2000 epileptic patients admitted to the Chalfont Centre for Epilepsy 
between 1931 and 1971 and taking anticonvulsants were followed up to the 
end o f 1977.  Mortality between  1951  and 1977 was greatly in excess of 
that  in  the  general  population  of England  and  Wales  in  that period 
allowing for age and sex.  Some of the excess was directly attributable to 
epilepsy,  but  there  were  also more  deaths from  suicide and circulatory, 
respiratory,  and malignant disease  than would be expected.  Apart from
122the  brain and central nervous system,  no particular site had a significant 
excess o f tumours.  In particular,  there were no liver tumours (and only 
one gallbladder carcinoma).  The authors concluded that it was unlikely 
that  the  liver  tumours produced on feeding phenobarbital  to  mice  are 
indicators of major human risk.
(Hauser, Annegers & Elveback, 1980)
This was another important study to come from the Rochester series.  516 
patients  with  epilepsy  were  identified  over  a  32  year period.  Single 
seizures, provoked seizures and  febrile seizures were excluded.  The SMR 
for  this period  of follow  up  was  2.3,  and  1.8 for  idiopathic  epilepsy. 
Patients with absence seizures and complex partial seizures had a normal 
life expectancy.  The SMR was highest in the early years after diagnosis 
and then progressively declined.
(Kurokawa, Fung, Hanai & Goya, 1982)
This study  followed 385 patients with epilepsy beginning under age 15.  22 
(5.7%)  patients  had  died  during  the first  10 years  after  the  onset  of 
epilepsy and another 11  (2.9%) between 11 and 24 years.  Mortality was 
significantly high in cases with the following clinical  features: (1) epilepsy 
with  onset  before  the  first  birthday  (mortality  being  25.5%),  (2) 
symptomatic epilepsy in aetiology (17.2%),  (3) infantile spasms (40.7%), 
tonic epilepsy  (33.3%)  or myoclonic epilepsy (33.3%)  as compared with 
grand mal (5.9~%)  in seizures type and (4) developmental retardation at 
the first visit (25.5%).  The authors highlighted a lack of seizure control in 
31 out o f 33 patients at the time of death.  The causes of death were status 
epilepticus or convulsion in  10, pneumonia in 5,  severe  emaciation in  3 
“cerebral palsy ”  in  5,  and drowning,  suffocation,  traffic  accidents  or 
acute lymphocytic leukaemia,  in one each, and unknown in 6.  Most of the 
patients died at home.
123(Annegers, Hauser & Shirts, 1984)
In  this  later  study  all-cause  and heart disease  mortality  and ischaemic 
heart  disease  incidence  among  patients  with  an  initial  diagnosis  of 
epilepsy while residents of Rochester, MN, from 1935 through 1979 were 
determined.  Death  rates from  heart  disease  were  slightly  elevated for 
persons with epilepsy.  The  increased death rate from heart disease was 
confined to persons less that 65 years of age.  The incidence of ischaemic 
heart disease and of sudden cardiac death as the initial manifestation of 
ischaemic  heart  disease  was  significantly  increased  in  persons  with 
epilepsy,  but the increase was primarily limited to those with symptomatic 
epilepsy  attributed  to  cerebrovascular  disease.  The  occurrence  of 
ischaemic  heart  disease  and sudden  cardiac  death  was  not  related  to 
anticonvulsant  medication  status.  There  was  a failure  in  this study  to 
differentiate  the  different  sub-types  of sudden  death  and  many  of the 
sudden cardiac deaths may have been SUDs.
(Leestma, Hughes, Teas & Kalelkar, 1985)
This  paper,  by  an  authority  on  the  subject,  reviewed  the  factors 
predisposing patients  with  epilepsy  to  sudden  unexpected  deaths,  and 
discussed  the following:  they  are  most  commonly  encountered by  the
forensic pathologist rather than the clinician.  Such deaths may represent 
1-1.5%  of all  “natural”  deaths  certified  by  the  medical  examiner  or 
coroner.  The  typical victim  is a  black male about 30 years of age who 
tends  to  abuse  alcohol,  with a  history of generalised epilepsy for more 
than 1 year and likely for more than 10 years.  There are a lack of obvious 
anatomic causes for the death at autopsy,  but 60-70% of cases will have a 
lesion  in  the  brain  (most commonly old trauma)  to explain the  epilepsy. 
Most  victims  have  no  blood levels  of anticonvulsant medications at  the 
time of death.
(Lund & Gormsen, 1985)
124In a small study of sudden unexpected death in treated epileptic patients. 
One  or  more  of  the  anticonvulsants  phenobarbital,  phenytoin  and 
carbamazepine  were found in  subtherapeutic  drug  levels  in  half of the 
cases and “lethal” concentrations, mainly of  phenobarbital, in one third of 
the cases.  The results suggested that non-compliance was a predisposing 
factor  for SUD in epilepsy.
(Massey & Schoenberg, 1985)
Average  annual  age-adjusted  mortality  rates  for  epilepsy  from  33 
countries for  1967-1973  were  calculated and compared to  earlier data 
(when  available) from  the  1950s.  Rates during 1967-1973 ranged from 
0.6 deaths/100,000/year (Denmark) to 4.0 deaths/100,000/year (Portugal). 
Countries  in  Latin  America  generally  had  higher  rates.  With  few 
exceptions,  epilepsy  morality  rates  have  declined over  time.  For  each 
country studied,  the rates were higher  for males.
(Muuronen, Kaste, Nikkila & Tolppanen, 1985)
This  study  looked at  mortality  rate from  heart disease  in patients with 
epilepsy and the elation to AEDs.  All patients with epilepsy in a specific 
hospital-based population,  known  to  be  taking AEDs  who  died during 
1978-80  were  studied.  O f  1399  deaths  of anticonvulsant  users,  258 
(18.4%)  were  caused by ischaemic heart disease.  This was significantly 
less (p less than 0.001)  than the 382 deaths from ischaemic heart disease 
(27.3%) observed among paired controls matched  for sex, age, and date of 
death.  The total cardiovascular mortality was also lower among patients 
with  epilepsy than among controls (p less than 0.02) despite there being 
more  deaths  due  to  cerebrovascular  disease  among  patients.  The 
difference  in  mortality from  ischaemic heart disease  was significant for 
both sexes and was not accounted for by excess deaths due to any other 
single cause.  Users of  phenytoin,  carbamazepine and barbiturates (alone 
or  in  combination)  showed 29%  less  mortality  due  to  ischaemic  heart 
disease than respective controls (p less than 0.001).
125(Neuspiel & Kuller, 1985)
This study examined all the sudden non-traumatic deaths in persons aged 
1 to 21 years in a defined population.  In nine years, the 207 deaths in this 
group (4.6/100,000 population/per year) comprised 22% of non-traumatic 
mortality.  Age-specific rates were highest between 1 and 4 years (mainly 
infections  and  undetermined  causes)  and  14  and  21  years  (mainly 
cardiovascular,  epilepsy,  intracranial haemorrhage,  and asthma).  Most 
epilepsy deaths were  unwitnessed and had absent or low anticonvulsant 
levels.
(Barraclough, 1987)
This study reviewed evidence from follow-up studies concerned with the 
mortality  of epilepsy which  suggested that the  suicide rate  is increased. 
The risk of suicide was higher for temporal lobe epilepsy, for epilepsy with 
a greater degree of handicap and in the early years of the condition.
(Luhdorf, Jensen & Plesner, 1987)
All patients in a clinic-based population who were over the age of 60 who 
experienced seizures between  1979-83,  were registered.  The numbers of 
deaths was registered until July 2,  1985.  162 patients were on no anti­
epileptic drugs prior to the study period,  and 87 patients had established 
epilepsy.  The  number  of deaths  among previously  untreated patients 
significantly  exceeded  expectation.  Mortality  did  not  correlate  to  the 
severity of epilepsy.  In patients with brain tumours all but one died within 
the first year.  Mortality among patients with post apoplectic seizures was 
significantly higher  than expected being especially during the first year. 
Numbers of deaths among patients with seizures of unknown cause did not 
differ  from the expected, neither did causes of death.  Numbers of deaths in
126patients  with  established  epilepsy  at  the  time  of  admission  was 
significantly higher than expected although none had malignant tumours 
and only 4 had post-apoplectic seizures thus illustrating the influence of 
selecting patients  with  chronic  active  epilepsy.  Eleven  patients  died 
suddenly  and  unexpectedly  of  unknown  cause,  which  was  more  than 
expected.  These  patients  were  found  dead  under  circumstances 
compatible  with death  occurring during a seizure.  The authors pointed 
out that epilepsy was mentioned on the death certificate in only once case, 
indicating  that  the  frequency  of  sudden,  unexpected  death  among 
epileptics could easily be underestimated.
(Wolfersdorf & Froscher, 1987)
This paper reviewed other work in this area.  The proportion of suicide in 
the overall mortality of epilepsy patients was about 8%,  about four times 
more frequent  than  in  the  general population.  An  affective  disorder 
leading to suicide may be caused reactivity, pharmaco-genically, or by the 
epileptic function disorder itself or by an underlying cerebral disease.  The 
paper said that for prophylaxis of suicide,  it is especially important to be 
informed  about  pharmaco-genetic  depressive  moods,  which  occur  in 
phenobarbital treatment.  Help is often possible by change of medication.
(Satishchandra, Chandra & Schoenberg, 1988)
This  report  utilised data from  the  National Centre for Health  Statistics 
which recorded all conditions mentioned on each death certificate for the 
entire  US  population.  Using  a  case-control  study  design,  all  the 
associated conditions at the time of death in patients with epilepsy for the 
year 1978 wee analysed.  Association between epilepsy and the following 
conditions reached statistical significance:  mental retardation,  cerebral 
palsy,  cerebrovascular disease,  myocardial ischaemia,  dementia, foreign 
body in pharynx and larynx, pneumonia, alcoholism and cirrhosis of liver. 
The meaning of all these associations was not explicit, but the authors then
111said that early recognition and proper management of these factors could 
significantly reduce the mortality and morbidity in epileptic patients.
(Kelling & Knowles, 1989)
This study looked at all sudden natural deaths between the ages of 2 and 
20  years  which  occurred  during  a  20-year  period,  identified from 
mortuary  records  of  a  specific  population.  Necropsy  reports  and 
histological  sections  were  reviewed;  169  sudden  natural  deaths  were 
identified amongst  1012  deaths  in  that  age  group.  Ninety-two  sudden 
deaths  occurred  to  children  with  recognised disorders;  and as  well as 
congenital heart disease,  and asthma,  epilepsy was one of the commonest 
problems identified.
(Leestma, Walczak, Hughes, Kalelkar & Teas, 1989)
This  study  is  important  as  it  attempted to  estimate  the  risk of SUD  in 
patients with epilepsy at the population level.  Sudden unexpected deaths 
were  monitored by  the  Office  of the Medical Examiner of Cook County 
(Chicago),  Illinois in a year-long prospective study.  It was revealed that 
victims of this complication of epilepsy were most commonly black males 
averaging 35 years of age who had infrequent generalised seizures and 
usually some structural lesion in the brain responsible for their seizures. 
They  tended  to  abuse  alcohol  and  have  poor  compliance  with 
anticonvulsant  medication.  The  electroencephalograms  displayed 
considerable variability from record to record.  At autopsy the heart, lung, 
and liver weights were  heavier and the  brain weights were  lighter  than 
expected.  The  authors speculated on the mechanisms involved that may 
include  autonomically  mediated  cardiac  arrhythmia  alone  or  in 
combination  with  sudden  “neurogenic”  pulmonary  oedema  and 
“backward” cardiac failure.
128(Dasheiff, 1991)
This report reviews the number of deaths that occurred in a population of 
patients  on  a  pre-surgery programme.  Seven  patients  died a  sudden 
unexpected death.  This  incidence  of sudden  unexpected death  was five 
times higher than the  1-2/1000 per year reported in the general epilepsy 
population.  The  authors  pointed  out  that  SUD  shares  some  of  the 
characteristics associated with sudden cardiac death,  which kills 300.000 
people  in  the  United States  each year.  A  cardiac  arrhythmia,  usually 
ventricular fibrillation,  is  the  most  common  terminal  event for  sudden 
cardiac  death  and  the  authors  speculated  that  it  is  also  the  leading 
candidate as the mechanism for sudden unexpected death.
(Earnest, Thomas, Eden & Hossack, 1992)
This  study  examined  44  cases  of SUD for  details  of seizure  history, 
treatment,  medical and psychological history,  events at the time of death, 
and post mortem findings.  Cases of status epilepticus, drowning or other 
identifiable  causes  of death were  excluded.  Two groups emerged:  five 
children  with  uncontrolled seizures  receiving multiple  AEDs  and good 
compliance  with  medications,  and 39 adults with  less frequent seizures, 
often  receiving monotherapy,  but noncompliant with medications.  Four 
children (80%) but only one adult (3%) had  fully therapeutic post-mortem 
AED  levels.  Sixty-three percent  of adults  recently  had experienced an 
unusually  stressful  life  event.  Investigation  of the  circumstances at the 
time o f death suggested two possible m odes of death:  (a) a seizure with 
an immediately fatal arrhythmia,  or,  (b) a seizure,  recovery,  then delayed 
secondary respiratory arrest or arrhythmia.
(Klenerman, Sander & Shorvon, 1993)
The  causes  of death  in  a  group  of patients  with  severe  epilepsy  in  long term 
residential  care  over  a  period  of  11  years  were  assessed  and  standardised 
mortality rate  (SMR)  determined.  A  total of 3392 patient-years were surveyed.
129One hundred and thirteen deaths were recorded in the period which gave an SMR 
of  1.9.  Most  deaths  were  due  to  cancer  (26%),  bronchopneumonia  (25%), 
circulatory  disease  (24%),  were  seizure-related  (12%)  or  due  to  sudden 
unexpected death (6%).  The highest SMRs in the neoplasm sub-group were due to 
cancers o f the pancreas  (SMR  =  6.2)  and hepatobiliary tumours (SMR  =  17.6). 
Twenty per cent of patients died of epilepsy or epilepsy related causes.  One in 
every 480 patients died due to a sudden unexpected death.  This study in a highly 
selected population seems to confirm suggestions that mortality rates are higher in 
patients with epilepsy than in the general population.
(Cockerell OC et al, 1994)
This was an important study, the first report on mortality from the NGPSE and the 
first to report mortality prospectively in a truly community based cohort.  The SMR 
for  the  whole  cohort  was  2.5  (95%  Cl 2.1-2.9)  and 3.0  (95%  Cl 2.5-3.7) for 
patients with definite epilepsy.  The SMR for idiopathic epilepsy was 1.6 (1.0-2.4), 
for  remote  symptomatic  epilepsy  4.3(3.3-5.5)  and  acute  symptomatic  epilepsy 
2.9(1.7-4.5).  The commonest causes of death were pneumonia (SMR 7.2), cancer 
(3.5) and stroke (3.7).
(Nilsson L et al, 1997)
This Swedish hospital based study looked at 9061 patients over the age of 15 years 
and over a 53520 patient year period in which 4001 deaths were observed.  This 
yielded an SMR of 3.6 (95% Cl 3.5-3.70. SMR was significantly increased in all 
age groups. Excess mortality was due to a wide range of causes including 
malignancy (SMR 2.6; 2.4-2.8), ischaemic disease (SMR 3.1; 3.0-3.3) and 
respiratory disease (SMR 4.0; 3.6-4.5).  This confirmed the increased mortality in 
patients with epilepsy noted in previous studies.
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List of General Practitioners currently participating in the NGPSE
D K.N. Addey
D S. Ahmad
D H. W. Aitken
D M. Al-Saleem
D S.m. Amin
D N. Amin
D J. C. Anderson
D D. I. Anderson
D Y. Anthony
D D. P. Archer
D N. Amott,
D S. M. Ashby
D Y. C. Au
D S. Bailey
D J. W. Baker
D R. Baker
D F. C. Ballinger
D B. R. Bannar-Martin
D D. Clare
D P. M. Barrie
D S.K. Bassi
D Beazer
D D.J. Bell
D S.J. Bellamy
D R. B. Bennet
D R. B. Bennet
D E. N. Nenson
D R. Bertram
D Bhanja
D M. A. Bielenky
D C. E. Birchall
D K. Biswas
D F. J. Borchardt
D P. Bosworth
D G. M. P. Boyes
D B. H. Boyle
D J. G. Bradbrooke
D P. Bradley
D D. Brodie
D . P. G. Brown
D Biyant
D .B. S. Bryant
D . R. J. Buckle
D . R. Bull
D . A.J. Burch
D . K. Burch
D . S. Burcombe
D . S. Burgoyne
D . R. H. Burton
D . R. H. Burton
D . D.F. Burwood
D . S. Butcher
D . Butcher,
D . D. N. Greig
Dr. J. R. Bywater 
Dr. M. F.A. Cahill 
Dr. G. R. Caird 
Dr. Calder 
Dr. G. E. Clavert 
Dr. P. D. Campion 
Dr. C. Campion-Smith 
Dr. W. Drysdale 
Dr. T. J. Cantor 
Dr. S. Came 
Dr. T. A. Carney 
Dr. J. Carrol 
Dr. B. E. Carter 
Dr. P. M. Carter 
Dr. R. J. s. Cave 
Dr. G. J. Charlwood 
Dr. D. A. Chidwick 
Dr. J. D. Churcher 
Dr. Elsby 
Dr. R. C. Clare 
Dr. P. Claydon 
Dr. C. Clayton-Payne 
Dr. A. Coggan 
Dr. R. W. Coles 
Dr. M. Collins 
Dr. P H. Cook 
Dr. A. Cook 
Dr. H. Corcoran 
Dr. D. J. Corlett 
Dr. H. Cotton 
Dr. P. Cottrell 
Dr. E.J. Coutinho 
Dr. H. L. Coysh 
Dr. D. Craig 
Dr. P. J. Craven 
Dr. J. A. Cree 
Dr. N. R. Crossley 
Dr. I. D. Cruickshank 
Dr. M. Cunningham 
Dr. M. T. Cwynarski 
Dr. J. Czaudema 
Dr. M. D’Souza 
Dr. S. L. Davidson 
Dr. F. Davidson 
Dr. H.C.R. Davies 
Dr. A. W. Davies 
Dr. P. H. Davison 
Dr. S. C. Davoodbhoy 
Dr. F. W. Debney 
Dr. A. R. Del Mar 
Dr. C. I. Dellaportas 
Dr. P. J. Dennis 
Dr. A. Dhesi,
Dr. P. Jeavons
Dr. L. H. Dhiya 
Dr. G. A. Dinnis 
Dr. J. B. Donald 
Dr. R. R.Donmall 
Dr. S. Dove 
Dr. J. Dowell 
Dr. M. Doyle
Dr. A. R. Duke 
Dr. Dunn 
Dr. R. J. Dunstan 
Dr. A. J. Dutton 
Dr. Dyer 
Dr. L. Dyson 
Dr. N. E. Early 
Dr. M. P. Eddington 
Dr. D. A. Edmonds 
Dr. Elder
Dr. A. R. Emerson 
Dr. H. Enright 
Dr. P. R. Evans 
Dr. K. G. Evans 
Dr. D. J. Fairclough 
Dr. T. M. Farley 
Dr.  A. Farmer 
Dr. G. Fletcher 
Dr. B. A.Flintan 
Dr. R. Fosket 
Dr. I. L. Foster 
Dr. R.D. Fouracre 
Dr. P. M. Francis 
Dr. A. Frazer 
Dr. G.K. Freeman 
Dr. A. French 
Dr. A. R. Gall 
Dr. B Geffin 
Dr. D. Gelipter 
Dr. R. L. Gibbins 
Dr. J. S. Gibson 
Dr. J. R. Gilbert 
Dr. B. V. Gill 
Dr. S. C. Gillam 
Dr. J. B. Glass 
Dr. J. D.Goddard 
Dr. D.M.G. Goodridge 
Dr.  D.Gordon 
Dr. J. Granger 
Dr. G. R. Green 
Dr. R. W. Green 
Dr. D.J. Green 
Dr. R. M. Greenfield 
Dr. E. D. Gregson 
Dr. M. McBride
131Dr. S.K. Griffith 
Dr. H. G. Gunton 
Dr. P. E. Haddon 
Dr. J. L. Hadley 
Dr. S. A. Hall 
Dr. W. Hall 
Dr. I. Hamilton 
Dr. R.  A. Hamlin 
Dr. C.H. Hand 
Dr. M. C. Hannan 
Dr. M. Harland 
Dr. D. W. Harley 
Dr. A. Harris 
Dr. J. J. Harris 
Dr. R. G. Harrison 
Dr. K. R. Harrison 
Dr. E. A. Harrison 
Dr. R. Harrod 
Dr. Hassan 
Dr. M. Hassenfuss 
Dr. Hassey 
Dr. T. Hatch 
Dr. Hawkins 
Dr. J. L. Haworth 
Dr. K. A. Heatley 
Dr. G. D. Heaton 
Dr. I. N. Hempshall 
Dr. F. Hennessey 
Dr. C. Henry 
Dr. J. Hewlett 
Prof Higgins 
Dr. F. Higgs 
Dr. S. Highton 
Dr. A. P. Hill 
Dr. S. Hilton 
Dr. I. M. Hiscock 
Dr. S. J. Hogg 
Dr. R. Hollands 
Dr. R. Holloway 
Dr. S. G. Holmes 
Dr. D.H. Hood 
Dr. P. Hopkins 
Dr. P. Horsfield 
Dr. B. Hourihane 
Dr. T. R. Howard 
Dr. A. Howe 
Dr. I. E.Hughes 
Dr. M. E. Hughes 
Dr. D. Hughes 
Dr. C. Hulbert 
Dr. M. H. Husain 
Dr. W. Isherwood 
Dr. M. Jackson 
Dr. N. R. Jackson 
Dr. P. W. James 
Dr. I. Jamieson 
Dr. R. J. Jarvis 
Dr. L. G. Posser 
Dr. D. J. Poulton 
Dr. P. Preston
Dr. J. M. Jones 
Dr. K. J. Jones 
Dr. M. R. Jones 
Dr. B. Jones 
Dr. W. M. Jordan 
Dr. J. F. Judge 
Dr. A. Jumaily 
Dr. J. Kane 
Dr. J. F. Kedward 
Dr. M. R. Kennedy 
Dr. I. S. Kewley 
Dr. S. J. King 
Dr. R. H. King 
Dr. K. N. Kini 
Dr. R.N. Kirby 
Dr. P Kirk-Smith 
Dr. S. Kitson 
Dr. J. Kloer 
Prof. J. D. Knox 
Dr. Koppel 
Dr. M. G. Kremer 
Dr. J. M. Lakeman 
Dr. D. C. Langley 
Dr. M. J. Latham 
Dr. J. Launer 
Dr. D. Law 
Dr. D. Lawton 
Dr. C. Lay 
Dr. Lean 
Dr. C. P Lennon 
Dr. P. L. Lewis 
Dr. A. Lightfoot 
Dr.  C. Littlejohn 
Dr. G. Livingstone 
Dr. R. Lloyd 
Dr. N. Lloyd-Jones 
Dr. M. Logan 
Dr. J. London 
Dr. J. Lorimer 
Dr. J. R. Lough 
Dr. P. W. Love 
Dr. B. M. Lower 
Dr. Lundy 
Dr. A. J. Macdonald 
Dr. F. M. Parrish 
Dr. R. M. MacKenzie 
Dr. I. D. Mackenzie 
Dr. N. MacLennan 
Dr. A. G. Males 
Dr. S. Mallik 
Dr. P. Markus 
Dr. W. Marsen 
Dr. A. J. Marshall 
Dr. D. A. Martin 
Dr. J. D.Martin 
Dr. D. N. Masters 
Dr. A. Matthews 
Dr. A. P. Smaling 
Dr. D. W. Smith 
Dr. P. K. Smith
Dr. T. J. McConnell 
Dr. J. L. McCorrigan 
Dr. McCullagh 
Dr. B. McCullough 
Dr. H. M. McDermott 
Dr. McIntosh 
Dr. M. McKendrick 
Dr. McKinstiy 
Dr. J. J. McMullan 
Dr. V. M. McVey 
Dr. P. B. Medcalf 
Dr. R. Mee 
Dr. A. J. Membrey 
Dr. R. J. Meridith 
Dr. H. Merrilees 
Dr. A. Meynell 
Dr. C. S. Middleton 
Dr. J. A. Mir 
Dr. K. M. Mishra 
Dr. S. Mohammed 
Dr. M. Momen 
Dr. C. G. Moore 
Dr. M. Morgan 
Dr. J. Morrell 
Dr. D. C. Morrell 
Dr. E. Morris 
Dr. J. R. Morton 
Dr. J. P.  Mounty 
Dr. A. J. Muir 
Dr. K. Muncey 
Dr. S. Murray 
Dr. Murphy 
Dr. J. Neary 
Dr. A. S. Nijjar 
Dr. H. Norminton 
Dr. P O’Neill 
Dr. J. O’Neill 
Dr. A. Oakanfull 
Dr. N. Padfield 
Dr. A. N. Painter 
Dr. D. A. Palmer 
Dr. A. Palmer 
Dr. V. Parker 
Dr. J. Parkes
Dr. C. Patel 
Dr. J. Paton 
Dr. M. G. Patten 
Dr. M. M. Peddie 
Dr. S. C. Pennell 
Dr. B. A. Perkins 
Dr. M. C. Phillis 
Dr. R. A. Pietroni 
Dr. N. Pile 
Dr. R. S. Pinches 
Dr. P. V. Player 
Dr. S. L. Pocklington 
Dr. D. A. Wood 
Dr. M. J. Wright 
Dr. D. S. Wright
132Dr. L. Price 
Dr. J. F. Primavesi 
Dr. M. A. Pringle 
Dr. R. Proudlove 
Dr.  G. Pye
Dr. A.Raban-Williams 
Dr. F. I. Stewart 
Dr. K. Radia 
Dr. S. Ramsbottom 
Dr. H. E. Rees 
Dr. G. D. Reilly 
Dr. C. Renwick 
Dr. K. Richards 
Dr. M. I. Richardson 
Dr. M. Riddoch 
Dr. R. Ridsdill-Smith 
Dr. P. R. Tasker 
Dr. C. H. Rigby 
Dr. M. S. Rigler 
Dr. D. J. Riley 
Dr. G. W. Roberts 
Dr. R. C. Robinson 
Dr. J. C. Robinson 
Dr. H. J. Rodgers 
Dr. L. V. Ross 
Dr. Rowland 
Dr. J. V. Rubner 
Dr. C. S. Ruck 
Dr. A. O. Russell 
Dr. Russell 
Dr. P Ryba 
Dr. S. Rye 
Dr. W. Sagar 
Dr. Sagar 
Dr. J. S. Samill 
Dr. H. Sapper 
Dr. D. Sapsford 
Dr. J. Saunders 
Dr. J. S. Savage 
Dr. D. Savage 
Dr. J. Savory 
Dr.  C.L. Scott 
Dr. S. K. Sehmi 
Dr.  S. T. Selvan 
Dr. P. Sengupta 
Dr.  S. C. Shah 
Dr. E. H. Shaw 
Dr. C. Shearer 
Dr. A. N. Sherwood 
Dr. C. Short 
Dr. C. Side,
Dr. J. D. Silverman 
Dr.  Singh 
Dr. G.  Singh 
Dr. C. M. Skott
Dr. P. R. Soper 
Dr. M. A. Spencer 
Dr. P. Sprackling 
Dr. S. M. Stanton 
Dr. W. M. Steele 
Dr. D. Stewart
Dr. S. H. Street 
Dr. C. Stubbings 
Dr. R. A. Suchett-Kaye 
Dr. S.Sudlow 
Dr. J. Suffield 
Dr. D.J. Sumner 
Dr. M. Sutherland 
Dr. K. M. Sykes 
Dr. D. R. Tant
Dr. N. H. Taylor 
Dr. M. P. Taylor 
Dr. Taylor 
Dr. M. B. Taylor 
Dr. J. P. Taylor 
Dr. J. D. Temple 
Dr. H. A. Thomas 
Dr. R. S. Thomas 
Dr. J. M. Thompson 
Dr. Thompson 
Dr. O. Thurtle 
Dr. G. J. Titmas 
Dr. V. A. Todd 
Dr. D. A. Toorawa 
Dr. C. H. Tseung 
Dr. B. Tulloch 
Dr. R. Turner 
Dr. A. M. Valori 
Dr. R. Vibhuti 
Dr. M. Walter 
Dr. T. O. Ward 
Dr. E. Ward 
Dr. C. E. Warren 
Dr. J. Watkings 
Dr. Watson 
Dr. G. M. Watson 
Dr. J. V.Weinkove 
Dr. R. Whitbread 
Dr. D. Whitcher 
Dr. P. T. White 
Dr. W. Whitlow 
Dr. M. M. Wicks 
Dr. I. Widdrington 
Dr. C. J. Wilcox 
Dr. Willcox-Jones 
Dr. P. G. Williams 
Dr. J. B. Williamson 
Dr. P. Willis
Dr. R. H. Yearsley 
Dr. A. Zahorski
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THE NATIONAL GENERAL PRACTICE STUDY OF 
EPILEPSY ANNUAL GP FOLLOW UP FORM
NATIONAL GENERAL PRACTICE STUDY OF EPILEPSY AND EPILEPTIC
SEIZURES
(NGPSE)
FORM 5 -  YEARLY FOLLOW UP
This is a follow up about a patient you notified to the NGPSE.  Please could you arrange 
to see the patient to complete the questionnaire, (if the patient has changed practices, 
please provide as much detail as you can, so that the patient may be traced or followed up 
elsewhere).  PLEASE FILL IN ALL GREY SHADED BOXES (in as much detail as 
possible) and feel free to make any comment you wish which may amplify answers or 
reflect any difficulties you encounter when completing the questionnaire.
PLEASE RETURN THE COMPLETED FOR TO:  Dr. S.D. Shorvon
FREEPOST
Chalfont Centre for Epilepsy 
Chalfont, St. Peter, Bucks. SL9
7BR
1.  General Practitioner  2. Patient
If patient has changed address or general practice, please insert new address/general 
practice.  (If not known please give as much information as possible, indicate area etc.).
New Address  New General Practice
If patient has died please give details (date, cause of death etc.)
A MOST IMPORTANT AIM OF THE STUDY IS TO OBTAIN FULL INFORMATION 
ABOUT SEIZURE RECURRENCE -  PLEASE ANSWER IN THE GREY SHADED 
BOXES IN AS MUCH DETAIL AS POSSIBLE.__________________________
1343.  SEIZURES 
Date of entry to study:
Date of first seizure:
The last follow-up was on:
At last follow-up, details of recurrence were:
The seizures were described as:
3 .i  Number of seizures since last follow-up
3 .ii  Date of these seizures
3.iii  Timing (Asleep/awake/asleep and awake/don’t know)
3 .iv  If seizure type has changed, or if further information is available concerning
seizure recurrence, please give full details below:
We have the following information regarding 
Aetiology
Circumstances/precipitating factors
4.iv  If these have changed, please amend in as much detail as possible:
4.  Have there been ANY NEUROLOGICAL, MEDICAL 
ANDPSYCHOLOGICAL DEVELOPMENTS?  If so, please give further details:
5.  DRUG TREATMENT
The drug treatment previously notified was:
Drug  Dosage per day
6.i  If any drug change has occurred since the last follow up, please specify:
6. ii  Present anticonvulsant treatment:
1356.  Is the patient attending a hospital clinic because of the seizures? 
Yes/No/Don’t know
If yes please give details:
Hospital
Address
Consultant/Clinic
7.  We have classified the patient as follows
DEFINITE EPILEPSY  (  )
DEFINITELY NOT EPILEPSY  (  )
PROBABLE/POSSIBLE EPILEPSY  (  )
DON’T KNOW  (  )
Is this correct?  Yes/No/Don’t know
Comment re: diagnosis
Other Comments
Form completed by:
Date:
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